Program Book - International Congress on Schizophrenia Research

Transcription

ICOSR13_Covers 3/15/13 4:49 PM Page 1
14TH INTERNATIONAL CONGRESS
ON SCHIZOPHRENIA RESEARCH
JW MARRIOTT ORLANDO
Grande Lakes, Florida, USA
21-25 April 2013
ALL Attendees and Presenters
are required to register.
Your BADGE will be required
to enter all scientific sessions.
Your BADGE and a TICKET will be
required to enter all events and
meals.
JW MARRIOTT ORLANDO
GRANDE LAKES, FLORIDA, USA
MEDITERRANEAN BALLROOM
PREFUNCTION AREA
8:00 am - 8:00 pm
Registration
4.00 – 6.00 pm
Saturday 20 April 2013
Registration
Sunday
21 April 2013
Morning Coffee
7:00 am - 8:00 am
MEDITERRANEAN PORTE-COCHERE
YI Mentor Meetup
7:00 am - 8:00 am
Morning Coffee
7:00 am - 8:00 am
YI Mentor Meetup
7:00 am - 8:00 am
Morning Symposia
10:00 am - 12:00 pm
PALAZZO BALLROOM
Morning Symposia
10:00 am - 12:00 pm
PALAZZO BALLROOM
1. Carpenter (MB-1)
2. Cairns (PB-A)
3. Peters (PB-D)
4. Zipursky (PB-E)
5. Harvey (PB-F)
Morning Symposia
10:00 am - 12:00 pm
PALAZZO BALLROOM
1. McGrath (MB-1)
2. Marder (PB-A)
3. Braff (PB-D)
4. Bearden (PB-E)
5. Macciardi (PB-F)
1. Sawa (MB-1)
2. Harrison (PB-A)
3. Potkin (PB-D)
4. Sommer (PB-E)
5. McGurk (PB-F)
Morning Break
9:30 am
MEDITERRANEAN BALLROOM PREFUNCTION
AREA
Morning Break
9:30 am
AREA
Morning Break
9:30 am
AREA
Robert Schwarcz
Maryland Psychiatric Research Center
University of Maryland
Philip D. Harvey
University of Miami
Miller School of Medicine
Eric J. Nestler
Plenary Speaker
8:30 am
SALONS 4/5
Plenary Speaker
8:30 am
SALONS 4/5
Morning Remarks
8:15 am
SALONS 4/5
YI Mentor Meetup
7:00 am - 8:00 am
Morning Coffee
7:00 am - 8:00 am
Registration
8:00 am - 5:00 pm
PREFUNCTION AREA
Wednesday
24 April 2013
Icahn School of Medicine
at Mount Sinai
Plenary Speaker
8:30 am
SALONS 4/5
Morning Remarks
8:15 am
SALONS 4/5
Registration
7:00 am - 5:00 pm
PREFUNCTION AREA
Registration
7:00 am - 5:00 pm
PREFUNCTION AREA
Opening Remarks
8:00 am
SALONS 4/5
Tuesday
23 April 2013
Monday
22 April 2013
All Sessions and Events will be held exclusively in the JW Marriott Orlando, Grande Lakes
14TH INTERNATIONAL CONGRESS ON SCHIZOPHRENIA RESEARCH
21 - 25 April 2013 • Grande Lakes, Florida
1. Kleinman (MB-1)
2. Dazzan (PB-A)
3. Erhardt (PB-D)
4. Di Forti (PB-E)
5. Waddington (PB-F)
Morning Symposia
10:00 am - 12:00 pm
PALAZZO BALLROOM
Morning Break
9:30 am
AREA
William K Warren
Award Recipient
Plenary Speaker
8:30 am
SALONS 4/5
Closing Remarks
8:15 am
SALONS 4/5
YI Mentor Meetup
7:00 am - 8:00 am
Morning Coffee
7:00 am - 8:00 am
Registration
8:00 am – 12:00 pm
PREFUNCTION AREA
Thursday
25 April 2013
Opening Reception
6:00 – 9:00 pm
VALENCIA TERRACE & LAWN
ALL Attendees and Presenters
are required to register.
Your BADGE will be required
to enter all scientific sessions.
Your BADGE and a TICKET will be
required to enter all events and
meals.
JW MARRIOTT ORLANDO
GRANDE LAKES, FLORIDA, USA
PREFUNCTION AREA
8.00 am - 8:00 pm
Registration
Sunday
21 April 2013
Social Event
HAVANA: HOT! HOT! HOT!
7:00 - 10:00 pm
LAZY RIVER FIRE PIT
1. Siever (PB-A)
2. Davidson (PB-D)
3. Opler (PB-E)
4. Dazzan (PB-F)
5. Ranganathan (MB-1)
6. Mishara (MB-6)
Afternoon Oral Sessions & Symposia
3:00 - 5:30 pm
PALAZZO BALLROOM
1. Roberts (A)
2. Vinogradov (B)
3. Marx (C)
4. Nordentoft (D)
5. Kircher (E)
Colorado Springs, Colorado, USA
THE BROADMOOR
28 March – 01 April 2015
Please join us:
SCHIZOPHRENIA RESEARCH
14th INTERNATIONAL CONGRESS ON
Thank you for participating in the
1. Carter (PB A) OS
2. Park (PB D) OS
3. D'Souza (PB E) OS
4. Addington (MB-4) Symp
5. Bertolino (MB-1) Symp
6. Murray (MB-6) Symp
3:00 - 5:30 pm
PALAZZO BALLROOM
Abstract Categories:
Therapeutics: Treatment Trials; Drug
Side Effects & Physical Illness; Health
Economics & Services Research;
Neuroanatomy, Animal;
Neurochemistry, Animal & Clinical;
Neuroimaging, Neurochemical;
Neuropathology, Histology &
Biochemistry
1. Heimer (MB-4/5)
2. Velligan (PB-A)
3. Chan (PB-D)
4. Gaughran (PB-E)
5. Fleischhacker (PB-F)
Ticketed Event
(ALL TICKETS MUST BE
PURCHASED IN ADVANCE)
Workshops
(not accredited)
7:00 - 9:30 pm
PALAZZO BALLROOM
1. Dazzan (PB A) OS
2. McGurk (PB D) OS
3. Ragland (PB E) OS
4. Schulz (MB-4) Symp
5. Kumra (MB-1) Symp
6. Barch (MB-6) Symp
1. Brown (PB A) OS
2. Correll (PB D) OS
3. Roberts (PB E) OS
4. Weiden (MB-4) Symp
5. Oresic (MB-1) Symp
6. McCarley (MB-6) Symp
Town Hall & Workshops
(not accredited)
7:00 - 9:30 pm
PALAZZO BALLROOM
1. Levy (PB A) OS
2. Naber (PB D) OS
3. Reilly (PB E) OS
4. He (MB-4) Symp
5. Nuechterlein (MB-1) Symp
6. Cascella (MB-6) Symp
3:00 - 5:30 pm
PALAZZO BALLROOM
3:00 - 5:30 pm
PALAZZO BALLROOM
Neuroimaging, Structural &
Functional; Cognitive Neuroscience;
Epidemiology; Genetics, Basic &
Clinical; Diagnosis; Phenomenology;
Electrophysiology; Eye Movement
Physiology; Therapeutics:
Pharmacologic Probes
Clinical Neuropsychology; Functional
& Psychosocial Outcomes
1. Falkai (A)
2. Seidman (B)
3. Gur (C)
4. Cannon (D)
5. Lysaker (E)
6. Kurtz (F)
7. Melle (G)
8. Leitman (H)
Poster Symposia
Poster Abstract Session
& Lunch
12:00 - 2:30 pm
COQUINA BALLROOM
Poster Symposia
& Lunch
12:00 - 2:30 pm
COQUINA BALLROOM
1. Kirkpatrick (A)
2. Howes (B)
3. Woods (C)
4. Park (D)
5. Schultze-Lutter (E)
6. MacCabe (F)
7. Rowland (G)
8. Collip (H)
Poster Symposia
& Lunch
12:00 - 2:30 pm
COQUINA BALLROOM
Poster Symposia
& Lunch
12:00 - 2:30 pm
COQUINA BALLROOM
Thursday
25 April 2013
Wednesday
24 April 2013
1. Fillman (A)
2. Weickert (B)
3. Petryshen (C)
4. Berretta (D)
5. Morgan (E)
6. Purves-Tyson (F)
7. Smith (G)
8. Sawa (H)
Tuesday
23 April 2013
Monday
22 April 2013
All Sessions and Events will be held exclusively in the JW Marriott Orlando, Grande Lakes
14TH INTERNATIONAL CONGRESS ON SCHIZOPHRENIA RESEARCH
21 - 25 April 2013 • Grande Lakes, Florida
Registration
Meeting Materials
Info Desk & CME Desk
Family Forum
Morning Symposia
Morning Coﬀee
YI Mentor Meetup
Morning Break
Plenary Session
Town Hall & Workshops
IFoTS Clinical Update
LOBBY LEVEL
Poster Symposia
Lunch
Opening Reception
Cognition Satellite
Lunch
Prodromal Satellite
Breakfast
Prodromal Satellite Sessions
Cognition Satellite Sessions
LOWER LEVEL
Cognition Satellite Poster Session / Reception
Prodromal Satellite Poster Session / Lunch
YI Luncheon
YI Alumni Reunion & Reception
Citrus Garden
CONGRESS AIMS
Understanding schizophrenia is a leading challenge for medical research today.
Its disease
manifestations are complex, variable, and individually unique. Risk factors for the illness suggest that
genetic and early developmental processes are involved in the pathophysiology, but specific
mechanisms have not yet been defined. Drug abuse in schizophrenia is particularly problematic,
because it is a negative course-of-illness determinant, and may even be involved in onset of the illness.
Public, medical, and scientific interest in this illness is growing rapidly. This is in part due to the
substantial burden of the illness upon afflicted individuals, their families, and society. It is also
because rapidly expanding knowledge in brain sciences and new developments in technology create
new opportunities for advancing hypotheses and developing more effective treatments.
The
International Congress on Schizophrenia Research brings together the basic neuroscience and clinical
science, and now clinical practice, communities to foster the creative acquisition and dissemination of
new knowledge about the disease.
This program lists presentations for the Fourteenth International Congress on Schizophrenia Research at
the JW Marriott Orlando in Grande Lakes, Florida, 21-25 April 2013. Scientists representing the broad
range of disciplines involved with discovery in schizophrenia gather to exchange data, techniques, and
ideas. Their cutting-edge experimental work in schizophrenia is presented in the spirit of open
exchange and critical understanding.
Scientists from outside the schizophrenia field provide
presentations of work of emerging importance for application in schizophrenia. The Congress also
places special emphasis on introducing young investigators to the colleagueship of the schizophrenia
scientific community through young investigator travel awards. This year, the Family Forum and the
Clinical Update meetings demonstrate the readiness and commitment of our field to translation.
Attendees are current contributors to the scientific literature and participate actively in poster
sessions, oral presentations, workshops, and informal exchanges. The scope of the research presented
is broad, ranging from molecular genetics to socio-environmental factors, and include information to
enhance clinical care. Synthesis of these rich data for future growth in understanding schizophrenia
and its treatment is the challenge to each attendee.
CONGRESS ORGANIZERS
Carol A. Tamminga
S. Charles Schulz
CONGRESS COORDINATORS
Dorothy Denton
Cristan Tamminga
ADVISORY BOARD
Carlo Altamura
Nancy Andreasen
Anne Bassett
Francine Benes
David Braff
Peter Buckley
William Carpenter, Jr.
David Copolov
Timothy Crow
Michael Davidson
Lynn DeLisi
Wolfgang Fleischhacker
Robert Freedman
Jay Giedd
Terry Goldberg
Anthony Grace
Raquel Gur
Stephan Heckers
Steven Hirsch
Dilip Jeste
René Kahn
John Kane
Samuel Keith
Anthony Lehman
Jeffrey Lieberman
Dolores Malaspina
Robin Murray
Dieter Naber
Henry Nasrallah
John Waddington
Daniel Weinberger
YOUNG INVESTIGATOR AWARDEES
The Young Investigator Award of this Congress is intended to attract bright, young scientists to the field
of schizophrenia research and to this meeting. The contribution of young thinkers to scientific inquiry
in any discipline is critical. There were 140 applications for the Young Investigator Award; all were
commendable and many were superior. These are the 27 investigators who were selected by the
Review Committee as the best of the applicants. Congratulations to all applicants on the quality of
their work in this field.
Monica Aas
Alan Anticevic
Michael Eriksen Benros
Sarah E. Bergen
Savita G. Bhakta
Ricardo E. Carrion
Dina Collip
Helen Fisher
Melanie Foecking
Samantha Jane Fung
Margaret K. Hahn
Alkomiet Hasan
Leslie E. Horton
Carol Jahshan
Seung Suk Kang
Brian P. Keane
Oussama Kebir
James Bowes Kirkbride
Rebecca Kuepper
Charity Johanna Morgan
Bart D. Peters
Panos Roussos
Katy Natasha Thakkar
Jared Xavier Van Snellenberg
Johanna Wigman
Josh Woolley
Jared William Young
YOUNG INVESTIGATOR REVIEW COMMITTEE
Xavier Amador
Jeffrey Bedwell
Yue Chen
Donald Goff
Adrienne Lahti
Todd Lencz
Daniel Mathalon
Gary Remington
John Waddington
Mark Weiser
YOUNG INVESTIGATOR MENTOR PROGRAM COORDINATORS
Laura Rowland
Scott Sponheim
William K. Warren Medical Research Institute Award for Schizophrenia Research, 2011
Judith L. Rapoport, MD
In recognition of his fundamental contributions to the understanding of schizophrenia, the William K.
Warren Medical Research Award for Schizophrenia Research was presented to Dr. Rapoport in 2011. Dr.
Rapoport received her B.A. from Swarthmore College in 1955 and her M.D. from Harvard Medical School
in 1959. She obtained her clinical and research training at the Massachusetts Mental Health Center in
Boston, the Children's Hospital in Washington, D.C., and the Karolinska Hospital in Stockholm, Sweden.
Since 1984, Dr. Rapoport has been Chief of the Child Psychiatry Branch within the NIMH. She is an
elected member of the Institute of Medicine and a Fellow of the American Academy of Arts and
Sciences. Dr. Rapoport's laboratory investigates the clinical phenomenology, neurobiology and
treatment of psychiatric disorders in children, including Childhood Onset Schizophrenia, Attention
Deficit Hyperactivity Disorder and Obsessive Compulsive Disorder.
Since 1990, the NIMH has been recruiting patients with onset of schizophrenia before age 13. Major
goals are to study brain development during childhood and adolescence in early onset schizophrenia
patients. Preliminary genetic studies show association with a number of schizophrenia risk genes such
as GAD and NRG1, supporting continuity with the adult disorder. In addition, abnormal brain
developmental trajectories in patients and their full healthy siblings are seen in relation to risk alleles
for these genes. Treatment studies have shown the unique benefit of clozapine for treatment resistant
patients. A new study of transient cortical electrical stimulation has begun for control of selected
symptoms.
2013 WILLIAM K. WARREN MEDICAL RESEARCH INSTITUTE AWARD
FOR SCHIZOPHRENIA RESEARCH COMMITTEE
Nancy C. Andreasen
David L. Braff
Arvid Carlsson
William T. Carpenter, Jr.
Nikki Erlenmeyer-Kimling
Robert Freedman
David Lewis
Robin M. Murray
Judith L. Rapoport
S. Charles Schulz
Carol Tamminga
Daniel R. Weinberger
SCIENTIFIC PROGRAM COMMITTEE
Carlo Altamura
Alan Brown
Cameron Carter
Christoph Correll
John Csernansky
Paola Dazzan
Lynn DeLisi
Deepak D'Souza
Peter Falkai
Wolfgang Fleischhacker
Judith Ford
Anthony Grace
Paul Harrison
Stephan Heckers
Richard Keefe
James Koenig
Deborah Levy
Christine Marx
Susan McGurk
Dieter Naber
Henry Nasrallah
Sohee Park
Godfrey Pearlson
Daniel Ragland
James Reilly
Rosalinda Roberts
CONGRESS PARTNERS
William K. Warren Foundation
CONGRESS SUPPORTERS
(will be acknowledged at the meeting)
CONGRESS AFFILIATES
Schizophrenia Research Forum (SRF)
Schizophrenia International Research Society (SIRS)
CONGRESS SATELLITE MEETINGS
University of Miami
U Miami- International Congress Cognition Satellite Meeting
International Prodromal Research Network (IPRN)
IPRN - International Congress Prodromal Satellite Meeting
International Forum on Treatment of Schizophrenia
Clinical Update on Advances in Treatment of Schizophrenia
Family Forum
SCIENCE TO SERVICES: Progress in Schizophrenia Research from Around the Globe
SOCIAL EVENTS
Sunday 21 April 2013
OPENING RECEPTION
6:00 pm – 9:00 pm
Valencia Terrace
Name Badge Required
Tuesday 23 April 2013
HAVANA: HOT! HOT! HOT!
7:00 pm – 10:00 pm
Lazy River Fire Pit Poolside
Ticketed Event (ALL TICKETS MUST BE PURCHASED IN A DVANCE)
YOUNG INVESTIGATOR EVENTS
Monday 22 April 2013
7:00 am – 8:00 am
Mediterranean Porte-Cochere
YOUNG INVESTIGATOR MENTOR MEETUP
1:00 pm – 2:00 pm
Citrus Garden
YOUNG INVESTIGATOR’S LUNCHEON AND AWARD PRESENTATIONS
Tuesday, Wednesday, Thursday 23-25 April 2013
YOUNG INVESTIGATOR MENTOR MEETUP
7:00 am – 8:00 am
Mediterranean Porte-Cochere
All Young Investigator Applicants, Awardees, Review Committee Members, and Mentors
are Invited to all Young Investigator Events
YOUNG INVESTIGATOR ALUMNI EVENT
Tuesday 23 April 2013
5:30 pm – 7:00 pm
Citrus Garden
YOUNG INVESTIGATOR ALUMNI REUNION AND RECEPTION
Ticket and Name Badge Required
SPECIALIZED TRACTS
Individual abstracts will be noted with the following symbols:
Comorbid –emphasize drug abuse
Clinical – involve clinical applications
ICOSR13_Program-4 3/27/13 1:24 PM Page 1
INTERNATIONAL CONGRESS ON SCHIZOPHRENIA RESEARCH
April 21–25, 2013
Sunday, April 21, 2013
8:00 am
Registration — Mediterranean Ballroom Prefunction Area
6:00 pm
Opening Reception — Valencia Terrace & Lawn
Comorbid Abstracts
/
Clinical Abstracts
1
Monday, April 22, 2013
7:00 am
7:00 am
Morning Coffee — Mediterranean Ballroom Porte-Cochere
7:00 am
YI Mentor Meetup — Mediterranean Ballroom Porte-Cochere
8:00 am
Opening Remarks — Mediterranean Ballroom Salons 4/5
PLENARY SPEAKER 0422
8:30 am
EPIGENETIC MECHANISMS OF ADDICTION: WHAT WE CAN LEARN ABOUT
MENTAL ILLNESS
Mediterranean Ballroom Salons 4/5
Speaker: Eric J Nestler
9:30 am
Morning Break — Mediterranean Ballroom Prefunction Area
MORNING SYMPOSIUM 1-1
THE EARTH IS NOT FLAT: GRADIENTS IN THE EPIDEMIOLOGY OF
SCHIZOPHRENIA ACROSS THE GLOBE
Mediteranean Ballroom 1
Chair: John J McGrath
Discussant: Robin M Murray
10:00 am
LOW INCIDENCE OF SCHIZOPHRENIA IN ITALY
Alice Mule
10:30 am
THE EPIDEMIOLOGY OF SCHIZOPHRENIA: EXPERIENCE FROM RECENT STUDIES
IN NIGERIA
Oye Gureje
11:00 am
EPIDEMIOLOGY OF SCHIZOPHRENIA IN BRAZIL
Paulo R Menezes
11:30 am
SCHIZOPHRENIA RESEARCH IN INDIA: GAINING MOMENTUM
Rangaswamy Thara
PHARMACOLOGICAL APPROACHES FOR FACILITATING NONPHARMACOLOGICAL TREATMENTS
Palazzo Ballroom A
Chair: Stephen R Marder
Discussant: Sophia Vinogradov
10:00 am
2
PILOT STUDIES OF D-CYCLOSERINE ENHANCEMENT OF CBT & COGNITIVE
REMEDIATION IN SCHIZOPHRENIA
Donald Goff, J Gottleib, C Cather, I Bello
Clinical Abstracts
/
Comorbid Abstracts
10:30 am
FEASIBILITY, SAFETY AND EFFICACY OF THE COMBINATION OF D-SERINE AND
COMPUTERIZED COGNITIVE RETRAINING IN SCHIZOPHRENIA: AN
INTERNATIONAL COLLABORATIVE PILOT STUDY
D C D’Souza, R Radhakrishnan, E Perry, Savita G Bhakta, N Singh, B Pittman, M
Sharma, S Chaturvedi, M Bell, C Andrade
11:00 am
GUANFACINE ENHANCEMENT OF WORKING MEMORY: PROSPECTS FOR
AUGMENTING COGNITIVE REMEDIATION IN THE SCHIZOPHRENIA SPECTRUM
Larry J Siever, M M McClure, L C Zaluda, M Kilmade, A New, D M Barch, F S Graff,
Philip D Harvey
11:30 am
OXYTOCIN AND SOCIAL COGNITION TRAINING IN SCHIZOPHRENIA
Stephen R Marder
NEW FINDINGS FROM COGS AND BSNIP: ENDOPHENOTYPES, HERITABILITY
AND GENOMICS
Palazzo Ballroom D
Chair: David L Braff
Co-Chair: J Sweeney
Discussant: William T Carpenter
10:00 am
ENDOPHENOTYPES OF SCHIZOPHRENIA: MORE OR LESS HERITABLE THAN THE
DISORDER ITSELF IN THE COGS-1 FAMILY STUDY?
Gregory A Light, T A Greenwood, N Swerdlow, David L Braff
10:30 am
FACTOR STRUCTURE AND HERITABILITY OF COGS ENDOPHENOTYPES IN
SCHIZOPHRENIA
Larry J Seidman, G S Hellemann, Keith H Nuechterlein, David L Braff, T A Greenwood,
Kristin Cadenhead, M E Calkins, Robert Freedman, R E Gur, R C Gur, G A Light, A
Olincy, A D Radant, Larry J Siever, J M Silverman, J Sprock, W S Stone, C Sugar, N R
Swerdlow, D W Tsuang, M T Tsuang, Bruce I Turetsky, Michael F Green
11:00 am
MULTIVARIABLE INDICATORS OF DISTINCT AND SHARED HERITABLE DISEASE
RISK FOR SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR DISORDER FAMILIES
Brett A Clementz, Lauren E Ethridge, Jordan P Hamm, James L Reilly, G Thaker,
Cristan F Tamminga, Matcheri Keshavan, Godfrey D Pearlson, J Sweeney
11:30 am
GENETIC UNDERPINNINGS OF CLASSIC AND NOVEL ENDOPHENOTYPES FOR
SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR DISORDER FAMILIES IN THE B-SNIP
STUDY
Godfrey D Pearlson, S Meda, B Narayanan, B Clementz, M Stevens, C Tamminga, J
Sweeney, Matcheri Keshavan, C Berwise, K O’Neil
Comorbid Abstracts
/
Clinical Abstracts
3
22Q11.2 DELETION SYNDROME AS A WINDOW INTO ANOMALOUS
NEURODEVELOPMENT, AUTISM SPECTRUM AND PSYCHOSIS
Palazzo Ballroom E
Chair: Carrie E Bearden
10:00 am
COGNITIVE TRAJECTORIES, AUTISTIC SYMPTOMS & PSYCHOSIS IN
ADOLESCENTS WITH THE 22Q11.2 DELETION SYNDROME; A LONGITUDINAL
STUDY
Jacob A Vorstman, S N Duijff, P W Klaassen, Rene Kahn
10:30 am
LONGITUDINAL TRAJECTORIES OF NEUROANATOMY IN 22Q11.2 DELETION
SYNDROME: CAN WE PREDICT THE SCHIZOPHRENIA PRODROME?
Wendy R Kates, S V Faraone, k M Antshel, W Fremont
11:00 am
PSYCHOSIS-PRONENESS IN 22Q11.2 DELETION SYNDROME: CONVERGENT
BRAIN-BEHAVIOR DYSFUNCTION WITH IDIOPATHIC SCHIZOPHRENIA
Raquel E Gur, D Whinna, M Souders, R C Gur, Monica E Calkins, C Kohler, K
Bormann-Winter, C Conroy, K Ruparel, S Vanderkar, D McDonald-McGinn, E Zackai, B
Emanuel
11:30 am
TRANSCRIPTOME ANALYSIS REVEALS COMMON MOLECULAR PATHWAYS TO
22Q11DS AND IDIOPATHIC NEURODEVELOPMENTAL DISORDERS
Carrie E Bearden, M Jalbrzikowski, M Lazaro, A Huang, G Coppola
THE FUNCTIONAL ROLE OF MIR-137 IN THE ETIOLOGY OF SCHIZOPHRENIA
Palazzo Ballroom F
Chair: Fabio Macciardi
10:00 am
SCHIZOPHRENIA MIR-137 RISK GENOTYPE IS ASSOCIATED WITH DLPFC
HYPERACTIVATION
Theo G van Erp, I Guella, M Vawter, F Torri, Judith M Ford, K O Lim, Juan Bustillo, A
Belger, A Preda, D Nguyen, Jessica Turner, Daniel H Mathalon, Fabio Macciardi,
Steven G Potkin
10:30 am
THE EFFECTS OF A RISK ASSOCIATED MIR137 GENETIC VARIANT ON CORTICAL
FUNCTION IN INDIVIDUALS AT HIGH RAND LOW RISK OF PSYCHOSIS
Stephen M Lawrie, H Whalley
11:00 am
MIR-137 AND THE P300 WAVEFORM IN PATIENTS WITH SCHIZOPHRENIA
Jeroen Decoster, Marc De Hert, G Nagels, Inez Myin-Germeys, J Peuskens, Jim van
Os, Ruud van Winkel
11:30 am
MICRORNAS AND REGULATION OF GENE EXPRESSION IN SCHIZOPHRENIA
Steven G Potkin, I Guella, Marquis P Vawter, F Torri, A Sequeira, W Bunney, Theo G
van Erp, J Fallon, S Gaudi, Fabio Macciardi
4
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
POSTER PRESENTATIONS
Coquina Ballroom
POSTER SYMPOSIUM 1-1
“FIGHTING THE FIRE” IN THE BRAINS OF PEOPLE WITH SCHIZOPHRENIA
Coquina Ballroom
Chair: Stu Fillman
Poster No.
A
THE NEUROPATHOLOGICAL CONTRIBUTION OF PRENATAL INFLAMMATION TO
SCHIZOPHRENIA
S Giovanoli, Urs Meyer
A
SPECIFICITY OF SEROLOGICALLY DOCUMENTED INFLUENZA TO SCHIZOPHRENIA
Alan S Brown, F A Ennis, Y Bao, M Co, L Shen, C A Schaefer
A
UNDERSTANDING THE ROLE OF NEUROINFLAMMATION IN SCHIZOPHRENIA: HOW
PET CAN HELP
Janine Doorduin, E F de Vries, R A Dierckx, H C Klein
A
ELEVATED CYTOKINES IN BRAIN AND BLOOD DEFINE A SUBGROUP OF PEOPLE WITH
SCHIZOPHRENIA
Cynthia Shannon Weickert, T Weickert, R Lenroot, D Chang, V S Catts, Stu Fillman
IS THE STRIATUM THE POOR COUSIN TO THE PREFRONTAL CORTEX IN RELATION
TO THE NEURAL SUBSTRATE AND COGNITIVE DEFICITS OF SCHIZOPHRENIA?
Coquina Ballroom
Chair: Thomas Weickert
B
FRONTO-STRIATAL INTERACTIONS IN SCHIZOPHRENIA AND THEIR LINK TO
SYMPTOMS: PET AND FMRI FINDINGS
Oliver D Howes
B
REINFORCEMENT LEARNING AND WORKING MEMORY DEFICITS IN SCHIZOPHRENIA
PATIENTS
Florian Schlagenhauf, Anne Pankow, Lorenz Deserno, A Heinz
B
DOPAMINE D2 RECEPTOR IN FRONTO-STRIATAL PATHOLOGY IN SCHIZOPHRENIA: A
SHORT STORY
Cyndi S Weickert, A Vercammen, R Morris, D Rothmond
B
STRIATAL AND CORTICAL DOPAMINE FUNCTION IN A MOUSE MODEL OF THE
COGNITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
Eleanor H Simpson, S Krabbe, J Roeper, E R Kandel
Comorbid Abstracts
/
Clinical Abstracts
5
12:00–
2:30 p.m.
Coquina Ballroom
STAGING OF PROGRESSION IN SCHIZOPHRENIA IN THE BOSTON CIDAR: FROM
PHENOTYPE TO GENOTYPE
Coquina Ballroom
Chair: Tracey Petryshen,
Co-Chair: Martha Shenton,
Discussant: Tsung-Ung W Woo
C
PROGRESSION OF NEUROCOGNITIVE IMPAIRMENT FROM AT-RISK TO CHRONIC
PHASES OF SCHIZOPHRENIA IN THE BOSTON CIDAR STUDY
Larry J Seidman, Raquelle I Mesholam-Gately, Sarah E Bergen, W Stone, Joanne D Wojcik,
K Woodberry, A Cousins, M Friedman-Yakoobian, A Giuliano, A Gnong-Granato, J
Rodenheiser-Hill, S Hornbach, G Francis, C Pilo, Lauren E Gibson, R Serur, G Min, S
Hallinan, J Frazier, Matcheri Keshavan, Jill M Goldstein, M Shenton, Tracey Petryshen,
Tsung-Ung W Woo, Robert McCarley
C
SEX DIFFERENCES IN THE DEVELOPMENTAL TRAJECTORY OF VERBAL MEMORY
DEFICITS IN SCHIZOPHRENIA
Jill M Goldstein, B Abbs, H Thermenos, R Juelich, J Longenecker, R Mesholam-Gately, K
Woodbury, M Shenton, Robert McCarley, Larry J Seidman
C
ABNORMAL AUDITORY AND VISUAL EVENT-RELATED POTENTIALS IN PRODROMAL
AND FIRST EPISODE SCHIZOPHRENIA SUBJECTS AND THEIR CLINICAL CORRELATES
Robert McCarley, E Del Re, N Oribe, Y Hirano, K Spencer, M Niznikiewicz
C
GENETIC DETERMINANTS OF ABNORMALITIES IN BRAIN FUNCTION IN
SCHIZOPHRENIA
Tracey Petryshen, S Bergen, R Mesholam-Gately, Elisabetta del Re, S Purcell, Larry J
Seidman, Robert McCarley
SUGAR-COATED NEURONS: THE ROLE OF EXTRACELLULAR MATRIX IN
SCHIZOPHRENIA
Coquina Ballroom
Chair: Sabina Berretta
D
RECENT ADVANCES IN BRAIN EXTRACELLULAR MATRIX PHYSIOLOGY AND
PATHOLOGY
Jessica C Kwok, J Fawcett
D
PERINEURONAL NET ABNORMALITIES IN SCHIZOPHRENIA
Sabina Berretta, H Pantazopoulos, A Wallin
D
THE PERINEURONAL NET PROTECTS FAST-SPIKING PARVALBUMINE INTERNEURONS
AGAINST OXIDATIVE STRESS
K Q Do, J H Cabungcal, H Morishita, M Cuenod, T Hensch, P Steullet
D
PERINEURONAL NETS IN CORTICAL CIRCUIT PLASTICITY / STABILITY
Takao Hensch
6
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
PERSPECTIVES ON SOCIAL ADVERSITY AND PSYCHOSIS
Coquina Ballroom
Chair: Vera A Morgan,
Discussant: E Susser
E
TRAUMA, LIFE EVENTS AND PSYCHOSIS: EVIDENCE OF SYNERGISTIC EFFECTS
FROM THE SELCOH STUDY
Craig Morgan, S Frissa, M Verdecchia, R Stewart, N T Fear, A Reichenberg, M Hotopf, S L
Hatch
E
PSYCHOTIC-LIKE EXPERIENCES AND CUMULATIVE SOCIAL DISADVANTAGE IN A
MULTI-ETHNIC POPULATION-BASED ADOLESCENT SAMPLE
Wim Veling, M Adriaanse
E
CHILDHOOD TRAUMA AND PSYCHOTIC SYMPTOMS – CAUSE, EFFECT AND
DIRECTIONALITY: RESULTS FROM A PROSPECTIVE COHORT STUDY
Mary Cannon, H Keeley, P Corcoran, C Wasserman, V Carli, M Sarchiapone, C Hoven, D
Wasserman, I Kelleher
E
THE ASSOCIATION BETWEEN SOCIAL ADVERSITY AND PSYCHOSIS IN A WHOLE-OFPOPULATION COHORT OF HIGH RISK OFFSPRING OF MOTHERS WITH PSYCHOTIC
DISORDERS
Vera A Morgan, P Di Prinzio, S Shah, G Valuri, M Croft, A Jablensky
TESTOSTERONE AS A TRIGGER FOR SCHIZOPHRENIA
Coquina Ballroom
Chair: Tertia Purves-Tyson,
Co-Chair: Cyndi S Weickert
F
TESTOSTERONE POTENTIATES DOPAMINE SIGNALING IN THE ADOLESCENT MALE
RAT NIGROSTRIATAL PATHWAY
Tertia Purves-Tyson, K L Double, S Owens, D Handelsman, C Shannon Weickert
F
ROLE OF TESTOSTERONE IN BEHAVIOURAL ANIMAL MODELS OF SCHIZOPHRENIA
Maarten van den Buuse, A Gogos, R Hill
F
TESTOSTERONE INFLUENCES COGNITION AND BRAIN ACTIVITY IN MEN WITH
SCHIZOPHRENIA
Thomas Weickert, M Kyaw, L T Moore, R Morris, A Vercammen
F
ANTIPSYCHOTIC-LIKE POTENTIAL OF ANTIANDROGENIC DRUGS: MECHANISMS OF
ACTION AND THERAPEUTIC PERSPECTIVES
Marco Bortolato, R Frau, V Bini, P Devoto
Comorbid Abstracts
/
Clinical Abstracts
7
12:00–
2:30 p.m.
Coquina Ballroom
THE SOCIAL NEUROSCIENCE OF EMPATHY IN SCHIZOPHRENIA
Coquina Ballroom
Chair: Matthew J Smith,
Discussant: Morris D Bell
G
EMPATHY IN SCHIZOPHRENIA: EVIDENCE FROM EVENT-RELATED POTENTIALS (ERPS)
AND BEHAVIORAL MEASURES
Silvia Corbera, Morris D Bell, B E Wexler
G
EMPATHY AND THE MIRROR NEURON SYSTEM IN SCHIZOPHRENIA: AN EVALUATION
OF EEG MU WAVE SUPPRESSION
William P Horan, J Pineda, M Iacoboni, J Wynn, Michael F Green
G
ALTERATIONS IN EMPATHY AND ASSOCIATED BRAIN ACTIVATION ARE RELATED TO
FUNCTIONAL OUTCOME IN SCHIZOPHRENIA
Matthew J Smith, M P Schroeder, Samantha V Abram, M B Goldman, B Derntl, U Habel, J
Decety, J G Csernansky, H C Breiter
G
NEURAL MECHANISMS THAT SUPPORT SOCIAL RELATIONSHIPS IN SCHIZOPHRENIA
AND CLINICAL HIGH RISK
Christine Hooker, S H Lincoln, L M Tully, C Carey
SCHIZOPHRENIA AND THE ENDOCANNABINOID SYSTEM
Coquina Ballroom
Chair: Akira Sawa
H
THE ENDOCANNABINOID SYSTEM IN SCHIZOPHRENIA: WHY WE NEED TO PAY
ATTENTION
Daniele Piomelli
H
CANNABIS RECEPTORS TYPE 1 AND SCHIZOPHRENIA NEGATIVE SYMPTOMS
Dean Wong
H
CANNABIS RECEPTORS AND OXIDATIVE STRESS IN SCHIZOPHRENIA: PET/MRS
STUDY
Nicola Cascella
H
THE ENDOCANNABINOID SYSTEM IN SCHIZOPHRENIA – A MECHANISTICALLY NEW
APPROACH TO ITS PATHOPHYSIOLOGY AND TREATMENT
Marcus Leweke
8
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
POSTER SESSIONS
ABSTRACT CATEGORIES: CLINICAL NEUROPSYCHOLOGY; FUNCTIONAL & PSYCHOSOCIAL
OUTCOMES
001
EFFECTS OF YOGA ON COGNITION, GLUCOCORTICOID RECEPTOR, PSYCHIATRIC
SYMPTOMS, WEIGHT AND METABOLIC CHANGES IN CHRONIC SCHIZOPHRENIC
PATIENTS
Robert C Smith, S Boules, L Maayan, R Brown, P Gerbarg, M Mathew, E Visceglia, H
Sershen, a Lajtha, J Auta, A Guidotti, J M Davis
002
THE UNRELIABILITY OF RELIABILITY STATISTICS: A PRIMER ON CALCULATING
INTERRATER RELIABILITY IN CNS CLINICAL TRIALS
Danielle Popp, C H Mallinckrodt, Janet B Williams, M J Detke
003
COGNITIVE DEFICITS IN FIRST-EPISODE ANTIPSYCHOTIC-NAIVE SCHIZOPHRENIA
PATIENTS AT BASELINE AND AFTER 6 MONTHS OF AMISULPRIDE/ARIPIPRAZOLE
TREATMENT
Maria H Jensen, B Y Glenthøj, M Ø Nielsen, S Wulff, B Fagerlund
004
MOTIVATIONAL DEFICITS PRIOR TO THE ONSET OF PSYCHOSIS
Danielle Schlosser, Melissa Fisher, David Gard, Rachel Loewy, Sophia Vinogradov
006
HOW DOES THEORY OF MIND CHANGE WITH AGEING IN SCHIZOPHRENIA?
Aurélie Lagodka, T Gallarda, M C Bourdel, R Gadel, M Champagne, D Willard, J P Olié, R
Gaillard, M O Krebs, I Amado
007
FAMILY-BASED ANALYSIS ON IQ CHANGE IN NON-AFFECTIVE PSYCHOSIS
Neeltje van Haren, D van Dam, C Simons, P Quee
008
HIGH WORKING MEMORY LOAD INHIBITION OF IMPLICIT EMOTIONAL INTERFERENCE
CORRELATES WITH NEGATIVE SYMPTOMS AND FUNCTIONAL DISABILITY IN
SCHIZOPHRENIA
Quintino R Mano
009
SET SHIFTING DEFICITS ON CANTAB IED SET SHIFTING TASK IN 125 ANTIPSYCHOTICNAïVE, FIRST-EPISODE SCHIZOPHRENIA PATIENTS
Birgitte Fagerlund, Maria H Jensen, R Andersen, Bjørn H Ebdrup, Bob Oranje, A Gade, E L
Mortensen, B Y Glenthøj
010
COMMUNITY OUTCOME IN COGNITIVELY NORMAL SCHIZOPHRENIA PATIENTS
Eva Muharib, Walter Heinrichs, Stephanie McDermid Vaz, Ashley A Miles, Narmeen Ammari
011
ABERRANT PATTERNS OF VISUAL FACIAL INFORMATION USAGE IN SCHIZOPHRENIA
Cameron M Clark, V M Goghari, F Gosselin
Comorbid Abstracts
/
Clinical Abstracts
9
12:00–
2:30 p.m.
Coquina Ballroom
012
PERIPHERAL VASOPRESSIN BUT NOT OXYTOCIN RELATES TO SEVERITY OF ACUTE
PSYCHOSIS IN WOMEN WITH ACUTELY-ILL UNTREATED FIRST-EPISODE PSYCHOSIS
Leah H Rubin, C S Carter, J R Bishop, H Pournajafi-Nazarloo, M S Harris, S K Hill, J L Reilly,
J A Sweeney
013
LOW AND HIGH BIRTH WEIGHT ASSOCIATE WITH COGNITIVE IMPAIRMENT IN
PERSONS WITH SCHIZOPHRENIA AND THEIR FIRST-DEGREE RELATIVES
Minna Torniainen, A Wegelius, A Tuulio-Henriksson, J Lönnqvist, Jaana Suvisaari
014
DISJUNCTION OF CURRENT-NONCURRENT EMOTIONAL EXPERIENCE IN RECENTONSET SCHIZOPHRENIA BUT NOT IN ULTRA-HIGH RISK FOR PSYCHOSIS
Suk Kyoon An, K Jhung, J Park, Y Song, C Lee
015
PERFORMANCE ON DIGIT SYMBOL CODING TASKS IN SCHIZOPHRENIA PATIENTS
WITH HIGH AND LOW APATHY
Claire Kos, J Dlabac-de Lange, Leonie Bais, L van der Meer, R Knegtering, Andre Aleman
016
PREDICTORS OF IMPROVEMENT FOLLOWING COGNITIVE REMEDIATION IN PATIENTS
WITH SCHIZOPHRENIA
Jean-Pierre Lindenmayer, Anzalee Khan, Susan R McGurk, Saurabh Kaushik, A Thanju, Z
Taufiq
017
COMPUTERIZED ANALYSIS OF NATURAL SPEECH REVEALS NEUROCOGNITIVE
UNDERPINNINGS FOR ALOGIA BUT NOT BLUNTED AFFECT IN SEVERE MENTAL
ILLNESS
Alex S Cohen
018
THEORY OF MIND ABILITIES IN SCHIZOPHRENIA: A FAMILY STUDY
Briana Cassetta, Vina Goghari
019
A PILOT STUDY OF COGNITIVE ADAPTATION TRAINING AS A NURSING INTERVENTION
IN SCHIZOPHRENIA INPATIENTS
Annemarie P Stiekema, P J Quee, H Schneider, S van Slogteren, D Wiersma, D I Velligan, R
Bruggeman
020
PERSONALITY TRAITS OF ULTRA-HIGH RISK FOR PSYCHOSIS AND FIRST-EPISODE
SCHIZOPHRENIA
Yun Young Song, J Kang, S Lee, E Lee, S An
021
COMPARATIVE VALIDATION OF THE ISST-PLUS, THE S-STS, AND THE C-SSRS FOR
ASSESSING SUICIDAL THINKING AND BEHAVIOR
Larry Alphs, D V Sheehan, L Mao, Q Li, R May, E Hammond, C McCullumsmith, X Li, D
Williamson
022
ITEM RESPONSE ANALYSIS OF THE FIVE FACTOR STRUCTURE OF THE POSITIVE AND
NEGATIVE SYNDROME SCALE
Anzalee Khan, Philip D Harvey, Christian Yavorsky, Mark G Opler, Jean-Pierre Lindenmayer,
B Rothman
10
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
023
AFFECTIVE PROSODY IN PSYCHOSIS: RECENT EVIDENCE AND FUTURE DIRECTIONS
Susan Rossell, T van Rheenen, C Groot, A Gogos, N Joshua, A O’Regan
024
BILATERAL HEARING IMPAIRMENT IN CHILDHOOD PREDICTS PSYCHOSIS 40-YEARS
LATER
Brandon Abbs, S Cherkerzian, N Makris, S Buka, Larry J Seidman, J M Goldstein
025
THE “GLOBAL” COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA: FORGOTTEN BUT NOT
GONE
Dwight Dickinson, Jonathan Schaefer, Daniel R Weinberger
026
COMPARING THE NEUROCOGNITIVE PERFORMANCE OF STUDENTS WITH HIGH
SCHIZOTYPAL TRAITS TO THOSE WITH AND WITHOUT A LEARNING DISORDER
Michael Grossman, A Harrison, Christopher R Bowie
027
NORMAL-RANGE COGNITION DEFINED BY THE MATRICS CONSENSUS COGNITIVE
BATTERY (MCCB) IN SCHIZOPHRENIA
Walter Heinrichs, G Hall, Stephanie McDermid Vaz, N Ammari, J Curno, Ashley A Miles, E
Muharib, F Pinnock, J Goldberg, B Frey
028
THE RELATIONSHIP BETWEEN CORTISOL AND COGNITIVE FUNCTIONS IN
INDIVIDUALS AT CLINICAL HIGH-RISK OF DEVELOPING PSYCHOSIS
Daniel I Shapiro, Larry J Seidman, Jean Addington, Kristin Cadenhead, Tyrone Cannon, B A
Cornblatt, T H McGlashan, D O Perkins, M T Tsuang, Scott W Woods, Elaine F Walker
029
CAN NEUROPSYCHOLOGICAL PROFILE PREDICT CO-MORBID TRAUMATIC BRAIN
INJURY AND PSYCHOSIS?
Rachel A Batty, S L Rossell, N Thomas, A Francis, M Hopwood
030
NEUROCOGNITION IN CLINICAL HIGH RISK YOUNG ADULTS WHO DID OR DID NOT
CONVERT TO A FIRST SCHIZOPHRENIC PSYCHOSIS : A META-ANALYSIS
Amber De Herdt, M Wampers, D Vancampfort, M De Hert, L Vanhees, H Demunter, L Van
Bouwel, E Brunner, M Probst
031
DEVELOPMENT OF BRIEF VERSIONS OF THE WECHSLER INTELLIGENCE SCALE FOR
SCHIZOPHRENIA
Chika Sumiyoshi, M Uetsuki, M Suga, K Kasai, T Sumiyoshi
032
STABILITY AND CHANGE IN SYMPTOMS, COGNITION, AND COMMUNITY OUTCOME IN
SCHIZOPHRENIA
Ashley A Miles, Walter Heinrichs, Narmeen Ammari, J Goldberg, Stephanie McDermid Vaz
033
THE PSYCHOSIS CONTINUUM: EVIDENCES IN VERY EARLY ONSET SCHIZOPHRENIA,
SCHIZOAFFECTIVE AND BIPOLAR DISORDER FOR LANGUAGE AND THOUGHT
DISORDERS
Telma Pantano, C B Martins, Helio Elkis
Comorbid Abstracts
/
Clinical Abstracts
11
12:00–
2:30 p.m.
Coquina Ballroom
034
JUMPING TO CONCLUSIONS AND PSYCHOSIS
Maria A Falcone, B Wiffen, J O’Connor, A Kolliakou, H Taylor, M Russo, S Pintore, S Stilo, A
Paparelli, Marta M Di Forti, D Freeman, Robin M Murray, S Jolley
035
COGNITION AND CORTICAL THICKNESS ACROSS INTELLECTUAL ABILITY PATTERNS
IN SCHIZOPHRENIA
Narmeen Ammari, Walter Heinrichs, Ashley A Miles, Stephanie McDermid Vaz
036
THE ROLE OF LOWER ORDER COGNITIVE SKILLS ON EXECUTIVE DYSFUNCTION IN
SCHIZOPHRENIA
Erica Neill, S L Rossell
037
DIMINISHED RANGE OF EMOTION RESPONSES TO NEGATIVE ODORANTS IN
SCHIZOPHRENIA
Julie W Messinger, N Aujero, K McMahon, P Wong, P M Ramirez, L Opler, Dolores
Malaspina
038
STAGING OF OLFACTORY FUNCTIONING FROM AT-RISK TO CHRONIC PHASES OF
SCHIZOPHRENIA IN THE BOSTON CIDAR STUDY
Raquelle I Mesholam-Gately, S B Hallinan, S Hornbach, W S Stone, G Francis, C Pilo,
Lauren E Gibson, Joanne D Wojcik, K Woodberry, A Cousins, M Friedman-Yakoobian, A J
Giuliano, A Gnong-Granato, J Rosenheiser-Hill, R Serur, G Min, Matcheri Keshavan, Jill M
Goldstein, M Shenton, Tracey Petryshen, Sarah E Bergen, Tsung-Ung W Woo, Robert
McCarley, Larry J Seidman
039
STROOP TASK PERFORMANCE IN VIOLENT AND NON-VIOLENT PATIENTS WITH
SCHIZOPHRENIA
Stephanie Harris, Avi Reichenberg, D Murphy, Marco Picchioni
040
VISUAL COGNITION: A DIMENSIONAL MODEL FOR SCHIZOPHRENIA
Steffen Landgraf, Isabelle Amado, Marie-Odile Krebs, Elke van der Meer
041
SCHIZOTYPAL TRAITS AND THEIR RELATIONSHIP WITH ATTENTION AND WORKING
MEMORY ACROSS HEALTHY CONTROL AND SCHIZOPHRENIA GROUPS
Margaret T Nelson, L J Phillips, C Pantelis, M L Seal
042
QUANTIFYING COGNITIVE IMPAIRMENT IN RECENT-ONSET SCHIZOPHRENIA USING
THE MATRICS CONSENSUS COGNITIVE BATTERY (MCCB)
Amanda McCleery, Joseph Ventura, R S Kern, K L Subotnik, Denise Gretchen-Doorly, Keith
H Nuechterlein
043
THEORY OF COGNITIVE ABILITY IN SCHIZOPHRENIA: IMPLICATIONS FOR COGNITIVE
REMEDIATION
Ali Saperstein, Alice Medalia
044
THE EFFECT OF REBOXETINE AND HALOPERIDOL ON PREPULSE INHIBITION OF THE
STARTLE RESPONSE IN HEALTHY VOLUNTEERS
Louise Witten, B Glenthøj, A Mørk, J F Bastlund, B Steiniger-Brach, Bob Oranje
12
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
045
FACIAL AFFECT RECOGNITION IN YOUNG PATIENTS WITH FIRST-EPISODE, EARLYONSET PSYCHOSIS OR SCHIZOTYPAL DISORDER
Jens Richardt M Jepsen, B Fagerlund, A K Pagsberg, A M Christensen, Merete Nordentoft,
E L Mortensen
046
IMPAIRED, INTACT AND ENHANCED VISUOSPATIAL FUNCTIONS IN SCHIZOPHRENIA
AND THE IMPLICATION FOR PARIETAL ABNORMALITIES
Taylor L Benson, Sohee Park
048
EPISODIC FUTURE THINKING IN SCHIZOPHRENIA
Ya Wang, Y Wang, Q Zhao, C Yan, J Cui, X Hong, D Shum, Raymond C Chan
049
RELIEF OF CANNABIS WITHDRAWAL SYMPTOMS AND TYPES OF CANNABIS QUITTING
STRATEGIES IN PEOPLE WITH SCHIZOPHRENIA
Maju M Koola, Douglas Boggs, Deanna L Kelly, Fang Liu, Jared Linthicum, Hailey Turner,
Robert McMahon, David Gorelick
050
EFFECT OF CANNABIS USE ON THE COURSE OF SCHIZOPHRENIA IN MALE
PATIENTS: A PROSPECTIVE COHORT STUDY
Daniel van Dijk, M Koeter, Rene Kahn, R Hijman, W van den Brink
051
REASONS FOR CANNABIS USE IN FIRST-EPISODE PSYCHOSIS
Anna Kolliakou, H Sallis, C Joseph, J O’Connor, C Gayer-Anderson, A M Falcone, B Wiffen,
A Paparelli, G McQueen, H Taylor, M Di Forti, Z Atakan, K Ismail, R M Murray
052
IMPACT OF CANNABIS USE ON SYMPTOMS, FUNCTIONING, NEUROCOGNITION AND
CONVERSION TO PSYCHOSIS IN THREE HIGH-RISK SAMPLES
Andrea Auther, Ricardo E Carrion, D McLaughlin, B Cornblatt
053
TRAIT ANXIETY MEDIATES THE ASSOCIATION BETWEEN CANNABIS AND RISK OF
PSYCHOSIS
Lauren E Lombardo, R G Heimberg, D Anglin, A M Fineberg, Lauren E Gibson, C M Puleo,
Lauren M Ellman
054
REDUCING SELF-STIGMA TOWARD HELP-SEEKING IN HIGH SCHOOL YOUTH:
EFFECTS OF CLASSROOM PSYCHO-EDUCATION ABOUT SCHIZOPHRENIA AND
MENTAL ILLNESS
Rebecca Young, Leah I Hartman, N M Michel, A Winter, G L Flett, J O Goldberg
055
CYBERBULLYING, CHILDHOOD TRAUMA AND CLINICAL HIGH RISK OF PSYCHOSIS
Emilie Magaud, Karissa Nyman, Jean Addington
056
REDUCING STIGMA OF SCHIZOPHRENIA AMONG HIGH SCHOOL YOUTH: WHO
BENEFITS MOST FROM PSYCHO-EDUCATION?
Leah I Hartman, N M Michel, A Winter, R E Young, G L Flett, J O Goldberg
057
DO DISCRIMINATION AND VICTIMISATION LEAD TO MORE SELF-STIGMA AMONG
PEOPLE WITH PSYCHOTIC DISORDERS?
Ellen Horsselenberg, M Pijnenborg, Andre Aleman, J van Busschbach
Comorbid Abstracts
/
Clinical Abstracts
13
12:00–
2:30 p.m.
Coquina Ballroom
058
STEREOTYPE AWARENESS AND CHILDHOOD TRAUMA IN PEOPLE WITH
SCHIZOPHRENIA AND THEIR SIBLINGS
Catherine van Zelst, P Delespaul for GROUP
059
CHILDHOOD ADVERSITY AND SCHIZOTYPAL TRAITS: PRELIMINARY FINDINGS FROM
THE EU-GEI FIRST-EPISODE PSYCHOSIS CASE-CONTROL STUDY
Tjasa / Velikonja, K Hubbard, R Murray, R Handley, V Mondelli, M Di Forti, S Johnson, O
Mason, C Pariante, P Dazzan, H Fisher, C Morgan
060
SCHIZOPHRENIA CLINICAL SYMPTOM DIFFERENCES IN WOMEN VS. MEN WITH AND
WITHOUT A HISTORY OF CHILDHOOD PHYSICAL ABUSE
Deanna L Kelly, K Sullivan, Amber K Earl, V Stock, H Raley, D Warfel, L Rowland, J Jackson,
F Liu, Stephanie M Feldman, Heidi J Wehring, Kimberly R Warren, M M Koola, R P
McMahon
061
STRESS SENSITIVITY AND TRAUMA EXPOSURE: MEDIATION AND INCREASED ODDS
FOR CLINICAL HIGH RISK FOR PSYCHOSIS
Lauren E Gibson, D Anglin, J Klugman, A Fineberg, Lauren E Lombardo, C Puleo, Lauren
M Ellman
062
IS CHILDHOOD ADVERSITY ASSOCIATED WITH THE CLINICAL AND SOCIAL COURSE
OF SCHIZOPHRENIA? PRELIMINARY DATA FROM A ONE YEAR FOLLOW-UP STUDY
Antonella Trotta, J O’Connor, Marta M Di Forti, Paola Dazzan, C Pariante, Anthony S David,
Robin M Murray, H Fisher
063
REDUCED CORTISOL LEVELS DURING PSYCHOSOCIAL STRESS TASK IN INDIVIDUALS
AT HIGH RISK FOR PSYCHOSIS
Marita Pruessner, L Bechard-Evans, L Boekestyn, K Faridi, J C Pruessner, R Joober, A K
Malla
064
PREDICTORS OF DEVELOPING A PSYCHOSIS RISK SYNDROME IN YOUTH AT FAMILY
HIGH RISK OF DEVELOPING PSYCHOSIS
Jacqueline Stowkowy, J Addington
065
COGNITION AS A PREDICTOR OF FUNCTIONAL OUTCOME IN YOUTH AT FAMILIAL
HIGH RISK FOR SCHIZOPHRENIA
Summer A McKnight, Shaun M Eack, Matcheri Keshavan, D Montrose, D Mermon, J
Miewald
066
OUTCOMES OF EARLY TREATMENT IN YOUNG ADULTS WITH FIRST EPISODE
PSYCHOSIS AND AT HIGH RISK OF DEVELOPING PSYCHOSIS
Helen Lee, L Poon
067
VALIDATION OF THE GLOBAL FUNCTIONING ROLE/SOCIAL IN A CLINICAL SAMPLE OF
ADOLESCENTS
Camille Wilson, C Schimunek, E Kline, S Ereshefsky, D Denenny, E Thompson, T Tsuji, G
Epstein, S Pirmohamed, K Bussell, G Reeves, J Schiffman
14
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
068
A PROSPECTIVE, DESCRIPTIVE STUDY OF INDIVIDUALS WITH AT-RISK MENTAL STATE
FOR PSYCHOSIS RECEIVING PSYCHOTHERAPY IN SINGAPORE
Eugene Tay
069
COGNITIVE AND CLINICAL PREDICTORS OF FUNCTIONAL CAPACITY AND REALWORLD FUNCTIONING IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA
Lone Vesterager, Torben Christensen, Birthe Olsen, Marianne Melau, Gertrud Krarup, Hysse
Forchhammer, Merete Nordentoft
070
A FIRST EPISODE STUDY OF TRAJECTORIES OF PREMORBID CHILDHOOD AND
ADOLESCENT PSYCHOSOCIAL DEVELOPMENT IN SCHIZOPHRENIA
Leslie E Horton, Sarah I Tarbox, Thomas M Olino, Gretchen L Haas
071
WHITE AND AFRICAN AMERICAN FIRST EPISODE PSYCHOTIC PATIENTS: CULTURALLY
RELEVANT SYMPTOMS AND PATHWAYS TO CARE
Huijun Li, G Singleton, G Min, Larry J Seidman
072
NEUROCOGNITION, THEORY OF MIND, AND NEGATIVE SYMPTOMS ARE RELATED TO
FUNCTIONING IN FIRST-EPISODE SCHIZOPHRENIA
Joseph Ventura, Kenneth L Subotnik, Denise Gretchen-Doorly, A Ered, S A Wilson, Keith H
Nuechterlein
073
PREDICTORS OF SOCIAL AND ROLE FUNCTIONING IN PEOPLE AT HIGH RISK FOR
PSYCHOSIS, FIRST EPISODE OF SCHIZOPHRENIA, AND HEALTHY CONTROLS
Joanne D Wojcik, R I Mesholam-Gately, K A Woodberry, A Cousins, A Gnong-Granato, M
Friedman-Yakoobian, J Rodenheiser-Hill, Matcheri Keshavan, S Hornbach, R Serur, G Min,
Lauren E Gibson, G Francis, J Frazier, T Petryshen, W Woo, Jill M Goldstein, M Shenton,
Robert McCarley, Larry J Seidman
074
THE ASSOCIATION BETWEEN WORKING ALLIANCE, COMPLIANCE, SELF-EFFICACY
AND SOCIAL FUNCTION IN A COHORT OF 400 PATIENTS WITH FIRST-EPISODE
PSYCHOSIS
Marianne Melau, S Harder, Pia Jeppesen, A Thorup, C Hjortshøj, Merete Nordentoft
075
THE ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS (DUP) AND
LONG-TERM OUTCOME IN SCHIZOPHRENIA. META-ANALYSIS
Matti Penttilä, Noora Hirvonen, Matti K Isohanni, Erika Jääskeläinen, Jouko Miettunen
076
SPEECH PRODUCTION IN SCHIZOTYPY: THE LINK BETWEEN WORKING MEMORY
LOAD AND FUNCTIONING
Kyle S Minor, Alex S Cohen, Anne M Merrill, Theo C Manschreck
077
INTRA-INDIVIDUAL ASSOCIATION OF DAILY HASSLES AND COGNITIVE
PERFORMANCE: IMPLICATIONS FOR SCHIZOTYPY
Emma Walter, E Barkus
078
SCHIZOPHRENIA AND CO-MORBID PERSONALITY DISORDER: A GROUP TREATMENT
Hugo Wolters, Ellen Horsselenberg
Comorbid Abstracts
/
Clinical Abstracts
15
12:00–
2:30 p.m.
Coquina Ballroom
079
INCREMENTAL REAL WORLD VALIDITY OF THE CANADIAN OBJECTIVE ASSESSMENT
OF LIFE SKILLS IN SCHIZOPHRENIA
Stephanie McDermid Vaz, R W Heinrichs, A A Miles, N Ammari, S Archie, E Muharib, N
Michel, J O Goldberg
080
THE CLINICAL, DEMOGRAPHIC AND NEUROPSYCHOLOGICAL CORRELATIONS OF
INSIGHT IN PATIENTS WITH SCHIZOPHRENIA
Ruhollah Hosseini, P Anjedanimoghadamaragh
081
THE CROSS-CULTURAL ASSESSMENT OF FUNCTIONAL OUTCOME IN
SCHIZOPHRENIA
Dawn I Vellgian, Stephen R Marder, J Mintz, M Fredrick, S Dube, N Schooler
082
HETEROGENEITY IN SCHIZOPHRENIA COGNITIVE PROFILES MARKS OUTCOME
TRAJECTORY AND TREATMENT RESPONSE: TRANSLATIONAL IMPLICATIONS FOR
PATIENTS’ EARLY MANAGEMENT AND FOR CLINICAL TRIALS
Michel Maziade, T Paccalet, E Gilbert, N Rouleau, V Jomphe, M A Roy, C Mérette
083
COPING AS A MODERATING FACTOR BETWEEN PSYCHOTIC SYMPTOMS AND
FUNCTIONING IN ADOLESCENTS WITH MENTAL ILLNESS
Johanna Wigman, Ian Kelleher, Nina Devlin, Aileen Murtagh, Carol Fitzpatrick, Mary Cannon
084
A MODEL OF AMOTIVATION IN SCHIZOPHRENIA
Elaina Montague, Amanda Chue, J Choi
085
FUNCTIONAL SKILL ASSESSMENT IN PEOPLE WITH SERIOUS MENTAL ILLNESS:
EXAMINING SKILL KNOWLEDGE, SKILL CAPACITY AND NATURALISTIC SKILL
PERFORMANCE
Melisa Rempfer
086
THE EFFECTIVENESS OF IPS ENHANCED WITH COGNITIVE REMEDIATION AND
SOCIAL SKILLS TRAINING FOR PEOPLE WITH SEVERE MENTAL ILLNESS IN DENMARK:
A RANDOMISED CONTROLLED TRIAL
Thomas N Christensen, Merete Nordentoft
087
THE EFFECTS OF ERRORLESS LEARNING ON COMPETITIVE AND TRANSITIONAL
EMPLOYMENT IN A VA SUPPORTED EMPLOYMENT PROGRAM
Robert S Kern, K M Smith, S S Mitchell, J Iglesias, M Dolinsky, L F Reddy, Michael F Green
088
A RANDOMIZED CLINICAL TRIAL OF COGNITIVE REMEDIATION VERSUS COGNITIVE
BEHAVIORAL THERAPY TECHNIQUES IN VOCATIONAL REHABILITATION FOR ADULTS
WITH SCHIZOPHRENIA SPECTRUM DISORDERS – SAMPLE CHARACTERISTICS OF THE
FIRST 40 PARTICIPANTS IN EACH INTERVENTION
June U Lystad, H C Bull, T Ueland, E Falkum
089
MODEN : A FRENCH INTEGRATIVE REHABILITATION PROGRAM INCLUDING
COGNITIVE REMEDIATION THERAPY, EDUCATIONAL SESSIONS AND SOCIAL SKILLS
FOR PATIENTS WITH SCHISOPHRENIA
Marie-Cecile Bralet, C Hochard, L Kechid, C Gautier, T Lambert, S Orens, L Geret
16
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
090
COMMUNITY BASED SKILLS COACHING FACILITATES FUNCTIONAL IMPROVEMENT IN
PEOPLE WITH SCHIZOPHRENIA
Alice Medalia, K Choi, W Jock, T Herlands
091
ADDRESSING DEFEATIST BELIEFS IN VOCATIONAL REHABILITATION FOR
SCHIZOPHRENIA
Amanda Chue, Paul H Lysaker, Elaina Montague, Jimmy Choi
092
OCCUPATIONAL PROFILE AND DESIRE TO WORK OF PATIENTS WITH SCHIZOPHRENIA
TREATED ON AN OUTPATIENT PROGRAM: PRELIMINARY RESULTS
Larissa C Martini, D Souza, B Petreche, F Santos, A O Silva, P Barbosa, C Attux, R A
Bressan
093
PREDICTING EMPLOYMENT OUTCOMES AMONG VETERANS WITH SCHIZOPHRENIA:
THE IMPORTANCE OF SOCIAL COGNITION
L Felice Reddy, K M Smith, Robert S Kern
094
MONEY FOLLOWS THE PERSON: TRANSITIONING NURSING HOME RESIDENTS TO
INDEPENDENT LIVING
Natalie J Maples, Dawn I Vellgian, D Stoner, A Pittman, X Li, M Gold
095
BURDEN OF DISEASE: FAMILY CAREGIVING OF PATIENTS WITH PREDOMINANT
POSITIVE COMPARED TO PREDOMINANT NEGATIVE SYMPTOMS
Betsy Pohlman, Meryl Brod, Kathleen F Villa
096
BURDEN OF DISEASE: SIMILARITIES AND DIFFERENCES IN PATIENTS WITH
PREDOMINANT POSITIVE COMPARED TO PREDOMINANT NEGATIVE SYMPTOMS
Meryl Brod, Betsy Pohlman, Kathleen F Villa
097
POOR HYGIENE IN SCHIZOPHRENIA AND BIPOLAR DISORDER: HOW DOES IT LIMIT
THE DEPLOYMENT OF FUNCTIONAL SKILLS IN EVERYDAY LIFE?
Maya Gupta, J McGrath, A Pulver, Christopher R Bowie
098
RECOGNIZING SPECIFIC EMOTIONS UNIQUELY CONTRIBUTES TO FUNCTIONAL
OUTCOME IN SCHIZOPHRENIA
Samantha V Abram, Tatiana M Karpouzian, B Derntl, U Habel, J Reilly, Matthew J Smith
099
EMPATHY MEDIATES THE INFLUENCE OF WORKING MEMORY ON FUNCTIONAL
OUTCOME IN SCHIZOPHRENIA
Tatiana M Karpouzian, W P Horan, J M Fox, D J Cobia, H C Breiter, M J Smith
100
DIFFERENTIAL ROLE OF EMOTIONAL CONTEXT PROCESSING IN COMMUNITY
FUNCTIONING IN SCHIZOPHRENIA
Kee-Hong Choi, Myeong Ju Song, Petra Kleinlein
101
NEGATIVE SYMPTOMS AND EMOTIONAL RESPONDING DURING A SOCIAL
AFFILIATION INTERACTION TASK
Lauren Catalano, S G Park, K Llerena, A Malik, M E Bennett, J J Blanchard
Comorbid Abstracts
/
Clinical Abstracts
17
12:00–
2:30 p.m.
Coquina Ballroom
102
IMPACT OF COMORBID SOCIAL ANXIETY DISORDER ON SOCIAL COGNITION AND
REAL-LIFE FUNCTIONING IN PATIENTS WITH RECENT-ONSET SCHIZOPHRENIA
SPECTRUM DISORDERS
Amelie M Achim, M A Lavoie, R Ouellet, C Vallières, P L Jackson, M A Roy
103
FIRST IMPRESSIONS AND IMPLICIT EMOTION RECOGNITION IN SCHIZOPHRENIA
Fabien Tremeau, D Antonius, D C Javitt
104
SOCIAL SKILLS IN PATIENTS WITH SCHIZOPHRENIA, BIPOLAR DISORDERS AND
NORMAL CONTROLS
Helio Elkis
105
SOCIAL SELF-EFFICACY AND ITS RELATION TO SOCIAL COGNITION AND SOCIAL
FUNCTIONAL CAPACITY
Anja Vaskinn, K Sundet, Ingrid Melle, O A Andreassen, T Ueland
106
A STUDY OF THE RELATIONSHIP BETWEEN SELF-REPORT EMPATHY AND
SCHIZOTYPY TRAITS IN A LARGE NON-CLINICAL COLLEGE SAMPLE
Yi Wang, D L Neumann, D Shum, W Liu, H Shi, Chao Yan, Simon S Lui, Q Zhang, Z Li,
Raymond C Chan
107
METACOGNITION AND THE SUBJECTIVE EXPERIENCE OF RECOVERY IN
SCHIZOPHRENIA
Marina Kukla, Paul H Lysaker
108
MENTAL SIMULATION OF POSITIVE OUTCOMES IN PEOPLE WITH SCHIZOPHRENIA:
RELATIONSHIP WITH NEGATIVE SYMPTOMS AND SOCIAL FUNCTIONING
Vyv Huddy, G Drake, T Wykes
109
BUILDING A SOCIAL COGNITION TEST BATTERY FOR USE IN CLINICAL TRAILS: THE
SOCIAL COGNITION PSYCHOMETRIC EVALUATION (SCOPE) STUDY
Amy E Pinkham, B Buck, K Healey, D Penn
110
VALIDATION OF A NOVEL LABORATORY MEASURE OF SOCIAL COGNITION IN
SCHIZOPHRENIA
Gretchen L Haas, Leslie E Horton, J Luther
111
DISCREPANCIES BETWEEN SELF AND CLINICIAN RATINGS OF MOTIVATION AND
PLEASURE IN SCHIZOPHRENIA AND ITS RELATIONSHIP TO DEMOGRAPHIC AND
CLINICAL VARIABLES
Kristen Bradshaw, K Llerena, S G Park, Julie M McCarthy, M E Bennett, J J Blanchard
112
EXERCISE THERAPY TO IMPROVE MENTAL HEALTH IN SCHIZOPHRENIA: A
SYSTEMATIC REVIEW
Markus J Duncan, P Gorczynski, G Faulkner
113
CONDITIONS FOR A HEALTHY LIFESTYLE - FROM THE PERSPECTIVE OF PATIENTS
WITH PSYCHOSIS
Anniqa Foldemo, R Wardig, T Lindstrom, M Bachrach-Lindstrom, S Hultsjo
18
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
114
EVALUATION OF QUALITY OF LIFE, PSYCHOSOCIAL FUNCTIONING, AND MEDICATION
ADHERENCE AMONG PATIENTS SWITCHED TO LURASIDONE FROM OTHER
ANTIPSYCHOTICS
George Awad, Mariam Hassan, Antony Loebel, J Hsu, Krithika Rajagopalan
115
WHY DO SCHIZOPHRENIA PATIENTS DISCONTINUE PSYCHIATRIC TREATMENT?
STUDY FROM A RURAL COMMUNITY OF SOUTHERN INDIA
Naveen Kumar Channaveerachari, K Shanivaram Reddy, J Thirthalli, S Bijjal, N Renuka Devi,
N KrishnaReddy, J Ramakrishna, V Rawat, K Suresha K, B N Gangadhar
116
SHORT- AND LONG-TERM TREATMENT WITH LURASIDONE AND QUETIAPINE XR IN
PATIENTS WITH SCHIZOPHRENIA: EFFECT ON METABOLIC SYNDROME
Jonathan M Meyer, P Werner, J Cucchiaro, R Silva, A Pikalov, J Hsu, F Grossman, Antony
Loebel
117
EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: POOLED ANALYSIS OF THE 5 PANSS
FACTORS IN SHORT-TERM TRIALS
Robert Silva, J Cucchiaro, A Pikalov, Y Mao, P Werner, Antony Loebel, Stephen R Marder
118
EFFECT OF LURASIDONE ON DEPRESSIVE SYMPTOMS IN PATIENTS WITH
SCHIZOPHRENIA
Henry Nasrallah, Peter Werner, A Pikalov, J Hsu, J Cucchiaro, F Grossman, Antony Loebel
119
SWITCHING TO LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: TOLERABILITY AND
EFFECTIVENESS AT 6 WEEKS AND 6 MONTHS
Joseph P McEvoy, Leslie Citrome, J Hsu, Peter Werner, A Pikalov, J Cucchiaro, Antony
Loebel
120
LURASIDONE IN THE TREATMENT OF EARLY-STAGE SCHIZOPHRENIA: A POST-HOC
ANALYSIS OF THREE POOLED ACUTE TREATMENT STUDIES
Jeffrey A Lieberman, A Pikalov, J Hsu, J Cucchiaro, P Werner, F Grossman, Antony Loebel
121
RELAPSE PREVENTION AND REMISSION DURING 12 MONTHS OF DOUBLE-BLIND
TREATMENT WITH LURASIDONE VS. QUETIAPINE XR IN PATIENTS WITH
SCHIZOPHRENIA
Antony Loebel, J Cucchiaro, J Xu, J Hsu, K Sarma, A Pikalov, John M Kane
122
AWARENESS OF ILLNESS AS A PREDICTOR OF COOPERATION WITH COGNITIVE
ASSESSMENTS AND COGNITIVE BENEFITS OF ATYPICAL ANTIPSYCHOTIC
MEDICATION
Philip D Harvey, C Siu, A Loebel, J Cucchiaro, A Pikalov
123
IS THERE AN OVERLAP IN THE DOMAIN OF THEORY OF MIND BETWEEN AUTISM
SPECTRUM DISORDERS AND SCHIZOPHRENIA SPECTRUM DISORDERS? EXPLORING
QUALITATIVE DIFFERENCES
Leticia Boada, Guillermo Lahera, Ángel del Rey-Mejías, Celso Arango, Mara Parellada
Comorbid Abstracts
/
Clinical Abstracts
19
12:00–
2:30 p.m.
Coquina Ballroom
124
COMMON AND SPECIFIC COGNITIVE DEFICITS IN SCHIZOPHRENIA: RELATIONSHIPS
TO FUNCTION
Julia M Sheffield, James M Gold, J Daniel Ragland, Cameron Carter, Angus W MacDonald,
Steven M Silverstein, Milton Strauss, Deanna M Barch
125
USING ARTIFICIAL NEURAL NETWORKS TO PREDICT THE PROBABILITY OF
TREATMENT OBSERVANCE DURING ADAPTED PHYSICAL ACTIVITY
Yvonne N Delevoye-Turrell, Mauraine Carlier, Olivia Carlton, Brigitte Mainguet
126
INTACT VISUOSPATIAL MANIPULATION AND REDUCED WORKING MEMORY IN
SCHIZOPHRENIA: IMPLICATION FOR INTACT PARIETAL BUT IMPAIRED FRONTAL
SYSTEMS
Channing Cochran, Lindsey G. McIntosh, Sohee Park
127
SMOKING STATUS, COGNITION AND NEUROBIOLOGY IN SCHIZOPHRENIA
Farena Pinnock, Walter Heinrichs, Narmeen Ammari, Leah I Hartman, Geoffrey Hall
128
THE PROSPECTIVE ASSOCIATION OF MOTIVATIONAL DEFICITS AND PSYCHOSOCIAL
IMPAIRMENT IN INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
Daniel Fulford, Barbara K Stuart, Daniel H Mathalon, Sophia Vinogradov, Rachel Loewy
129
MECHANISMS OF FUNCTIONAL RECOVERY IN COGNITIVE THERAPY FOR
SCHIZOPHRENIA PATIENTS
Stefanie J Schmidt, Daniel R Mueller, Volker Roder
130
PREVALENCE AND PREDICTORS OF SYMPTOMATIC REMISSION IN COMMUNITYBASED PSYCHOSOCIAL REHABILITATION: THE IMPORTANCE OF SYMPTOMATIC
RESOLUTION FOR SUSTAINED REMISSION OVER TIME
Caroline Lim, Concepcion Barrio, John Brekke
EXAMINING THE DENTATE GYRUS GLUN1 KNOCKOUT MOUSE AS A SCHIZOPHRENIA
PSYCHOSIS MODEL
Masaya Yanagi, J Lister, S Southcott, I Lee, J Perez, W Li, C Meyer, K Gleason, Ana D Stan,
Subroto Ghose, S Birnbaum, C Tamminga
20
Clinical Abstracts
/
Comorbid Abstracts
ORAL SESSION 1-1
MARKERS OF VULNERABILITY IN SCHIZOPHRENIA
Palazzo Ballroom A
Chair: Alan S Brown
3:00 pm
DOES SOCIAL DEFEAT MEDIATE THE ASSOCIATION BETWEEN CHILDHOOD
TRAUMA AND PSYCHOSIS? EVIDENCE FROM THE SECOND NETHERLANDS
MENTAL HEALTH SURVEY AND INCIDENCE STUDY
Martine van Nierop, Jim van Os, N Gunther, C van Zelst, R de Graaf, M ten Have, S
van Dorsserlaer, M Bak, Inez Myin-Germeys, Ruud van Winkel
3:15 pm
UNEMPLOYMENT, ETHNICITY AND PSYCHOSIS
Jane Boydell, P Bebbington, V Bhavsar, E Kravariti, J van Os, Robin M Murray, R Dutta
3:30 pm
IMPACT OF ABUSE AND NEGLECT ON EPISODIC MEMORY IMPAIRMENTS IN
CHILDREN AT GENETIC RISK OF SCHIZOPHRENIA
Nicolas Berthelot, T Paccalet, C Mérette, N Rouleau, V Jomphe, E Gilbert, Michel
Maziade
3:45 pm
A DANISH NATIONWIDE STUDY ON THE RISK OF AUTOIMMUNE DISEASES IN
INDIVIDUALS WITH SCHIZOPHRENIA AND IN PERSONS WITH A FAMILY HISTORY
OF SCHIZOPHRENIA
Michael E Benros, Marianne G Pedersen, Helle Rasmussen, William Eaton, Merete
Nordentoft, Preben Mortensen
4:00 pm
SEROLOGICAL PREDICTORS OF MORTALITY IN A PROSPECTIVE SCHIZOPHRENIA
COHORT
Faith Dickerson, C Stallings, A Origoni, C Vaughan, S Khushalani, J Schroeder, R
Yolken
4:15 pm
STEM CELL SIGNALING IN ACUTE RELAPSE OF NON-AFFECTIVE PSYCHOSIS
William D Hill, Brian Miller, G Kondrikova, Peter F Buckley
4:30 pm
EXPLORING ASSOCIATIONS OF SERUM BDNF AND VERBAL LEARNING IN
INDIVIDUALS AT ULTRA HIGH-RISK FOR SCHIZOPHRENIA
Shauna M Overgaard, Brian Ginter, Dan Jensen, Rabindra Tambyraja, S C Schulz
4:45 pm
SPECIFICITY OF MATERNAL TOXOPLASMA GONDII TO RISK OF SCHIZOPHRENIA
IN OFFSPRING
Alan S Brown, J G Montoya, Y Bao, L Shen, C A Schaefer
5:00 pm
EVIDENCE FOR FAMILIAL RISK TO BOTH AUTISM AND PSYCHOSIS
Mary C Clarke, A Tanskanen, M O Huttunen, David R Cotter, Mary Cannon
5:15 pm
PUBERTY, PRUNING, AND SCHIZOTYPY: TOO LITTLE TOO EARLY?
Lindsey G McIntosh, Sohee Park
Comorbid Abstracts
/
Clinical Abstracts
21
ORAL SESSION 1-2
NEW CLINICAL TRIAL AND TRIAL METHODOLOGY RESULTS IN
SCHIZOPHRENIA
Palazzo Ballroom D
Chair: Christoph U Correll
3:00 pm
RECOVERY IN REMITTED FIRST EPISODE PSYCHOSIS AT 7-YEARS OF FOLLOWUP OF EARLY GUIDED DISCONTINUATION OR MAINTENANCE TREATMENT
Lex Wunderink, R M Nieboer, D Wiersma, S Sytema, F J Nienhuis
3:15 pm
ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA: A
DOUBLE-BLIND, RANDOMIZED, NON-INFERIORITY STUDY VS. ORAL
ARIPIPRAZOLE
W Wolfgang Fleischhacker, R Sanchez, P Perry, N Jin, T Peters-Strickland, B R
Johnson, R A Baker, A Eramo, R D McQuade, W H Carson, D Walling, John M Kane
3:30 pm
PROACTIVE (PREVENTING RELAPSE ORAL ANTIPSYCHOTICS COMPARED TO
INJECTABLES EVALUATING EFFICACY): RELAPSE, SYMPTOMS, AND MEDICATION
PROFILES OVER 30 MONTHS OF STUDY
Peter F Buckley, N R Schooler, D Goff, J Hsiao, A Kopelowicz, J Lauriello, T
Manschreck, A Mendelowitz, D Miller, J Severe, D R Wilson, J Mintz, J M Kane
3:45 pm
SPECIFIC EFFICACY OF COGNITIVE BEHAVIORAL THERAPY FOR THE
TREATMENT OF PERSISTENT POSITIVE SYMPTOMS IN SCHIZOPHRENIA
PATIENTS
Stefan Klingberg, A Wittorf, C Meisner, W Wölwer, G Wiedemann, A Bechdolf, J
Herrlich, B Müller, G Sartory, M Wagner, G Buchkremer
4:00 pm
A META-ANALYSIS OF PREFRONTAL RTMS TRIALS FOR NEGATIVE SYMPTOMS IN
SCHIZOPHRENIA: WHAT ARE THE OPTIMAL TREATMENT PARAMETERS?
H Knegtering, J J Dlabac-de Lange, Leonie Bais, A Aleman
4:15 pm
EFFECTS OF LISDEXAMFETAMINE DIMESYLATE IN ADULTS WITH CLINICALLY
STABLE SCHIZOPHRENIA AND PREDOMINANT NEGATIVE SYMPTOMS WITH OR
WITHOUT PROXY DEFICIT SYNDROME: A POST HOC ANALYSIS
Bryan Dirks, J P Lindenmayer, B Scheckner, S James, B Adeyi, C Kirsch, H Nasrallah
4:30 pm
THE EFFECT OF BITOPERTIN, A GLYCINE REUPTAKE INHIBITOR, ON KEY
NEGATIVE SYMPTOM DIMENSIONS AND ASSOCIATION WITH ESTIMATED GLYT1
OCCUPANCY
Daniel Umbricht, E Lentz, J Lalonde, M Martin-Facklam, L Santarelli
4:45 pm
CIRCADIAN RHYTHMS AND COGNITION: ACCOUNTING FOR TIME OF DAY
EFFECTS ENHANCES SIGNAL DETECTION IN CLINICAL TRIALS OF PROCOGNITIVE THERAPIES FOR SCHIZOPHRENIA
Michael R Hufford, V Davis, N Dgetluck, M Gawryl, D Hilt, A Rappaport, Richard Keefe
5:00 pm
ITEM RESPONSE THEORY ANALYSIS OF THE PANSS FROM THE NEWMEDS
REPOSITORY FROM 49 RCT’S
Stephen Z Levine, J Rabinowitz, I Caers, F Mandel, F Ménard, S Kapur
22
Clinical Abstracts
/
Comorbid Abstracts
ORAL SESSION 1-3
IMAGING AND POSTMORTEM CORTICAL ABNORMALITIES IN
SCHIZOPHRENIA: CIRCUITRY, NEUROCHEMISTRY, AND PSYCHOSIS
Palazzo Ballroom E
Chair: Rosalinda C Roberts
3:00 pm
A NOVEL APPROACH TO MEASURE BRAIN GLUTAMATE AND GLUTATHIONE IN
VIVO
S A Wijtenburg, Joshua Chiappelli, L E Hong, E A Spieker, F Gaston, Laura M Rowland
3:15 pm
INVESTIGATION OF N-ACETYL ASPARTATE AS A POTENTIAL BIOMARKER OF
TREATMENT RESISTANT SCHIZOPHRENIA – PRELIMINARY FINDINGS
Meghan E Mcilwain, V M Anderson, R R Kydd, B R Russell
3:30 pm
BIOLOGICAL AND CLINICAL DETERMINANTS OF TREATMENT RESISTANT
SCHIZOPHRENIA
Arsime Demjaha, Oliver D Howes, P K McGuire, S Kapur, Craig Morgan, P Fearon,
Julia M Lappin, Maxine X Patel, J Doody, U Reininghaus, K Morgan, P Jones, Paola
Dazzan, Robin M Murray
3:45 pm
IN VIVO BRAIN 1H MRS ASSESSMENT OF GABAERGIC AND GLUTAMATERGIC
DYSREGULATIONS IN SUBJECTS AT ULTRA-HIGH RISK FOR PSYCHOSIS
Camilo de la Fuente-Sandoval, P León-Ortiz, X Mao, P Alvarado-Alanis, O RodríguezMayoral, F Reyes-Madrigal, Ariel Graff-Guerrero, Rodolfo Solis-Vivanco, R Favila, D C
Shungu
4:00 pm
HIGHER GLUTAMATE LEVELS IN THE ASSOCIATIVE-STRIATUM RELATES WITH
LOWER CORTICAL THICKNESS IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE
PSYCHOSIS PATIENTS
Ariel Graff-Guerrero, M Chakravarty, P León-Ortiz, R Favila, S Stephano, M Azcárraga,
J Ramírez-Bermúdez, J P Lerch, Camilo de la Fuente-Sandoval
4:15 pm
TIME COURSE OF KETAMINE EFFECTS ON BRAIN GLUTAMATE AND GABA
LEVELS MEASURED WITH 1H MRS
Lawrence S Kegeles, X Mao, N Ojeil, R Massuda, M Pedrini, C M Chen, M Slifstein, A
Abi-Dargham, M Milak, C Rodriguez, D C Shungu
4:30 pm
GLYCOSYLATION OF GABA(A) RECEPTOR SUBUNITS IN SCHIZOPHRENIA
Toni M Mueller, Vahram Haroutunian, James H Meador-Woodruff
4:45 pm
PROTEOMIC INVESTIGATION OF THE POSTSYNAPTIC DENSITY IN THE BRAIN IN
SCHIZOPHRENIA
Melanie Foecking, Vibeke S. Catts, Patrick Dicker, Jane English, Gerard Cagney,
Cynthia Shannon Weickert, David R Cotter
5:00 pm
SYNAPTIC AND MITOCHONDRIAL CHANGES IN THE ANTERIOR CINGULATE
CORTEX IN SCHIZOPHRENIA
Rosalinda C Roberts, K Barksdale, J K Roche, Adrienne C Lahti
5:15 pm
PRE- AND POSTSYNAPTIC MARKERS OF CORTICAL PARVALBUMIN BASKET CELL
TERMINALS IN SCHIZOPHRENIA
Jill R Glausier, K N Fish, D Lewis
Comorbid Abstracts
/
Clinical Abstracts
23
AFTERNOON SYMPOSIUM 1-4
IMPROVING ADHERENCE TO MAINTENANCE ANTIPSYCHOTICS: A PROGRESS
REPORT
Mediterranean Ballroom 4
Chair: Peter J Weiden
3:00 pm
MOBILE ASSESSMENT AND TREATMENT FOR SCHIZOPHRENIA (MATS): A
MOBILE INTERVENTION FOR MEDICATION ADHERENCE, HALLUCINATIONS AND
SOCIALIZATION
Eric Granholm, Dror Ben-Zeev, P Link, Kristen Bradshaw, J Holden
3:30 pm
WHY SHOULD FIRST EPISODE PATIENTS TAKE MEDICATION? NEW APPROACHES
TO AN OLD PROBLEM
Peter J Weiden
4:00 pm
METHODOLOGICAL CONSIDERATIONS REGARDING MEDICATION NONADHERENCE AND RELAPSE TRIAL DESIGN: OBSERVATIONS FROM PROACTIVE
Peter F Buckley
4:30 pm
THE PLACE OF OBSERVATIONAL STUDIES IN ASSESSING THE EFFECTIVENESS
OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS
Peter M Haddad
MOLECULAR BIOMARKERS OF SCHIZOPHRENIA – FROM NEW INSIGHTS INTO
DISEASE PATHOPHYSIOLOGY TO DIAGNOSTIC TOOLS
Chair: Matej Oresic
Co-Chair: David R Cotter
Discussant: Jaana Suvisaari
3:00 pm
GENE-ENVIRONMENT INTERACTIONS AND EPIGENETICS DRIVING THE ONSET
OF PSYCHOTIC DISORDER?
Gunter Kenis, Jim van Os
3:30 pm
PROTEOMIC STUDY OF THE BRAIN IN SCHIZOPHRENIA - DOES IT HAVE A VALUE
IN BLOOD BASED BIOMARKER DISCOVERY?
David R Cotter, J English, M Focking, G Cagney
4:00 pm
OBESITY AND PSYCHOTIC DISORDERS: UNCOVERING COMMON MECHANISMS
THROUGH METABOLOMICS
Matej Oresic
4:30 pm
DISEASE BIOMARKERS FOR SCHIZOPHRENIA: FROM LABORATORY TO PATIENT
BEDSIDE
Sabine Bahn
24
Clinical Abstracts
/
Comorbid Abstracts
OSCILLATIONS IN SCHIZOPHRENIA: MULTIMODAL AND MULTIDISCIPLINARY
ADVANCES IN UNDERSTANDING
Chair: Robert McCarley
3:00 pm
THE ROLE OF GABA AND GLUTAMATE IN GAMMA BAND OSCILLATIONS:
OPTOGENETIC AND IN VITRO STUDIES IN THE MOUSE AND MRS STUDIES IN
PATIENTS WITH SCHIZOPHRENIA
Robert McCarley, T Kim, J McNally, K Spencer, Y Hirano, M Niznikiewicz, A Lin
3:30 pm
DOES THE NMDA-RECEPTOR ANTAGONIST, KETAMINE, REPRODUCE THE EEG
GAMMA OSCILLATION ABNORMALITIES OBSERVED IN SCHIZOPHRENIA? A TEST
OF THE NMDA-RECEPTOR HYPOFUNCTION MODEL
Daniel H Mathalon, B J Roach, J Jaeger, H Gunduz-Bruce, J H Krystal, J M Ford
4:00 pm
MEASURING GAMMA-BAND OSCILLATIONS IN SCHIZOPHRENIA WITH
MAGNETOENCEPHALOGRAPY: A TRANSLATIONAL PERSPECTIVE
Peter Uhlhaas
4:30 pm
INTEGRATING EEG GAMMA OSCILLATIONS AND THE FMRI BOLD SIGNAL AT THE
SINGLE TRIAL LEVEL
Christoph Mulert
WORKSHOP 1-1
7:00 pm
FIRST PERSON SESSION
Chair: Hakon Heimer
WORKSHOP 1-2
7:00 pm
TREATMENT DEVELOPMENT IN NEGATIVE SYMPTOMS
Palazzo Ballroom A
Chair: Dawn I Vellgian
WORKSHOP 1-3
7:00 pm
NEW INSIGHTS ON THE NATURE AND SIGNIFICANCE OF NEUROLOGICAL
SIGNS IN SCHIZOPHRENIA SPECTRUM DISORDERS
Palazzo Ballroom D
Chair: Raymond C Chan
WORKSHOP 1-4
7:00 pm
VITAMIN D AND SCHIZOPHRENIA
Palazzo Ballroom E
Chair: Fiona P Gaughran
Comorbid Abstracts
/
Clinical Abstracts
25
WORKSHOP 1-5
7:00 pm
26
ARE DEPOT ANTIPSYCHOTICS MORE EFFECTIVE THAN THEIR ORAL MOTHER
COMPOUNDS?
Palazzo Ballroom F
Chair: W Wolfgang Fleischhacker
Clinical Abstracts
/
Comorbid Abstracts
Tuesday, April 23, 2013
7:00 am
7:00 am
7:00 am
8:15 am
8:30 am
ASSESSMENT AND TREATMENT OF COGNITIVE AND FUNCTIONAL
IMPAIRMENTS IN SCHIZOPHRENIA: THE STATE OF THE ART OF COGNITIVE
REMEDIATION INTERVENTIONS
Speaker: Philip D Harvey
9:30 am
FUTURE CLASSIFICATION OF PSYCHOTIC DISORDERS: DSM-5 AND ICD-11
Chair: William T Carpenter
Co-Chair: Wolfgang Gaebel
10:00 am
THE STATUS OF PSYCHOTIC DISORDERS IN DSM-5
Rajiv Tandon
10:30 am
SIGNIFICANT CONTROVERSIES WITH DSM-5
William T Carpenter
11:00 am
THE STATUS OF PSYCHOTIC DISORDERS IN ICD-11
Wolfgang Gaebel
11:30 am
COGNITIVE IMPAIRMENT AS A SPECIFIER IN PSYCHOTIC DISORDERS IN ICD-11
Michael F Green
NON-CODING RNA DYSREGULATION AND FUNCTION IN SCHIZOPHRENIA
Palazzo Ballroom A
Chair: Murray Cairns
10:00 am
CAUSES AND CONSEQUENCES OF DYSREGULATED MICRORNA BIOGENESIS IN
SCHIZOPHRENIA
Murray Cairns, N J Beveridge, D Santarelli, Sharon Hollins, P Tooney, C Duncan, P
Schofield, C Shannon-Weickert
10:30 am
REGULATORY RNAS AND EPIGENETIC PROCESSES IN SCHIZOPHRENIA
Claes Wahlestedt
Comorbid Abstracts
/
Clinical Abstracts
27
11:00 am
THE LONG NON-CODING RNA GOMAFU IS ACUTELY REGULATED IN RESPONSE
TO NEURONAL ACTIVATION AND INVOLVED IN SCHIZOPHRENIA-ASSOCIATED
ALTERNATIVE SPLICING
Guy Barry, J A Briggs, D P Vanichkina, E M Poth, N J Beveridge, V S Ratnu, S P
Nayler, K Nones, J Hu, T W Bredy, S Nakagawa, F Rigo, R J Taft, M J Cairns, S
Blackshaw, E J Wolvetang, J S Mattick
11:30 am
MICRORNAS IN OLFACTORY NEUROEPITHELIUM OF SCHIZOPHRENIC PATIENTS:
BIOMARKERS AND NEURONAL REGULATORS
Noam Shomron, E Mor, S Kano, C Colantuoni, Akira Sawa, R Navon
IS THE PSYCHOSIS CONTINUUM FOR REAL? THE COGNITIVE,
ENVIRONMENTAL, AND NEURAL CORRELATES OF ‘REAL’ PSYCHOTIC
EXPERIENCES IN THE GENERAL POPULATION
Palazzo Ballroom D
Chair: Emmanuelle Peters
Co-Chair: Sohee Park
Discussant: Anthony S David
10:00 am
NEUROBIOLOGICAL CORRELATES OF AUDITORY VERBAL HALLUCINATIONS IN
NON-CLINICAL INDIVIDUALS
Iris E Sommer, K Diederen, O Howes, P Shotbold, R S Kahn
10:30 am
CHILDHOOD TRAUMA AND AUDITORY VERBAL HALLUCINATIONS
Kirstin Daalman, K M Diederen, E M Derks, R van Lutterveld, Iris E Sommer, R S Kahn
11:00 am
THE ROUTE TO PSYCHOSIS: WHAT DIFFERENTIATES INDIVIDUALS WITH
PSYCHOTIC EXPERIENCES WITH AND WITHOUT A ‘NEED-FOR-CARE’?
Emmanuelle Peters, T Ward, C Brett, A Lovatt, K Gaynor, O Mason, P Garety
11:30 am
SCHIZOTYPY AND PSYCHOTIC-LIKE SYMPTOMS IN A NON-CLINICAL SAMPLE OF
YOUNG ADULTS
Thomas R Kwapil
SCHIZOPHRENIA IS NOT A PROGRESSIVE DISEASE
Palazzo Ballroom E
Chair: Robert Zipursky
Co-Chair: William T Carpenter
10:00 am
SCHIZOPHRENIA DOES NOT SHOW PROGRESSIVE CLINICAL DETERIORATION
Robin M Murray, C Morgan, P Dazzan, P Fearon, G Doody, Marta M Di Forti, p Jones,
J Lappin, a Demjaha
10:30 am
COGNITION IS STATIC AFTER A FIRST EPISODE OF PSYCHOSIS
Eileen M Joyce
11:00 am
WHY KRAEPELIN WAS RIGHT: BRAIN LOSS IN SCHIZOPHRENIA IS RELATED TO
DECLINE IN IQ
Rene Kahn
28
Clinical Abstracts
/
Comorbid Abstracts
11:30 am
INTEGRATING THE CLINICAL, IMAGING AND COGNITIVE EVIDENCE: EXPECTING
RECOVERY NOT PROGRESSION IN SCHIZOPHRENIA
Robert Zipursky
INNOVATIVE APPROACHES TO THE ASSESSMENT OF REAL-WORLD
OUTCOMES IN SCHIZOPHRENIA
Palazzo Ballroom F
Chair: Philip D Harvey
10:00 am
VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT: DEVELOPMENT AND
VALIDATION OF A COMPUTERIZED ASSESSMENT OF FUNCTIONAL SKILLS
Richard Keefe, S Ruse, V Davis, A Atkins
10:30 am
ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: USING
SMARTPHONE TECHNOLOGY TO ASSESS REAL WORLD FUNCTIONING
Eric Granholm, J Holden, J Swendsen
11:00 am
MULTIMODAL ASSESSMENT OF FUNCTIONAL CAPACITY WITH REMOTELY
DELIVERABLE TECHNOLOGY TASKS: FINANCIAL MANAGEMENT; HEALTH
MANAGEMENT AND MEDICATION MANAGEMENT
Sara J Czaja, D Loewenstein, S Nair
11:30 am
SOCIAL COGNITION PSYCHOMETRIC EVALUATION: USING CONSENSUS
DEVELOPMENT TO IMPROVE THE MEASUREMENT OF SOCIAL COGNITION
Philip D Harvey, A Pinkham, D Penn
Comorbid Abstracts
/
Clinical Abstracts
29
12:00–
2:30 p.m.
Coquina Ballroom
EVOLVING CONCEPTS IN NEGATIVE SYMPTOMS
Coquina Ballroom
Chair: Brian Kirkpatrick
Poster No.
A
NEGATIVE SYMPTOM FACTORS IN DEFICIT AND NONDEFICIT SCHIZOPHRENIA:
RELATIONSHIP WITH FUNCTIONAL OUTCOME
Silvana Galderisi, A Mucci, P Bucci, M Maj
A
NEGATIVE SYMPTOM SUBDOMAINS – REFINING ASSESSMENT AND UNDERSTANDING
FUNCTIONAL SIGNIFICANCE
William P Horan, A Bender, Michael F Green
A
MOTIVATION AND PLEASURE AND EMOTIONAL EXPRESSIVITY DIMENSIONS PREDICT
CLINICAL PRESENTATION AND FUNCTIONAL OUTCOME
Gregory P Strauss
A
NOVEL PHARMACOLOGICAL APPROACHES FOR THE TREATMENT OF NEGATIVE
SYMPTOMS
Robert W Buchanan
DOPAMINE, GABA AND GLUTAMATE: FROM CIRCUITS TO NEW TREATMENTS
Coquina Ballroom
Chair: Oliver D Howes,
Discussants: John M Kane, Daniel C Javitt
B
AMYGDALAR REGULATION OF HIPPOCAMPAL GABA CELL IS MEDIATED BY KAINATE
RECEPTORS
Francine M Benes
B
INTERNEURON DEFICITS, HIPPOCAMPAL DISINHIBITION, AND PSYCHOSIS: LESSONS
FROM TRANSPLANT STUDIES IN A MOUSE MODEL OF SELECTIVE INTERNEURON
DEFICITS
Holly Moore, A I Gilani, S A Anderson, M E Ross, S A Schobel, M Inan, M O Chohan, N H
Chaudhury, S Paskewitz, S A Small, N Chuma
B
ARE THERE NEUROBIOLOGICALLY DISTINCT SUB-TYPES OF SCHIZOPHRENIA?
Oliver D Howes
B
THE DEVELOPMENT OF NEW DRUGS FOR SCHIZOPHRENIA: FROM DOPAMINE
BLOCKADE TO MGLU AGONISM
Bruce Kinon
30
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
ATTENUATED PSYCHOSIS SYNDROME: GETTING READY FOR DSM-6
Coquina Ballroom
Chair: Scott W Woods,
Discussant: William T Carpenter
C
ATTENUATED PSYCHOSIS SYNDROME AND PSYCHOTIC SYMPTOMS IN THE
COMMUNITY: A TRANSITION ANALYSIS
Jim van Os
C
PUBLIC AND PERSONAL STIGMA RELATED TO THE ATTENUATED PSYCHOSIS
SYNDROME
Cheryl M Corcoran, L Yang, A Wonpat-Borja
C
ANTIDEPRESSANT MEDICATION USE IN ATTENUATED PSYCHOSIS SYNDROME:
COMMUNITY SELECTION AND OUTCOME
Thomas H McGlashan, Jean Addington, Carrie E Bearden, Kristin Cadenhead, Tyrone
Cannon, B Cornblatt, Daniel H Mathalon, D Perkins, Larry J Seidman, M Tsuang, Elaine F
Walker, Scott W Woods
C
ANTIPSYCHOTIC MEDICATION USE IN ATTENUATED PSYCHOSIS SYNDROME:
COMMUNITY SELECTION AND OUTCOME
Scott W Woods, Jean Addington, Carrie E Bearden, Kristin Cadenhead, Tyrone Cannon, B
Cornblatt, Daniel H Mathalon, D Perkins, Larry J Seidman, M Tsuang, Elaine F Walker, T H
McGlashan
SELF DISTURBANCES IN SCHIZOPHRENIA: FROM PHENOMENOLOGY TO
FUNCTIONAL NEUROANATOMY
Coquina Ballroom
Chair: Sohee Park,
Co-Chair: Henry Nasrallah
D
ABANDONED BODY, WEAKENED SELF AND THE INTERNAL LANDSCAPE OF
SCHIZOPHRENIA
Sohee Park, L G McIntosh, J E Bass
D
ALTERED COROLLARY DISCHARGE IN THE SACCADIC EYE MOVEMENT SYSTEM OF
Katy N Thakkar, J D Schall, S Heckers, Sohee Park
D
ABNORMALITIES IN NEURAL CIRCUITRY OF SELF REFLECTION IN EARLY COURSE
SCHIZOPHRENIA
Matcheri Keshavan, B Brent, L Seidman, M Shad
D
KNOWING ME, KNOWING YOU: FUNCTIONAL IMAGING AND COGNITIVE STUDIES OF
INSIGHT AND SELF PROCESSING
Anthony S David, N J Bedford, B Wiffen
Comorbid Abstracts
/
Clinical Abstracts
31
12:00–
2:30 p.m.
Coquina Ballroom
ATTENUATED PSYCHOTIC SYMPTOMS IN THE GENERAL POPULATION: IMPACT OF
AGE AND ASSESSMENT ON PREVALENCE AND PSYCHOPATHOLOGICAL
SIGNIFICANCE
Coquina Ballroom
Chair: Frauke Schultze-Lutter
E
SELF-REPORTED ATTENUATED PSYCHOTIC SYMPTOMS AS FORERUNNERS OF
SEVERE MENTAL DISORDERS LATER IN LIFE
Mark Weiser, M Drukker, B P Dohrenwend, i Levav, R Yoffe, Jim van Os, Michael Davidson
E
PREVALENCE OF PRODROMAL RISK SYNDROMES AMONG “NON HELP-SEEKING”
YOUNG ADOLESCENTS IN THE COMMUNITY: INFLUENCE OF ASSESSMENT CRITERIA
Mary Cannon, I Kelleher
E
PREVALENCE OF AT-RISK CRITERIA OF PSYCHOSIS IN THE SWISS GENERAL
POPULATION BETWEEN 8 AND 40 YEARS
Benno G Schimmelmann, C Michel, Frauke Schultze-Lutter
E
ASSOCIATION OF AT-RISK CRITERIA WITH CURRENT MENTAL DISORDERS, QUALITY
OF LIFE, AND HELP-SEEKING BEHAVIOR: RESULTS FROM A TELEPHONE SURVEY OF
YOUNG ADULTS FROM THE SWISS GENERAL POPULATION
Frauke Schultze-Lutter, C Michel, B Schimmelmann
WHERE THERE’S SMOKE, THERE’S FIRE: CIGARETTE SMOKING AND RISK FOR
PSYCHOSIS
Coquina Ballroom
Chair: James H MacCabe,
F
CIGARETTE SMOKING IS EQUALLY STRONGLY ASSOCIATED WITH PSYCHOTIC-LIKE
EXPERIENCES AS CANNABIS USE
Marco P Boks, W van Gastel, James H MacCabe, C D Schubart, A Vreeker, W Tempelaar,
Rene Kahn
F
TOBACCO USE AND PSYCHOTIC EXPERIENCES IN UK TEENAGERS – EVIDENCE
FROM THE ALSPAC LONGITUDINAL STUDY
Suzi Gage, M Hickman, J Heron, M R Munafo, G Lewis, S G Zammit
F
AGE AT FIRST TOBACCO USE AND RISK OF SUBSEQUENT PSYCHOSIS-RELATED
OUTCOMES: A BIRTH COHORT AND NESTED SIBLING-PAIR STUDY
John J McGrath, J Najman, G Williams, W Bor, J Scott
F
NICOTINE DEPENDENCE AND ILLNESS SEVERITY IN SCHIZOPHRENIA
Sameer Jauhar, R Krishnadas, S Telfer, S Shivashankar, R G McCreadie
32
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
THE MEANING OF GABA DYSFUNCTION IN SCHIZOPHRENIA
Coquina Ballroom
Chair: Laura M Rowland,
Discussant: Juan R Bustillo
G
IN VIVO GABA IN EARLY AND LATE SCHIZOPHRENIA
Laura M Rowland, S A Wijtenburg, K Kontson, E Hong, J West, R A Edden, H H Holcomb, P
B Barker
G
GABA ABNORMALITIES IN SCHIZOPHRENIA: RELATION TO FUNCTION
Lawrence S Kegeles, C M Chen, X Mao, N Ojeil, R Gil, M Slifstein, A Abi-Dargham, A
Stanford, S H Lisanby, C Schroeder, D C Shungu
G
GLUTAMATE IN THE ASSOCIATIVE STRIATUM DECREASES AFTER 4 WEEKS OF
ANTIPSYCHOTIC TREATMENT IN FIRST-EPISODE PSYCHOSIS: A LONGITUDINAL 1HMRS STUDY
Camilo de la Fuente-Sandoval, P León-Ortiz, M Azcárraga, S Stephano, R Favila, L DíazGalvis, P Alvarado-Alanis, J Ramírez-Bermúdez, Ariel Graff-Guerrero
G
GABA AND GLUTAMATE DYSREGULATION IN SCHIZOPHRENIA AND BIPOLAR
DISORDERS
Juan Bustillo, T Jones, H Chen, N Lemke, C Abbott, c Gasparovics
NEWS FROM THE STRESS FRONT: BIOLOGICAL PATHWAYS TO PSYCHOSIS
Coquina Ballroom
Chair: Dina Collip,
Co-Chair: Inez Myin-Germeys
H
ATTENUATED CORTISOL AWAKENING RESPONSE IN MALE PATIENTS WITH RECENT
ONSET PSYCHOSIS: ASSOCIATION WITH SELF-REPORTED PARENTAL BONDING
Marita Pruessner, N Vracotas, R Joober, J C Pruessner, A K Malla
H
DAILY LIFE STRESS SENSITIVITY ALONG THE PSYCHOSIS CONTINUUM: ROLE OF
CORTISOL AND HIPPOCAMPAL VOLUME
Dina Collip, P Habets, M Marcelis, Tineke Lataster, Jim van Os, Inez Myin-Germeys
H
THE EFFECTS OF STRESS AND OF ITS BIOLOGICAL MEDIATORS ON THE ONSET AND
CLINICAL OUTCOME OF PSYCHOSIS
Valeria Mondelli
H
GLUCOCORTICOIDS AND NEUROPATHOLOGICAL PATHWAYS IN PSYCHOSIS
Elaine F Walker
H
PITUITARY VOLUME AND SALIVARY CORTISOL IN DRUG-NAïVE FIRST EPISODE OF
PSYCHOSIS SUBJECTS, ULTRA-HIGH RISK SUBJECTS AND HEALTHY CONTROLS
Dorte Nordholm, B Glenthoj, E Rostrup, L Randers, M O Nielsen, Valeria Mondelli, Paola
Dazzan, Merete Nordentoft
Comorbid Abstracts
/
Clinical Abstracts
33
12:00–
2:30 p.m.
Coquina Ballroom
POSTER SESSIONS
ABSTRACT CATEGORIES: EPIDEMIOLOGY; GENETICS, BASIC; GENETICS, CLINICAL;
DIAGNOSIS; PHENOMENOLOGY; ELECTROPHYSIOLOGY; EYE MOVEMENT PHYSIOLOGY;
THERAPEUTICS: PHARMACOLOGIC PROBES
001
GASTROINTESTINAL ORIGINS OF INFLAMMATION IN SCHIZOPHRENIA
Emily G Severance, K Gressitt, Faith Dickerson, Robert Yolken
002
CHILDHOOD INFECTION AND SCHIZOPHRENIA IN ADOLESCENCE AND EARLY
ADULTHOOD: A DANISH COHORT STUDY
Philip R Nielsen, M E Benros, P B Mortensen
003
LYME DISEASE AND SCHIZOPHRENIA: CASE STUDIES FROM AN ADJUNCTIVE
MINOCYCLINE STUDY
Amber K Earl, Kelli M Sullivan, D Warfel, Stephanie M Feldman, Charles M Richardson,
Gopal Vyas, Robert W Buchanan, Joseph P McEvoy, Richard Keefe, Heidi J Wehring, M M
Koola, Deanna L Kelly
004
META-ANALYSIS OF OXIDATIVE STRESS IN SCHIZOPHRENIA: CLINICAL STATUS AND
ANTIPSYCHOTIC EFFECTS
Joshua Flatow, Peter F Buckley, Brian Miller
005
CHILDHOOD RESIDENTIAL MOBILITY, SCHIZOPHRENIA AND BIPOLAR DISORDER: A
POPULATION-BASED STUDY IN DENMARK
Diana Paksarian, C B Pedersen, W W Eaton, P B Mortensen
006
MIGRATION, PSYCHOSIS AND IMMUNE ACTIVATION: A PILOT STUDY
Wim Veling, J Counotte, J W Dierssen, H Drexhage
007
SEX DIFFERENCES IN THE RISK OF SCHIZOPHRENIA AND AFFECTIVE DISORDERS IN
OFFSPRING FOLLOWING MATERNAL BEREAVEMENT DURING AND AFTER
PREGNANCY
Jean-Christophe Debost, L Petersen, A S Khashan, T B Henriksen, P B Mortensen
008
EARLY ILLNESS COURSE PREDICTS RELAPSE AND FUTURE SERVICE USE
FOLLOWING INTERVENTION FOR FIRST EPISODE PSYCHOSIS
Julia M Lappin, M Heslin, P Fearon, Robin M Murray, P B Jones, G Doody, Ben Lomas, K
Donoghue, T Croudace, Craig Morgan, Paola Dazzan
009
CAN THE SOCIAL ENVIRONMENT DRIVE YOU MAD?
Simona A Stilo, Marta M Di Forti, Robin M Murray, Craig Morgan
010
THE ROLE OF NEGATIVE PERCEPTIONS OF OTHERS IN THE ASSOCIATIONS
BETWEEN SEVERE TRAUMA AND FIRST EPISODE PSYCHOSIS IN A UK SAMPLE
Adanna Onyejiaka, Helen Fisher, C Gayer-Anderson, S Borges, K Hubbard, C Gardener,
Stephanie Beards, S Sowden, A Kurti, Valeria Mondelli, Marta M Di Forti, Robin M Murray, C
Pariante, Paola Dazzan, R Handley, Craig Morgan
34
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
011
THE IMPACT OF CHILDHOOD AND ADULT ADVERSITY ON RISK OF PSYCHOSIS
Stephanie Beards, H L Fisher, C Gayer-Anderson, K Hubbard, T Velikonja, A Onyejiaka, C
Gardener, S Sowden, S Borges, Valeria Mondelli, C Pariante, Paola Dazzan, R Handley,
Craig Morgan
012
USE OF CANNABIS IN ADOLESCENCE MODIFIES ITS PSYCHOMIMETIC EFFECTS IN
EARLY ADULTHOOD: EVIDENCE FROM A SNOWBALL SAMPLE
Miguel Ruiz-Veguilla, M Ferrin
013
CANNABIS USAGE AND MOLECULAR EPIDEMIOLOGY OF SCHIZOPHRENIA IN
PAKISTAN
Ishrat Aziz
014
RECOVERY IN SCHIZOPHRENIA – META-ANALYSIS
Jouko Miettunen, P Juola, N Hirvonen, John J McGrath, S Saha, M Isohanni, J Veijola, E
Jääskeläinen
015
SOCIO-ENVIRONMENTAL AND SUBSTANCE USE-RELATED PREDICTORS OF
DURATION OF UNTREATED PSYCHOSIS
Michael T Compton, M E Kelley, B Broussard
016
DURATION OF UNTREATED ILLNESS AND ONSET-RELATED VARIABLES IN
SCHIZOPHRENIA VERSUS NON AFFECTIVE PSYCHOSES
Beatrice Penzo, I M Guerrieri, G Spagnolin, B Dell’Osso, A C Altamura
017
PSYCHOSIS PREVALENCE, PROFILE, COMORBIDITY AND COGNITION. NOVEL DATA
FROM THE AUSTRALIAN NATIONAL PSYCHOSIS SURVEY
Vera A Morgan, A Waterreus, A Jablensky, A Mackinnon, J McGrath, V Carr, R Bush, D
Castle, M Cohen, C Harvey, C Galletly, H Stain, A Neil, P McGorry, B Hocking, S Shah, J
Badcock, S Saw
018
THE VIP-STUDY; CONCORDANCE RATES AND HERITABILITY IN SCHIZOPHRENIA,
BASELINE REGISTER-BASED DATA FROM A DANISH TWIN STUDY
Rikke Hilker, Merete Nordentoft, B Glenthoj
019
THE HERITABILITY OF ADVANCING PATERNAL AGE
Emma M Frans, H Larsson, P Lichtenstein, N Långström, C M Hultman
020
OBSTETRIC COMPLICATIONS AS RISK FACTORS FOR SCHIZOPHRENIA SPECTRUM
PSYCHOSES IN OFFSPRING OF MOTHERS WITH PSYCHOTIC DISORDER
Jaana Suvisaari, V Taxell-Lassas, M Pankakoski, J Haukka, J Lönnqvist, L Häkkinen
021
EFFECT OF ILLNESS EXPRESSION AND LIABILITY ON FAMILIAL ASSOCIATIONS OF
CLINICAL AND SUBCLINICAL PSYCHOSIS PHENOTYPES
Tineke Lataster, K Verweij, W Viechtbauer for GROUP
022
THE CO-OCCURRENCE OF HALLUCINATIONS AND DELUSIONS IN GROUPS WITH
DIFFERENT GENETIC RISK FOR PSYCHOSIS
Feikje Smeets, T Lataster & GROUP Investigators
Comorbid Abstracts
/
Clinical Abstracts
35
12:00–
2:30 p.m.
Coquina Ballroom
023
PROGRESSION IN BRAIN TISSUE LOSS, ANTIPSYCHOTIC MEDICATION AND
OUTCOMES IN SCHIZOPHRENIA – THE NORTHERN FINLAND 1966 BIRTH COHORT
STUDY
Matti K Isohanni, J Veijola, J Moilanen, H Koponen, A Alaräisänen, Sanna Huhtaniska,
Jouko Miettunen, E Jääskeläinen
024
CAUSES- AND CORRELATES OF DEATH IN THE FIRST TEN YEARS OF TREATMENT
FOR SCHIZOPHRENIA SPECTRUM DISORDERS
Ingrid Melle, J O Johannessen, J I Røssberg, U H Haahr, T K Larsen, I Joa, E Simonsen, T
H McGlashan, S Friis
025
LIFE EXPECTANCY AND CARDIOVASCULAR DEATHS OF PATIENTS WITH BIPOLAR
DISORDER OR SCHIZOPHRENIA IN THE NORDIC COUNTRIES
Thomas M Laursen, K Wahlbeck, J Hällgren, J Westman, H Alinaghizadeh, M Gissler,
Merete Nordentoft
026
URINARY TRACT INFECTIONS IN ACUTE RELAPSE OF PSYCHOSIS
Chelsea Bodenheimer, K Graham, A Ezeoke, Peter F Buckley, Brian Miller
027
BREAST CANCER SCREENING AND DIAGNOSES FOR WOMEN 40-64 YEARS WITH
MENTAL HEALTH AND SUBSTANCE USE DISORDERS
Kelli M Sullivan, M Abrams, Stephanie M Feldman, C Myers, R P McMahon, Deanna L Kelly
028
SUICIDALITY AND SCHIZOPHRENIA
Jennifer Orel
029
RISK OF SUICIDE ACCORDING TO LEVEL OF PSYCHIATRIC CONTACT
Carsten R Hjorthøj, T Madsen, E Agerbo, Merete Nordentoft
030
PSYCHOMETRIC PROPERTIES OF THE SELF-REPORT VERSION OF THE QUICK
INVENTORY OF DEPRESSIVE SYMPTOMS (QIDS-SR16) QUESTIONNAIRE IN PATIENTS
WITH SCHIZOPHRENIA
Agna A Bartels-Velthuis, I M Lako, J T Wigman, R M Klaassen, C J Slooff, K Taxis
031
HELP-SEEKING BEHAVIOR IN YOUNG ADULTS FROM THE SWISS GENERAL
POPULATION REPORTING ATTENUATED PSYCHOTIC SYMPTOMS
Benno G Schimmelmann, C Michel, Frauke Schultze-Lutter
032
A 14-YEAR FOLLOW-UP OF GENDER DIFFERENCES OF PERSONS WITH
SCHIZOPHRENIA IN RURAL CHINA
Mao-Sheng Ran, C Tang, W Mao, C Chan, E Chen, Y Conwell
033
CO-HABITATION OF CHILDREN AND THEIR PARENTS WITH PSYCHOTIC DISORDERS: A
PROSPECTIVE DANISH NATIONWIDE REGISTER-BASED COHORT STUDY
Anne Ranning, T Laursen, Carsten R Hjorthøj, Merete Nordentoft
034
PSYCHOTIC EXPERIENCES AND SOCIAL FUNCTIONING: A LONGITUDINAL STUDY
Sarah A Sullivan, G H Lewis, N Wiles, A Thompson, J Evans
36
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
035
EARLY EPSTEIN BARR VIRUS (EBV) EXPOSURE, NEURODEVELOPMENT AND
CHILDHOOD PSYCHOTIC SYMPTOMS: FINDINGS FROM THE ALSPAC BIRTH COHORT
Golam M Khandaker, J Stochl, S Zammit, G Lewis, P Jones
036
A POPULATION-BASED STUDY OF PSYCHOTIC SYMPTOMS IN CHILDREN AGED 11-12
YEARS
Pia Jeppesen, L Clemmensen, A Munkholm, M Rimvall, C U Rask, T Joergensen, Jim van
Os, A M Skovgaard
037
EPISTASIS BETWEEN COMT VAL(158)MET AND DRD3 SER(9)GLY POLYMORPHISMS ON
COGNITIVE FUNCTION OF INDIVIDUALS WITH SCHIZOPHRENIA
Alexandre A Loch, Martinus T van de Bilt, Danielle S Bio, Carolina M do Prado, Rafael T de
Sousa, Leandro L Valiengo, Marcus V Zanetti, Ricardo A Moreno, Wagner F Gattaz
038
AGE AT ONSET OF SCHIZOPHRENIA: CANNABIS, COMT, AND THEIR INTERACTIONS
Kimberly R De Sousa, A K Tiwari, D E Giuffra, B Mackenzie, C C Zai, J L Kennedy
039
EFFECT OF COMT-GENE POLYMORPHISMS ON THREAT PERCEPTION IN
SCHIZOPHRENIA AND HEALTHY SUBJECTS
Narayan R Mutalik, John P John
040
GENOMIC SURVEY OF PREPULSE INHIBITION (PPI) AND ITS SENSITIVITY TO
AMPHETAMINE (AMPH) IN HEALTHY ADULTS
Savita G Bhakta, Jo Talledo, Sarah N Lamb, Justin Kei, Neal R Swerdlow
041
INTERACTIONS BETWEEN BDNF VAL66MET GENE POLYMORPHISM, CHILDHOOD
ADVERSE EVENTS AND BRAIN VOLUME ABNORMALITIES IN SCHIZOPHRENIA AND
BIPOLAR DISORDERS
Monica Aas, Unn K Haukvik, Srdjan Djurovic, Ørjan Bergmann, Steinar Lorentzen, Ole A
Andreassen, Ingrid Agartz, Ingrid Melle
042
BRAIN DERIVED NEUROTROPIC FACTOR (BDNF) IS ASSOCIATED WITH CHILDHOOD
TRAUMA IN FIRST EPISODE PSYCHOSIS
Christos Theleritis, Helen Fisher, I Schafer, L Winters, Craig Morgan, J Garabette, J
Breedvelt, I Sambath, F Gaughran, K Ismail, Z Atakan, S Smith, P Girardi, P McGuire, Robin
M Murray, Stefania Bonaccorso
043
CORTICAL SURFACE AREA CORRELATES OF STON2 GENE SER307PRO
POLYMORPHISM IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS
Xiang Bo
044
THE TRYPTOPHAN DEGRADATION PATHWAY AND COGNITION: A GENE-, BRANCH-,
AND PATHWAY-LEVEL ANALYSIS
Jonathan Schaefer, R S Wallwork, J Trampush, D R Weinberger, D Dickinson
045
POLYGENIC SCORE IN PATIENTS WITH PSYCHOTIC DISORDER PREDICTS IQ IN THEIR
UNAFFECTED SIBLINGS
Claudia Simons, Ruud van Winkel, A Richards, M O’Donovan
Comorbid Abstracts
/
Clinical Abstracts
37
12:00–
2:30 p.m.
Coquina Ballroom
046
NEUROCOGNITIVE CHARACTERIZATION OF GENOME WIDE SIGNIFICANT RISK
VARIANTS FOR SCHIZOPHRENIA
Gary Donohoe, A Hargreaves, S Kelly, O Mothersill, E Rose, D Morris, A Corvin
047
PARANOIA IN SOCIAL SITUATIONS – A MATTER OF GENE-ENVIRONMENT
INTERACTION
Jeroen Decoster, Martine van Nierop, E Pishva, W Viechtbauer, Jim van Os, Inez MyinGermeys, Ruud van Winkel
048
THE DRD2 GENOTYPE INFLUENCES FLUID REASONING IN PEOPLE WITH
SCHIZOPHRENIA AND HEALTHY CONTROLS
Debora A Rothmond, T W Weickert, C Pantelis, R Lenroot, S Killcross, M Seal, G K Murray,
S Catts, Cynthia Shannon Weickert
049
ASSOCIATION OF DOPAMINERGIC AND SEROTONINERGIC NEUROTRANSMITTERS
WITH SCHIZOPHRENIA: A POPULATION- BASED CASE-CONTROL STUDY AND METAANALYSIS
Shiau Foon Tee, Pek Yee Tang, Han Chern Loh
050
CYTOTOXICITY OF DISC1-BOYMAW FUSION PROTEINS MAY CONTRIBUTE TO
PATHOGENESIS OF MAJOR PSYCHIATRIC DISORDERS IN THE SCOTTISH
SCHIZOPHRENIA FAMILY
Xianjin Zhou, B Ji, K Higa, M Kim, J Young
051
15Q13.3 MICRODELETION IN SCHIZOPHRENIA: DELINEATING THE ADULT PHENOTYPE
Chelsea Lowther, A Bassett, G Costain, K Russell, P Forsythe, A Lionel, C Marshall, S
Scherer, D Merico
052
A GENOME-WIDE ASSOCIATION STUDY OF SCHIZOPHRENIA IN THE FINNISH
POPULATION ISOLATE
Johanna Liuhanen, J Kauppinen, O Pietiläinen, T Varilo, J Lönnqvist, J Veijola, Jaana
Suvisaari, T Paunio
053
GLDC RARE COPY NUMBER VARIANT MAY BE A RISK FACTOR FOR PSYCHOTIC
DISORDER
Scott Hebbring, Y Ji, J Liu, D Malhortra, S McCarthy, J Sebat, R Weinshilboum, D Levy
054
A GENOMIC MAP OF BRAIN HYPOXIA-RESPONSIVE GENES FOR ANNOTATION OF
COPY NUMBER VARIATION (CNV) DATA IN SCHIZOPHRENIA
Rainald Schmidt-Kastner, J van Os, Gunter Kenis
055
PLASMA ENZYMATIC ACTIVITY LEVEL BUT NOT GENOTYPES OF ANGIOTENSIN
CONVERTING ENZYME DIFFER BETWEEN HEALTHY CONTROLS AND SCHIZOPHRENIA
PATIENTS
Ary Gadelha, Camila M Yonamine, Vanessa K Ota, Vitor Oliveira, Rodrigo A Bressan, Sintia I
Belangero, Mirian A Hayashi
38
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
056
MAPPING RECESSIVE RISK VARIANTS FOR SCHIZOPHRENIA IN AN INBRED
POPULATION
Hader Mansour, J Wood, K Chowdari, A Watson, W Fathi, M Elassy, I Ali, A Eissa, A Yassin,
H Salah, S Tobar, H Gaafar, W El-Bahaei, Z Gomaa, Vishwajit Nimgaonkar
057
WHOLE GENOME SEQUENCING IN A FOUNDER POPULATION
Todd Lencz, S Mukherjee, S Carmi, S Guha, Anil K Malhotra, A Darvasi, I Pe’er
058
LY2140023 MONOHYDRATE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA:
PHARMACOGENETIC ANALYSIS WITHIN A CLINICAL TRIAL ASSESSING EFFICACY IN
TREATING ACUTELY ILL PATIENTS
Laura Nisenbaum, B A Millen, F Zhao, A Downing, A Quigley, J Kohler, M Smith, Bruce
Kinon
059
A PROMOTER POLYMORPHISM IN DRD2: ASSOCIATION WITH SCHIZOPHRENIA AND
TREATMENT RESPONSE TO ANTIPSYCHOTIC DRUGS
Leticia M Spindola, V K Ota, Ary Gadelha, A F Santos Filho, Marcos L Santoro, J J Mari, M I
Melaragno, M A Smith, R A Bressan, S I Belangero
060
MELANOCORTIN-3 RECEPTOR GENE MAY PREDICT ANTIPSYCHOTIC INDUCED
WEIGHT GAIN
Nabilah Chowdhury, A K Tiwari, E J Brandl, Jeffrey A Lieberman, H Meltzer, J L Kennedy, D
Mueller
061
EXPRESSION OF NEUROTRANSMITTER RECEPTORS AND REGULATORY GENES IN
PERIPHERAL BLOOD OF FIRST EPISODE OF PSYCHOSIS PATIENTS BEFORE AND
AFTER ANTIPSYCHOTIC TREATMENT
Vanessa K Ota, C S Noto, Ary Gadelha, Marcos L Santoro, P N Silva, J J Mari, M I
Melaragno, M A Smith, Q Cordeiro, R A Bressan, S I Belangero
062
MMPI-2 VULNERABILITY INDICATORS FOR SCHIZOPHRENIA: UCLA FAMILY STUDY OF
BIOLOGICAL PARENTS OF OFFSPRING WITH CHILDHOOD-ONSET AND YOUNG
ADULTHOOD-ONSET SCHIZOPHRENIA
Stephanie M Woo, Kenneth L Subotnik, R F Asarnow, Keith H Nuechterlein, D L Fogelson, I
I Gottesman, H E Kuppinger, G S Hellemann
063
A STUDY OF MINOR PHYSICAL ANOMALIES IN PATIENTS WITH SCHIZOPHRENIA,
THEIR HEALTHY SIBLINGS AND CONTROLS
Yu Sang Lee
064
PSYCHOSIS PRONENESS UNDERLYING FAMILIAL SUBGROUPS IN BIPOLAR DISORDER
Katherine Burdick, K Mahon, M M Perez-Rodriquez, Anil K Malhotra
065
IMAGING CORTICAL AND SUBCORTICAL TRANSCRIPTS AFTER DIFFERENT NMDA
MODULATING AGENTS: IMPLICATION FOR DOPAMINE-GLUTAMATE INTERACTION IN
PSYCHOSIS
Felice Iasevoli, Federica Marmo, Carmine Tomasetti, Elisabetta F Buonaguro, Chiara
Sarappa, Anna Eramo, Andrea de Bartolomeis
Comorbid Abstracts
/
Clinical Abstracts
39
12:00–
2:30 p.m.
Coquina Ballroom
066
DEFECTIVE AXONAL TRANSPORT AND AUTOPHAGY INSTIGATED BY
PSYCHOSTIMULANTS
Toshi Tomoda
067
TRANSIENTLY DECREASED EXPRESSION OF DISC1 WITHIN THE DEVELOPING
AMYGDALA AND INCREASED ANXIETY-LIKE BEHAVIOR DURING THE JUVENILE
PERIOD: CONVERGENT FINDINGS
Hannah J White, D C Gooding, A P Auger, C J Auger
068
LACK OF NETO1, A NEW PICK1 INTERACTING PROTEIN, INDUCED SCHIZOPHRENIARELATED BEHAVIORAL PHENOTYPES IN MICE
Tatiana V Lipina, C Tang, E A Ivakine, R Rasquinha, R R McInnes, J C Roder
069
LACK OF C4-SHORT GENES AS A POSSIBLE GENETIC MECHANISM OF COMPLEMENT
C4B PROTEIN LEVEL REDUCTIONS IN SCHIZOPHRENIA
Karine R Mayilyan, Y L Wu, B Kolachana, K McBride, C Y Yu, D R Weinberger
070
REFINING GENETIC CONTROL OF GENE EXPRESSION IN THE HUMAN BRAIN
Andrew E Jaffe, Jeffrey T Leek, Carlo Colantuoni
071
COMBINED EFFECT OF MATERNAL INFECTION AND ADOLESCENT CANNABINOID
EXPOSURE ON MICRORNA EXPRESSION IN THE ENTORHINAL CORTEX
Sharon Hollins, K Zavitsanou, R Walker, M Cairns
072
DIFFERENTIAL EXPRESSION OF MICRORNAS IN CEREBROSPINAL FLUID IN PATIENTS
WITH SCHIZOPHRENIA
Juan A Gallego, Todd Lencz, Jason Gentile, Christopher Morell, Nisha Chitkara, Anil K
Malhotra
073
IMPACT OF MIR-137 IN SCHIZOPHRENIA REVEALED BY ITS PUTATIVE TARGETS
Carrie Wright, Jessica Turner, N I Perrone-Bizzozero
074
DETECTION OF YOUTH AT CLINICAL HIGH RISK FOR PSYCHOSIS IN A NON-CLINICAL,
UNDERGRADUATE POPULATION
Lauren M Ellman, Lauren E Gibson, A M Fineberg, Lauren E Lombardo, D M Kern, S D
Maxwell, D M Anglin
075
STRESS EXPOSURE AND SENSITIVITY IN CLINICAL HIGH-RISK ADOLESCENTS AND
YOUNG ADULTS: CONVERSION AND SEX EFFECTS
Hanan D Trotman, Carrie Holtzman, Elaine F Walker, Jean Addington, Kristin Cadenhead,
Tyrone Cannon, Barbara Cornblatt, Robert Heinssen, Thomas H McGlashan, Diana Perkins,
Larry J Seidman, Ming Tsuang, Scott W Woods
076
PREDICTORS OF RECOVERY IN EARLY PSYCHOSIS
Emily Liffick, N Mehdiyoun, J Vohs, M Gaunnac, M Francis, A Breier
40
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
077
PREDICTION OF PSYCHOSIS IN INDIVIDUALS AT CLINICAL HIGH RISK FOR
PSYCHOSIS: INITIAL FINDINGS FROM THE NAPLS 2 CONSORTIUM
Ricardo E Carrion, B Cornblatt, Jean Addington, Carrie E Bearden, Kristin Cadenhead,
Robert Heinssen, Daniel H Mathalon, Thomas H McGlashan, Diana Perkins, Larry J
Seidman, Ming T Tsuang, Elaine F Walker, Scott W Woods, Tyrone Cannon
078
THE SCHIZOPHRENIA PRONENESS INSTRUMENT, CHILD AND YOUTH VERSION (SPICY): PRACTICABILITY AND DISCRIMINATIVE VALIDITY
Frauke Schultze-Lutter, P Walger, Benno G Schimmelmann, L Fux
079
INCIDENTAL RADIOLOGICAL FINDINGS ON BRAIN MAGNETIC RESONANCE IMAGING
IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS AND HEALTHY CONTROLS
Irina Falkenberg, Stefania Benetti, William Petterson-Yeo, Paola Dazzan, Andy Simmons,
Steven Williams, Philip McGuire
080
SUICIDE ATTEMPTS CORRELATE WITH DELUSIONAL CONTENT IN THE FIRST EPISODE
OF SCHIZOPHRENIA
Jun Matsuoka, Yuichi Yamashita, M Baba, E Funada, M Suyama, M Itokawa, R Izawa
081
THEORY OF MIND IN PSYCHOSIS: PERFORMANCE SIMILARITIES IN SCHIZOPHRENIA
AND BIPOLAR DISORDER
Tamsyn E Van Rheenen, Susan Rossell
082
ASSOCIATION OF METACOGNITION AND SOCIAL COGNITION WITH
NEUROCOGNTION, NEGATIVE SYMPTOMS AND FUNCTION IN SCHIZOPHRENIA
Paul H Lysaker, Kelly D Buck, G Dimaggio, M Brune
083
DEFICITS IN AWARENESS OF OTHERS MENTAL STATES AND INTENTIONS:
COMPARISON OF SOCIAL COGNITION AND METACOGNITIVE CAPACITIES BETWEEN
PERSONS WITH PSYCHOSIS AND OTHERS EXPERIENCING PROLONGED BUT NON
PSYCHIATRIC CONDITIONS
Jamie Ringer, Jerillyn S Kent, Sean C Matthews, Paul H Lysaker
084
INSIGHT AND THEORY OF MIND IN EARLY PSYCHOSIS
Jenifer Vohs, P L Lysaker, J Hamm, L Nabors, E Liffick, M Gaunnac, N Mehdiyoun, A Breier
085
AN EXPLORATORY EXAMINATION OF PERFECTIONISTIC SELF-PRESENTATION IN
PSYCHOSIS
Sabrina Hassan, Rohan Ganguli, G L Flett, P L Hewitt
086
TRAIT DEPRESSION IN SCHIZOPHRENIA AND ITS FUNCTIONAL AND CLINICAL
CORRELATES
Joshua Chiappelli, K Nugent, L E Hong
087
SANS, NSA, AND SDA: CORRELATIONS AND FORMULAS FOR CONVERTING SCORES
BETWEEN NEGATIVE SYMPTOM SCALES IN PATIENTS WITH SCHIZOPHRENIA
Adrian Preda, Theo G van Erp, D Nguyen, Steven G Potkin
Comorbid Abstracts
/
Clinical Abstracts
41
12:00–
2:30 p.m.
Coquina Ballroom
088
SANS/SAPS AND PANSS: FORMULAS FOR CONVERTING SCORES BETWEEN TWO
SCHIZOPHRENIA SYMPTOM SCALES
Theo G van Erp, A Preda, Steven G Potkin
089
TOWARDS A DEFINITION OF ANHEDONIA IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Clementine Edwards, Matteo Cella, N Tarrier, T Wykes
090
SUBTYPES OF ANHEDONIA IN BROADLY-DEFINED SCHIZOPHRENIA SPECTRUM
DISORDERS
Benjamin Trachik, Diane C Gooding, C C Chan, L Kadison, C Puentes, Jeffrey S Bedwell
091
THE EXPRESSION AND UNDERLYING PSYCHOLOGICAL MECHANISMS OF POSITIVE
AND NEGATIVE SCHIZOTYPAL PERSONALITY DIMENSIONS
Neus Barrantes-Vidal, T Sheinbaum, T Domínguez-Martínez, Thomas R Kwapil
092
SCHNEIDER SYMPTOMS’ EFFECT ON RELAPSE, REMISSION, SYMPTOM SEVERITY
AND LIFE QUALITY IN FIRST EPISODE SCHIZOPHRENIA PATIENTS DURING THE
FOLLOW-UP PERIOD
Alp Ucok, E Akturan
093
“INTERNAL” VERSUS “EXTERNAL” AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA:
SYMPTOM AND COURSE CORRELATES
Nancy M Docherty, T J Dinzeo, A McCleery, E K Bell, M K Shakeel, A Moe
094
INTRODUCING THE HAT: PRELIMINARY REPORT ON THE HALLUCINATION
ASSESSMENT TOOL
Sarah Keedy, B Kern, Y Gao, D Yohanna
095
DOES THOUGHT DISORDER INFLUENCE QUALITY OF LIFE IN SCHIZOPHRENIA,
INDEPENDENT OF DEPRESSION AND NEUROCOGNITIVE DEFICITS?
Eric J Tan, S L Rossell
096
PREDICTORS OF BIZARRE DELUSIONS IN PSYCHOTIC DISORDERS
Abdullah C Yuksel, Seheryeli Yilmaz, Gresa Carkaxhiu, Ariana Nesbit, Bruce Cohen, Dost
Ongur
097
ASSESSMENT OF SCHIZOPHRENIA USING THE DIMENSIONAL COMPONENT OF THE
STANDARD FOR CLINICIANS’ INTERVIEW IN PSYCHIATRY (SCIP)
Ahmed Aboraya, D Elswick, J Berry, C Hill
098
IS THERE A SYMPTOMATIC DISTINCTION BETWEEN THE AFFECTIVE PSYCHOSES AND
SCHIZOPHRENIA?
Sameer Jauhar, Rajeev Krishnadas, David Cunningham-Owens, Eve C Johnstone, Stephen
M Lawrie
099
THEMATIC CONTENT OF SUBTHRESHOLD POSITIVE SYMPTOMS IN THOSE AT
CLINICAL HIGH RISK OF PSYCHOSIS
Catherine Marshall, K Cadenhead, Tyrone Cannon, B Cornblatt, T McGlashan, D Perkins,
Larry J Seidman, M Tsuang, E Walker, S Woods, J Addington
42
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
100
ANXIETY DISORDERS IN RECENT-ONSET PSYCHOSIS: AN ENDEMIC PHENOMENON?
Marc-André Roy, Michel Maziade, Amelie M Achim, C Vallières, Marie-France Demers, A
Labbé, C Mérette
101
SCHIZOPHRENIA SUBTYPES: NO LONGER IN USE IN THE SCIENTIFIC PSYCHIATRIC
LITERATURE
David L Braff, A J Rissling, S Langton, William T Carpenter
102
COMMUNICATING A DIAGNOSIS OF SCHIZOPHRENIA: EXPERIENCES AND
PERCEPTIONS OF CARERS
Sue Outram, Brian Kelly, Carmel M Loughland, G Harris, Martin Cohen, H Sandhu, m
Vamos, t Levin, C Bylund, Y Landa
103
COMMUNICATING A DIAGNOSIS OF SCHIZOPHRENIA: EXPERIENCES AND
PERCEPTIONS OF MENTAL HEALTH CLINICIANS
Brian Kelly, S Outram, C Loughland, G Harris, F Kelly, M Cohen, H Sandhu, M Vamos, T
Levin, C Bylund, Y Landa
104
MINIMAL SELF-AWARENESS IN SCHIZOPHRENIA: A META-ANALYTIC REVIEW
Ji-Won Hur, Jun Soo Kwon, Sohee Park
105
SCHIZOTYPY AND PHENOMENOLOGICAL CHARACTERISTICS OF AUTOBIOGRAPHICAL
MEMORY
Andrew E Deptula, Jeffrey S Bedwell
106
SOCIAL WORLD INTERACTIONS IN PSYCHOSIS: FROM MACRO TO MICRO
ENVIRONMENT TO BIOLOGY
Dina Collip, Johan Lataster, Nicole Geschwind, Hanneke Wigman, Marieke Wichers, Jim
van Os, Inez Myin-Germeys
107
EXAMINING KETAMINE AND CANNABIS MODELS OF SCHIZOPHRENIA: EVIDENCE OF
SELF-REFERENT MEMORY IMPAIRMENT
Madelaine C Burley, L Wilkins, T A Girard
108
INTERPRETATION OF OBSERVED NON-FAMILIALITY IS STUDIES OF SCHIZOPHRENIA
Loring J Ingraham
109
USE OF ARTIFICIAL NEURAL NETWORKS IN THE DIAGNOSIS OF METABOLIC
SYNDROME IN SCHIZOPHRENIC PATIENTS
Jeroen Van Schependom, Guy Nagels, Weiping Yu, Marc De Hert
110
SEX AND LATERALITY DIFFERENCES IN PARKINSONIAN IMPAIRMENT AND
TRANSCRANIAL ULTRASOUND IN NEVER-TREATED SCHIZOPHRENICS AND THEIR
FIRST DEGREE RELATIVES
Gabriel A de Erausquin, D E Kamis, L M Stratton, L M Alba-Ferrara, N V Florenzano, E
Padilla, B Molina-Rangeon, G Guerrero, M Calvó
111
ANTI NEURONAL CELL SURFACE ANTIBODIES AS A CAUSE OF SCHIZOPHRENIA
Belinda Lennox, J Deakin, M Zandi, L Scoriels, A Cox, A Coles, A Vincent
Comorbid Abstracts
/
Clinical Abstracts
43
12:00–
2:30 p.m.
Coquina Ballroom
112
STIMULUS DURATION AND CONTEXT MODERATE GAMMA-BAND AUDITORY NEURAL
ABNORMALITIES IN SCHIZOPHRENIA
Jordan P Hamm, W T Oliver, Matthew E Hudgens-Haney, Anastasia M Bobilev, Peter F
Buckley, J E McDowell, B A Clementz
113
AUDITORY PROCESSING IN SCHIZOPHRENIA: LOW FREQUENCY BUT NOT 40 HZ
STEADY-STATE ABNORMALITIES
J Christopher Edgar, Y Chen, M R Lanza, B C Howell, V Chow, K Heiken, S Liu, M Huang, J
Canive
114
CORTICAL EXCITABILITY IN SCHIZOPHRENIA: A META-ANALYSIS OF TRANSCRANIAL
MAGNETIC STIMULATION STUDIES
Hulegar A Abhishekh, Urvakhsh M Mehta, K Thennarasu, Jagadisha Thirthalli
115
THE ASSOCIATION BETWEEN IMPAIRED SENSORY GATING AND WHITE MATTER
INTEGRITY IN SCHIZOPHRENIA
Holly K Hamilton, T J Williams, K L Narr, Keith H Nuechterlein, K L Subotnik, C M Yee
116
GENETIC ASSOCIATION OF SLOW ALPHA OSCILLATIONS IN RESTING STATE EEG OF
SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR DISORDER SUBJECTS FROM THE B-SNIP
STUDY
Balaji Narayanan, K O Neil, M C Stevens, C Tamminga, J Sweeney, Matcheri Keshavan, B
Clementz, Godfrey D Pearlson, G Ruano, A Windermuth
117
DISTINCT AND SHARED NEURAL ABNORMALITIES DURING RESPONSE INHIBITION IN
BIPOLAR DISORDER AND SCHIZOPHRENIA
Abe Van Voorhis, S Sponheim, Seung Suk Kang, Angus W MacDonald, Vina Goghari
118
REDUCED P3 AMPLITUDE AND THETA POWER DURING STOP TASK PERFORMANCE IN
SCHIZOPHRENIA
Matthew J Hoptman, E M Parker, P Sehatpour, E C Dias, M E Ross, J DiCostanzo, G Silipo,
D C Javitt
119
ELECTROPHYSIOLOGICAL COMPONENTS ASSOCIATED WITH CONTEXT PROCESSING
IMPAIRMENT IN SCHIZOPHRENIA
Jessica A Jones, Seung Suk Kang, Angus W MacDonald, Scott R Sponheim
120
EMOTION REGULATION ABNORMALITIES IN SCHIZOPHRENIA: COGNITIVE
REAPPRAISAL FAILS TO DECREASE THE NEURAL RESPONSE TO UNPLEASANT
STIMULI
Gregory P Strauss, E Kappenman, A Culbreth, L Catalano, B Lee, James M Gold
121
AFFECTIVE PICTURE PROCESSING AND AROUSAL IN SCHIZOPHRENIA: AN ERP
ANALYSIS
Peter Clayson, P Bachman, K H Nuechterlein, K Subotnik, Joseph Ventura, C Yee
122
NEUROPHYSIOLOGICAL AND BEHAVIOURAL RESPONSES TO COMMUNICATION
ABNORMALITIES IN SCHIZOPHRENIA
Michael W Best, Christopher R Bowie
44
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
123
NEUROCOGNITION, SOCIAL COGNITION, FUNCTIONAL OUTCOME AND MISMATCH
NEGATIVITY IN SCHIZOPHRENIA PATIENTS AND THEIR FIRST DEGREE RELATIVES
Seung-Hwan Lee, K Sung, K Lee, E Moon, C Kim
124
STARTLE REACTIVITY AND HABITUATION DIFFERENCES IN THE PSYCHOSIS
PRODROME: FINDINGS FROM THE NORTH AMERICAN PRODROMAL LONGITUDINAL
STUDY (NAPLS)
Kristin Cadenhead, J Addington, Tyrone Cannon, B Cornblatt, D Mathalon, T McGlashan, D
Perkins, Larry J Seidman, M Tsuang, Elaine F Walker, S Woods, Carrie E Bearden
125
PSYCHOPHYSIOLOGICAL DEFICITS IN CHILDREN AND ADOLESCENTS WITH
PSYCHOSIS OR ADHD: PRELIMINARY EVIDENCE FOR LESS PREPULSE INHIBITION OF
THE STARTLE REFLEX IN PSYCHOSIS THAN IN ADHD
Jacob Rydkjaer, J R Jepsen, B Fagerlund, B Y Glenthøj, A K Pagsberg, B Oranje
126
REDUCED P3A AMPLITUDES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE PSYCHOSIS
PATIENTS AND INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
Rodolfo Solis-Vivanco, Alejandra Mondragon-Maya, Pablo Leon-Ortiz, Yaneth RodriguezAgudelo, Kristin Cadenhead, Camilo de la Fuente-Sandoval
127
DECREASED MISMATCH NEGATIVITY (MMN) AMPLITUDE IN ANTIPSYCHOTIC-NAïVE
FIRST EPISODE PSYCHOSIS PATIENTS AND CLINICAL HIGH RISK FOR PSYCHOSIS
SUBJECTS
Alejandra Mondragon, Rodolfo Solis-Vivanco, Y Rodriguez-Agudelo, P Leon-Ortiz, Camilo
de la Fuente-Sandoval
128
INVESTIGATION OF ANHEDONIA IN SCHIZOPHRENIA USING THE POSTAURICULAR
REFLEX
Rachel Aaron, Taylor L Benson, H Nichols, S Benning, Sohee Park
129
DISORGANIZED MOVEMENT PATTERNS PREDICT POSITIVE SYMPTOMS IN
SCHIZOPHRENIA
Sebastian Walther, F Ramseyer, H Horn, Werner Strik, Wolfgang Tschacher
130
INDIVIDUALIZED BRAIN INHIBITION AND EXCITATION PROFILE IN RESPONSE TO
PAIRED PULSE TMS
Ann Summerfelt, Xiaoming Du, H H Holcomb, L E Hong
131
PREPULSE INHIBITION AND ANTISACCADE PERFORMANCE AS INDICATE IMPAIRED
ATTENTION MODULATION OF COGNITIVE INHIBITION IN 22Q11DS
Kathryn McCabe, Rebbekah J Atkinson, Ulrich Schall, Carmel M Loughland, Linda E
Campbell
132
P50 AUDITORY SENSORY GATING FROM INFANCY TO 4 YEARS OF AGE DURING
SLEEP
Sharon Hunter, Randal G Ross
Comorbid Abstracts
/
Clinical Abstracts
45
12:00–
2:30 p.m.
Coquina Ballroom
133
PRENATAL MATERNAL IMMUNE ACTIVATION ALTERS THE DEVELOPMENT OF
INHIBITORY INTERNEURONS IN THE PREFRONTAL CORTEX
Sarah E Canetta, Alan S Brown, Christoph Kellendonk
134
GABAERGIC INTERNEURONS IN A MODEL OF SCHIZOPHRENIA
Barbara Gisabella, V Y Bolshakov, Francine M Benes
135
NEUROPHYSIOLOGICAL BASIS FOR COGNITIVE CONTROL IN PARIETAL AND
PREFRONTAL CORTEX OF MONKEYS
Rachael K Blackman, M V Chafee
136
THE EFFECTS OF TREATMENT WITH A DOPAMINE D2/D3 RECEPTOR ANTAGONIST ON
P3A AND P3B AMPLITUDES IN DRUG-NAïVE SCHIZOPHRENIA
Mikkel Erlang, Bob Oranje, Sanne Wulff, Signe W Düring, B Glenthoj
137
BEHAVIORAL, COGNITIVE, NEUROENDOCRINE AND PSYCHOPHYSIOLOGICAL
EFFECTS OF SALVINORIN A IN HUMANS: IMPLICATIONS FOR THE KAPPA OPIOID
RECEPTOR IN PSYCHOSIS
Mohini Ranganathan, A Schnakenberg, P Skosnik, R A Sewell, Deepak C D’Souza
138
CLINICAL TESTING OF A D1 AGONIST FOR COGNITIVE ENHANCEMENT IN THE
SCHIZOPHRENIA SPECTRUM
Larry J Siever, L C Zaluda, M M McClure, K S Strike, D R Rosell, D M Barch, Philip D
Harvey, R R Girgis, Jeffrey A Lieberman
139
AN ALPHA7-NICOTINIC RECEPTOR AGONIST IN COMBINATION WITH RISPERIDONE
VERSUS OLANZAPINE
Robert Freedman, A Olincy, J G Harris, L Johnson, W R Kem, Robert W Buchanan
140
RISPERIDONE NORMALIZES NEUROPHYSIOLOGICAL MARKERS OF ATTENTIONAL
DEFICITS IN UNTREATED FIRST EPISODE PSYCHOSIS
Lauren E Ethridge, James L Reilly, Margret S Harris, John A Sweeney
141
CAN D2/3 BLOCKADE IMPROVE BASIC INFORMATION PROCESSING IN FIRST EPISODE
SCHIZOPHRENIA?
Signe W Düring, B Oranje, B Glenthoej
142
COMPREHENSIVE MULTIMODAL APPROACHES TO SUSTAIN TREATMENT ADHERENCE
FOR PSYCHOSIS
Marie-France Demers, C Lizotte, J Bourbeau, J Bouchard, J Brisson, C M Leblanc, M
Lagacé, E Malenfant, G Chalifour
143
INVOLVEMENT OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR IN
HIPPOCAMPAL NORADRENERGIC NEUROTRANSMISSION AND MEMORY FUNCTION
Anders Fink-Jensen, D Dencker, G Wörtwein, J Wess, P Weikop
144
ESTROGEN PREVENTS SCHIZOPHRENIA-LIKE DISRUPTIONS OF SENSORY GATING
CAUSED BY APOMORPHINE
Shane Thwaites, Maarten van den Buuse, A Gogos
46
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
145
CATECHOLAMINE DEPLETION NORMALIZES MANIA-LIKE BEHAVIOR OF DOPAMINE
TRANSPORTER KNOCKDOWN MICE
Jared W Young, Jordy van Enkhuizen, Adam L Halberstadt, Mark A Geyer
146
COMPARATIVE EFFECTIVENESS OF LONG-TERM TREATMENT WITH ATYPICAL
ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA
Andrei Pikalov, Leslie Citrome, J Hsu, Peter Werner, J Cucchiaro, Antony Loebel
147
TAXOMETRIC INTEGRATION OF NEUROCOGNITIVE BIOMARKERS REVEALS DISTINCT
BIOTYPE STRUCTURES IN PSYCHOSIS INDEPENDENT OF PHENOMENOLOGICAL
DIAGNOSES
Brett A Clementz, Matcheri Keshavan, Godfrey D Pearlson, J Sweeney, C Tamminga
148
A PILOT STUDY OF BEST PRACTICES USING IMAGING IN NEW-ONSET PSYCHOSIS
Suzanne C Geier, Michael O’Sullivan, Danielle Goerke, S C Schulz
149
NEUROPHYSIOLOGICAL ASSOCIATIONS OF PERCEPTUAL DISTURBANCE IN
INDIVIDUALS CHARACTERIZED BY CLINICAL HIGH-RISK FOR PSYCHOSIS
Jason K Johannesen, Scott W Woods, Joshua Kenney, Brenton M Roman, Daniel H
Mathalon
150
SENSORY GATING RATIO VARIES BASED ON THE PRESENCE OR ABSENCE OF
AUDITORY VERBAL HALLUCINATIONS
Andrew Meier, Jon Houck, Jessica Turner, Per Lysne, Corbin Wilhelmi, Rose Bigelow,
Robert J Thoma
151
VERGENCE EYE MOVEMENT DEFICITS IN A COHORT OF PATIENTS WITH
SCHIZOPHRENIA
Mark S Bolding, Paul D Gamlin, David White, Timothy J Gawne, Claire Moore, Adrienne C
Lahti
152
SOCIAL ADVERSITY IN CHILDHOOD INCREASES RISK FOR PSYCHOSIS THROUGH
SOCIAL ADVERSITY IN ADULTHOOD
Simona A Stilo, Ulrich Reininghaus, Marta M Di Forti, Robin M Murray, Craig Morgan
153
MIGRATION STATUS: A PREDICTOR OF THE DURATION OF UNTREATED PSYCHOSIS
Sanne Apeldoorn, Bouke Sterk, Atique Islam
154
THE RELATIONSHIP BETWEEN PSYCHOTIC EXPERIENCES, COMMON MENTAL
DISORDER AND HELP-SEEKING WITHIN A REPRESENTATIVE COMMUNITY SAMPLE
John G Mills, Craig Morgan, Stephani L Hatch, Souci Frissa, Maria Verdecchia, Robert
Stewart, Nicola T Fear, Abraham Reichenberg, Matthew Hotopf, SELCoH Study Team, Philip
K McGuire
155
THE MORTALITY OF SCHIZOPHRENIA AND OTHER PSYCHOSES IN A 10-YEAR
FOLLOW-UP STUDY OF FIRST EPISODE PSYCHOSIS
Ulrich Reininghaus, Rina Dutta, Craig Morgan, Paola Dazzan, Gill Doody, Paul Fearon, Julia
Lappin, Margaret Heslin, Ben Lomas, James Kirkbride, Robin Murray, Tim Croudace, Peter
Jones
Comorbid Abstracts
/
Clinical Abstracts
47
12:00–
2:30 p.m.
Coquina Ballroom
156
THE MISDIAGNOSIS HYPOTHESIS REVISITED: DO DIAGNOSTIC MEASURES OF
SCHIZOPHRENIA AND OTHER PSYCHOSES FUNCTION DIFFERENTLY ACROSS ETHNIC
GROUPS?
Ulrich Reininghaus, Arsime Demjaha, Kevin Morgan, Tom Craig, Gill Doody, Paul Fearon,
Gerard Hutchinson, Peter Jones, Robin Murray, Paola Dazzan, Craig Morgan
157
EARLY TRAUMA, AGE AT EXPOSURE, AND CONVERSION TO PSYCHOSIS IN CLINICAL
HIGH-RISK YOUTH
Sarah I Tarbox, Jean Addington, Kristin Cadenhead, Tyrone Cannon, Barbara A Cornblatt,
Diana O Perkins, Larry J Seidman, Ming T Tsuang, Elaine F Walker, Robert Heinssen,
Thomas H McGlashan, Scott W Woods
158
PSYCHOSIS AND THE GENES OF THE LAMP: CONFIRMATION OF AN OBSTETRIC
COMPLICATIONS X AKT1 INTERACTION TO INCREASE THE RISK OF PSYCHOSIS
Alessandra Paparelli, Rebecca Smith, Conrad Iyegbe, Marta M Di Forti, Elvira Bramon, J
Powell, Muriel Walshe, Robin M Murray
159
ASSOCIATION OF SCN2A VARIANTS WITH COGNITIVE ABILITY IN SCHIZOPHRENIA,
AND ADDITIONAL SUPPORT FROM ANALYSES OF UNAFFECTED SIBLINGS,
INDEPENDENT SCHIZOPHRENIA SAMPLES, FMRI, AND MRNA EXPRESSION IN BRAIN
Dwight Dickinson, Richard E Straub, Joey W Trampush, Yuan Gao, Ningping Feng, Kristin L
Bigos, Ryota Hashimoto, Graham Baum, Joseph H Callicott, Thomas M Hyde, Karen F
Berman, Joel Kleinman, Daniel R Weinberger
160
FURTHER LONGITUDINAL AND CASE-ONLY EVIDENCE THAT THE AKT1 RS2494732
POLYMORPHISM INFLUENCES THE RISK FOR PSYCHOSIS IN CANNABIS USERS
Ruud van Winkel, J Decoster, Marc De Hert, g Group Investigators
161
EARLY SENSORY PROCESSING DEFICITS DURING AN AUDITORY ODDBALL TASK ARE
GREATER THAN P3 ABNORMALITIES AND MORE ARE CONSISTENTLY FAMILIAL
ACROSS PSYCHOTIC DISORDERS
Lauren E Ethridge, J P Hamm, J R Shapiro, Ann Summerfelt, Sarah Keedy, M C Stevens,
Godfrey D Pearlson, C Tamminga, N N Boutros, Matcheri Keshavan, B Clementz, J
Sweeney
162
THE OTHER HUMAN GENOME: THE ROLE OF THE MICROBIAL METAGENOME IN THE
PATHOGENESIS OF SCHIZOPHRENIA
Robert Yolken, Faith Dickerson
163
GENETIC VARIATION IN ABCB1 ASSOCIATED WITH P300 AMPLITUDE IN
SCHIZOPHRENIA
Jeroen Decoster, Marc De Hert, W Viechtbauer, G Nagels, Inez Myin-Germeys, J Peuskens,
Jim van Os, Ruud van Winkel
48
Clinical Abstracts
/
Comorbid Abstracts
ORAL SESSION 2-1
THE DIAGNOSTIC AND PROGNOSTIC POTENTIAL OF NEUROANATOMICAL
MARKERS IN PSYCHOSIS: CAN THEY BENEFIT CLINICAL PRACTICE?
Palazzo Ballroom A
Chair: Paola Dazzan
3:00 pm
WHITE MATTER TRACT INTEGRITY AND NEUROCOGNITIVE MATURATION FROM
CHILDHOOD TO LATE ADULTHOOD
Bart D Peters, Philip Szeszko, Toshikazu Ikuta, Kimberly Cameron, Patricia Gruner,
Daniel Prendergast, John Cholewa, Majnu John, Pamela DeRosse, Anil K Malhotra
3:15 pm
USING MULTIMODAL SUPPORT VECTOR MACHINE TO IDENTIFY INDIVIDUALS AT
ULTRA HIGH RISK OF PSYCHOSIS
Isabel Valli, Andre Marquand, Andrea Mechelli, Marie Raffin, Stefania Tognin, Paolo
Fusar-Poli, Paul Allen, M L Seal, Philip McGuire
3:30 pm
NORMAL BIRTH WEIGHT VARIATION AFFECTS CORTICAL SURFACE AREA, BUT
NOT THICKNESS, IN PSYCHOSIS PATIENTS AND HEALTHY CONTROLS, WITH
ASSOCIATIONS TO WORKING MEMORY PERFORMANCE
Unn Kristin Haukvik, Lars Morten Rimol, Cooper Roddey, Cecilie Bhandari Hartberg,
Elisabeth Heffermehl Lange, Anja Vaskinn, Ingrid Melle, Ole A Andreassen, Anders M
Dale, Ingrid Agartz
3:45 pm
DISTINGUISHING BETWEEN EARLY-ONSET SCHIZOPHRENIA AND CLINICAL HIGHRISK FOR PSYCHOSIS IN ADOLESCENTS BY MEASURING REGIONAL CORTICAL
THICKNESS
Dan Jensen, C Schimunek, Sanjiv Kumra
4:00 pm
BRAIN GRAY MATTER INTERMEDIATE PHENOTYPES ACROSS THE CATEGORICAL
DSM-IV DIAGNOSES AND THE PSYCHOSIS DIMENSION: BIPOLAR –
SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP)
Elena I Ivleva, A S Bidesi, S A Meda, D Dodig, B Witte, M S Keshavan, G D Pearlson, J
A Sweeney, B A Clementz, G K Thaker, C A Tamminga
4:15 pm
SUBTYPING SCHIZOPHRENIA THROUGH PATTERNS OF CORTICAL THINNING
Katherine Blizinsky, K Alpert, D Cobia, J G Csernansky, Lei Wang
4:30 pm
CHANGES IN BRAIN VOLUME AND DOPAMINE BLOCKADE IN DRUG-NAïVE FIRSTEPISODE SCHIZOPHRENIA PATIENTS AFTER 3 MONTHS OF ANTIPSYCHOTIC
MONOTHERAPY
Henrik Noerbak, Bjørn H Ebdrup, W Barré, L Pinborg, E Rostrup, B Glenthoej
4:45 pm
WHITE MATTER INTEGRITY AS A MARKER OF TREATMENT RESPONSE IN FIRSTEPISODE PSYCHOSIS
Tiago Reis Marques, Heather Taylor, Christopher Chaddock, Flavio Dell’Acqua,
Rowena Handley, Valeria Mondelli, Stefania Bonaccorso, Marta M Di Forti, Andrew
Simmons, Anthony S David, Robin M Murray, Carmine Pariante, Shitij Kapur, Paola
Dazzan
Comorbid Abstracts
/
Clinical Abstracts
49
5:00 pm
BRAIN MORPHOMETRY AND WHITE MATTER INTEGRITY OF THE CORPUS
CALLOSUM IN CHRONIC AND FIRST EPISODE SCHIZOPHRENIA: A COMBINED
MRI AND DTI STUDY
Kang Sim, S C Gan, G L Yang, W Nowinski
5:15 pm
PREDICTION OF DISEASE STATUS AND ILLNESS COURSE IN SCHIZOPHRENIA
PATIENTS USING STRUCTURAL MRI BRAIN PATTERN CLASSIFICATION
Mireille Nieuwenhuis, Hugo Schnack, S Wood, C Pantelis, P McGorry, J MirandaMourao, Paola Dazzan
ORAL SESSION 2-2
FUNCTIONAL OUTCOMES IN SCHIZOPHRENIA SPECTRUM DISORDERS
Palazzo Ballroom D
Chair: Susan R McGurk
3:00 pm
THE EFFECT OF LIFESTYLE INTERVENTIONS ON PSYCHOSOCIAL FUNCTIONING
AND WELL-BEING IN PATIENTS WITH SEVERE MENTAL ILLNESS
Lisette van der Meer, Annemarie P Stiekema, A M Dethmers, R A Schoevers, R
Bruggeman, E Corpeleijn, Frederike Jörg
3:15 pm
NEGATIVE SYMPTOMS AND EFFORT IN SCHIZOPHRENIA
Julie M McCarthy, H M Johnsson, K Llerena, S G Park, K R Bradshaw, Lauren
Catalano, M E Bennett, J J Blanchard
3:30 pm
SOCIAL INCLUSION FOR YOUNG PEOPLE WITH AND WITHOUT PSYCHOSIS: THE
IMPACT OF SELF-BELIEFS AND BELIEFS OF OTHERS
Clio Berry, K Greenwood
3:45 pm
FUNCTIONAL OUTCOMES, FUNCTIONAL CAPACITY, AND COGNITIVE IMPAIRMENT
IN SCHIZOTYPAL PERSONALITY DISORDER
Margaret M McClure, Philip D Harvey, Christopher R Bowie, B Iacoviello, Larry J
Siever
4:00 pm
CLIENT AND STAFF CONTRIBUTIONS TO STAFF PERCEPTION OF CLIENT
FUNCTIONING ACROSS DOMAINS IN COMMUNITY MENTAL HEALTH
Emily B Treichler, W D Spaulding
4:15 pm
COURSE OF SYMPTOMS ASSOCIATED WITH FUNCTIONAL OUTCOME IN
PSYCHOSIS: A LONGITUDINAL STUDY
Mayke Janssens, / H D. Heering, L L Boyette, N E M. van Haren for GROUP
4:30 pm
THE RELATIONSHIP BETWEEN PERFORMANCE ON THE UPSA AND REAL-WORLD
FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA
Giovanna M Musso, J Riley, Pamela DeRosse, K E Burdick, Amy Duhig, Anil K
Malhotra
4:45 pm
DIRECT AND MEDIATED PATHS: THE ROAD FROM NEUROCOGNITION, SOCIAL
COGNITION, AND FUNCTIONAL COMPETENCE TO EVERYDAY FUNCTIONING
Christopher R Bowie, Giovanna M Musso, Pamela DeRosse, K Burdick, A Duhig, Anil
K Malhotra
50
Clinical Abstracts
/
Comorbid Abstracts
5:00 pm
INDIVIDUALLY TAILORED AND FLUID TREATMENT ALGORITHMS TO ADDRESS
WORK-RELATED SOCIAL AND COGNITIVE IMPAIRMENTS IN ADULTS WITH
SEVERE MENTAL ILLNESS
Jimmy Choi, Morris D Bell, Paul H Lysaker, S Essock
5:15 pm
COGNITIVE REMEDIATION AND SUPPORTED EMPLOYMENT: MODERATORS AND
MEDIATORS OF VOCATIONAL OUTCOMES
Morris D Bell, Silvia Corbera, B Wexler
ORAL SESSION 2-3
COGNITIVE NEUROSCIENCE PERSPECTIVES ON MEMORY NETWORK
DYSFUNCTION IN SCHIZOPHRENIA AND CLINICAL RISK STATES
Palazzo Ballroom E
Chair: John D Ragland
3:00 pm
A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY OF SOURCE MEMORY
AND ITS RELATION TO COGNITIVE INSIGHT IN FIRST-EPISODE SCHIZOPHRENIA
Lisa Buchy, Colin Hawco, Michael Bodnar, Sarah Izadi, Jennifer Dell’Elce, Katrina
Messina, Ashok Malla, Ridha Joober, Martin Lepage
3:15 pm
REDUCED HABITUATION IN PATIENTS WITH SCHIZOPHRENIA
Lisa E Williams, J U Blackford, A Luksik, I Gauthier, Stephan Heckers
3:30 pm
ALTERED HIPPOCAMPAL AND STRIATAL FUNCTION DURING SALIENCE
PROCESSING IN PEOPLE AT ULTRA HIGH RISK FOR PSYCHOSIS
Matthijs G Bossong, Paul Allen, Oliver D Howes, Carly Samson, Beverley Quinn, Ilaria
Bonoldi, Philip McGuire
3:45 pm
INTRINSIC FUNCTIONAL CONNECTIVITY OF THE DENTATE GYRUS OF THE
HIPPOCAMPUS IS ALTERED IN SCHIZOPHRENIA
New-Fei Ho, Garth Coombs, Adam Z Nitenson, Juan Eugenio Iglesias, David C
Henderson, Joshua L Roffman, Daphne J Holt
4:00 pm
DISRUPTED HIPPOCAMPAL RESTING STATE FUNCTIONAL CONNECTIVITY IN
UNMEDICATED PATIENTS WITH SCHIZOPHRENIA – THE ROLE OF GLUTAMATE
Nina V Kraguljac, David M White, Jennifer A Hadley, Meredith A Reid, Adrienne C Lahti
4:15 pm
CONJUNCTIVE MEMORY AS A PARADIGM TO INVESTIGATE HIPPOCAMPUS
SUBFIELD FUNCTION IN SCHIZOPHRENIA
Tanusree Das, P Mikhailos, A R Preston, Elena I Ivleva, A Wagner, C Tamminga
4:30 pm
NEURAL CORRELATES OF RECOLLECTION AND FAMILIARITY DEFICITS IN
SCHIZOPHRENIA
John D Ragland, L A Libby, A Yonelinas, Tyler A Lesh, Tara A Niendam, M Solomon, C
S Carter, C Ranganath
4:45 pm
DISRUPTED FUNCTIONAL CONNECTIVITY DURING MEMORY ENCODING AND
RETRIEVAL IN YOUTH AT CLINICAL HIGH RISK FOR SCHIZOPHRENIA
Kristen M Haut, Theo van Erp, Barbara Knowlton, Carrie E Bearden, Tyrone Cannon
Comorbid Abstracts
/
Clinical Abstracts
51
5:00 pm
DEFICIENT HIPPOCAMPAL ACTIVATION DURING LEARNED IRRELEVANCE IN
SUBJECTS AT RISK FOR SCHIZOPHRENIA: AN FMRI STUDY
Janardhanan C Narayanaswamy, Vijay Danivas, Venkataram Shivkumar, Sri Mahavir
Agarwal, Sunil V Kalmady, Anekal C Amaresha, Virupaksha H Shanmugam, Ganesan
Venkatasubramanian
5:15 pm
REDUCED CEREBELLAR ACTIVITY DURING VERBAL MEMORY ENCODING
PREDICTS CONVERSION TO PSYCHOSIS: BASELINE FMRI FINDINGS FROM THE
NORTH AMERICAN PRODROME LONGITUDINAL STUDY
Sarah McEwen, Amira Ibrahim, Theo G van Erp, Carrie E Bearden, Elaine F Walker, Lei
Zhou, Larry J Seidman, Heidi W Thermenos, B Cornblatt, Doreen M Olvet, Peter B
Kingsley, Diana Perkins, Aysenil Belger, Joshua Bizzell, Kristin Cadenhead, Ming
Tsuang, Heline Mirzakhanian, Jean Addington, Brad Goodyear, Jacqueline Stowkowy,
Daniel H Mathalon, Thomas H McGlashan, Scott W Woods, Tyrone Cannon
ADVANCES IN MEDICATION DEVELOPMENT AND ASSESSMENT
Chair: S C Schulz
Co-Chair: C Tamminga
3:00 pm
LURASIDONE: NEW FINDINGS IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR
DISORDER
Antony Loebel
3:15 pm
ANTIPSYCHOTIC UPDATE: ILOPERIDONE
Peter Weiden
3:30 pm
A META ANALYSIS OF THE EFFICACY OF INHALED LOXAPINE FOR THE ACUTE
TREATMENT OF AGITATION IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR 1
DISORDER: BASELINE SEVERITY ANALYSIS
James Cassella
3:45 pm
PHARMACOLOGY AND D3 RECEPTOR-MEDIATED ACTIVITY OF CARIPRAZINE, A
DOPAMINE D3/D2 RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC CANDIDATE
Stephen R Zukin, S Durgam, N Adham, I Gyertyan, B Kiss, I Laszlovszky
4:00 pm
LY2140023 MONOHYDRATE IN THE TREATMENT OF PATIENTS WITH
SCHIZOPHRENIA: RESULTS OF 2 CLINICAL TRIALS ASSESSING EFFICACY IN
TREATING ACUTELY ILL PATIENTS AND THOSE WITH PROMINENT NEGATIVE
SYMPTOMS
Bruce Kinon, B A Millen, A C Downing, L Zhang, V L Stauffer, S W Andersen, J C
Gomez
4:15 pm
ITI-007 AND ITS METABOLITE IC200131 FOR THE TREATMENT OF ACUTE AND
RESIDUAL SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS
Kimberly E Vanover
4:30 pm
THE EFFECT OF BITOPERTIN, A GLYCINE REUPTAKE INHIBITOR, ON
FUNCTIONING AND AVOLITION IN PATIENTS WITH PREDOMINANT NEGATIVE
SYMPTOMS
Dan Umbricht
52
Clinical Abstracts
/
Comorbid Abstracts
4:45 pm
PERINATAL CHOLINE SUPPLEMENTATION IS ASSOCIATED WITH EARLIER
MATURATION OF P50 SENSORY GATING
Randal G Ross, Sharon Hunter, L McCarthy, J Beuler, A K Hutchison, B D Wagner, S
Leonard, K E Stevens, Robert Freedman
NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA: UPDATE
Chair: Sanjiv Kumra
3:00 pm
PROGRESSIVE CORTICAL CHANGES IN CHILDREN AND ADOLESCENTS WITH
PSYCHOSIS: CLINICAL AND THERAPEUTICAL IMPLICATIONS
Celso Arango, C Rapado-Castro, J Castro-Fornieles, J Gonzalez-Pinto, S Otero, I
Baeza, C Moreno, M Graell, J Janssen, D Moreno, M Desco, M Parellada
3:30 pm
BRAIN NETWORK PROFILES FOR ATTENTION, MEMORY AND EMOTION IN
CHILDREN AND ADOLESCENTS AT RISK FOR SCHIZOPHRENIA
Vaibhav Diwadkar
4:00 pm
BRAIN ABNORMALITIES IN CHILDHOOD-ONSET SCHIZOPHRENIA (COS)
Nitin Gogtay
4:30 pm
TRACT-SPECIFIC ANALYSIS OF WHITE MATTER INTEGRITY DISRUPTION IN EARLYONSET SCHIZOPHRENIA
Sanjiv Kumra
THE COGNITIVE AND AFFECTIVE NEUROSCIENCE OF PSYCHOTIC SYMPTOMS
Chair: Deanna M Barch
3:00 pm
TOWARDS A MECHANISTIC UNDERSTANDING OF COGNITIVE DISTURBANCES IN
SCHIZOPHRENIA
Alan Anticevic, J D Murray, M Ichinose, X J Wang, P R Corlett, J H Krystal
3:30 pm
GOAL REPRESENTATION, PREFRONTAL CORTEX, AND IMPAIRED MOTIVATION IN
SCHIZOPHRENIA
Deanna M Barch, E Dowd, C Mann, Y S Chung, K Becerril
4:00 pm
FORMALIZING ABERRANT SALIENCE: PREDICTION ERROR & DELUSIONS
Philip R Corlett, J R Taylor, P C Fletcher, J H Krystal
4:30 pm
SCHIZOPHRENIA PATIENTS WHO HEAR VOICES COMMENTING HAVE HYPERCONNECTIVITY IN CORTICAL-STRIATAL-AMYGDALA LOOPS
Judith M Ford, B J Roach, T vanErp, A Belger, Jessica Turner, B Mueller, D Keator, A
Preda, J Vaidya, Sarah McEwen, H Shanbhag, Vince Calhoun, Steven G Potkin, Daniel
H Mathalon
7:00 pm
Havana: Hot,Hot,Hot! — Lazy River Fire Pit
Comorbid Abstracts
/
Clinical Abstracts
53
Wednesday, April 24, 2013
8:00 am
7:00 am
7:00 am
8:15 am
8:30 am
THE KYNURENINE PATHWAY OF TRYPTOPHAN DEGRADATION: LINKS TO
SCHIZOPHRENIA AND OTHER MAJOR BRAIN DISEASES
Speaker: Robert Schwarcz
9:30 am
MOLECULAR SIGNATURE FOR COGNITION MAY BE REFLECTED IN CELLS
FROM BIOPSIED TISSUES OF SCHIZOPHRENIA PATIENTS
Chair: Akira Sawa
10:00 am
DISC1 SERINE-713 IS INVOLVED IN NEURAL CELL FATE CONTROL AND A KEY
PATHOLOGY OF SCHIZOPHRENIA: STUDY WITH HUMAN STEM CELLS
Koko Ishizuka
10:30 am
INCREASED AUTOFLUORESCENCE ARE RELATED TO OXIDATIVE STRESS AND
COGNITIVE FUNCTION IN SCHIZOPHRENIA
Chi-Ying Lin
11:00 am
INCREASED SUSCEPTIBILITY TO APOPTOSIS IN ANTIPSYCHOTIC-NAïVE FIRSTEPISODE SCHIZOPHRENIA PATIENTS
Patricia Gasso
11:30 am
MOLECULAR PROFILING OF COGNITION IN SCHIZOPHRENIA
Nicola Cascella
NEXT-GENERATION SEQUENCING APPROACHES TO SCHIZOPHRENIA AND
ITS NEURODEVELOPMENTAL ORIGINS
Palazzo Ballroom A
Chair: Paul Harrison
10:00 am
ALTERNATIVE TRANSCRIPTS, ALLLELIC VARIATION, AND NEXT GENERATION
SEQUENCING IN SCHIZOPHRENIA
Thomas M Hyde
10:00 am
EVOLUTION, DEVELOPMENT AND DISORDERS OF NEOCORTICAL CIRCUITS
Nenad Sestan
54
Clinical Abstracts
/
Comorbid Abstracts
10:30 am
EXPLORING THE SMALL WORLD OF MINI-EXONS IN THE HUMAN BRAIN
THROUGH RNA-SEQ
Yuan Gao
11:00 am
PATHWAY APPROACHES TO NEURODEVELOPMENTAL DISORDERS: PUSHING
FUNCTIONAL GENOMICS INTO SYSTEMS BIOLOGY
Caleb Webber
WHAT DOES RESTING STATE FMRI TEACH US ABOUT BRAIN ABNORMALITIES
IN SCHIZOPHRENIA?
Palazzo Ballroom D
Chair: Steven G Potkin
10:00 am
VOXELWISE AND INDEPENDENT COMPONENTS ANALYSIS OF LOW-FREQUENCY
FLUCTUATIONS IN THE FBIRN RESTING STATE DATASET
Jessica Turner, E Damaraju, T van Erp, Daniel H Mathalon, Judith M Ford, J Voyvodic,
A Belger, J Bustillo, Sarah McEwen, Steven G Potkin, Vince Calhoun
10:30 am
THALAMO-CORTICAL DYSCONNECTIVITY IN SCHIZOPHRENIA
Judith M Ford, B J Roach, H Shanbhag, T van Erp, Jessica Turner, A Belger, J Vaidya,
A Preda, Sarah McEwen, D Keator, Vince Calhoun, B Mueller, Stephan Heckers,
Steven G Potkin, Daniel H Mathalon
11:00 am
DYNAMICS OF INTRINSIC CONNECTIVITY NETWORKS IN SCHIZOPHRENIA
Vince Calhoun, E Allen, Judith M Ford, Daniel H Mathalon, A Preda, T van Erp, E
Damaraju
11:30 am
MINING THE GOLD IN RESTING STATE BOLD: DISCUSSION OF METHODS AND
FINDINGS FROM THE FBIRN SCHIZOPHRENIA STUDY
Daniel H Mathalon
THE LONG SEARCH FOR AN INFLAMMATORY COMPONENT IN
SCHIZOPHRENIA
Palazzo Ballroom E
Chair: Iris E Sommer
Co-Chair: Fuller Torrey
Discussant: Richard Noll
10:00 am
MASSIVELY PARALLEL HIGH THROUGHPUT SEQUENCING-A SENSITIVE METHOD
TO IDENTIFY OF NOVEL MICROBIAL AGENTS IN INDIVIDUALS WITH
SCHIZOPHRENIA (AT LONG LAST)
Robert Yolken, Faith Dickerson
10:24 am
ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH COGNITIVE DEFICITS IN
SCHIZOPHRENIA
Faith Dickerson, C Stallings, A Origoni, C Vaughan, S Khushalani, R Yolken
10:48 am
SERUM BIOMARKERS FOR PSYCHIATRIC DISORDERS
Sabine Bahn
Comorbid Abstracts
/
Clinical Abstracts
55
11:12 am
NEUROINFLAMMATION IN TEMPORAL CORTEX OF PATIENTS WITH RECENT
ONSET SCHIZOPHRENIA
Bart van Berckel, T van der Doef, Matthijs G Bossong, R Boellaard, N van Haren, A D
Windhorst, W Cahn, A A Lammertsma, Rene Kahn
11:36 am
META-ANALYSES ON ANTI-INFLAMMATORY TREATMENTS FOR PATIENTS WITH
SCHIZOPHRENIA
Iris E Sommer, L D de Witte, M Begemann, R S Kahn
COGNITIVE FUNCTIONING AND ENHANCEMENT STRATEGIES FOR CLIENTS
RECEIVING SUPPORTED EMPLOYMENT
Palazzo Ballroom F
Chair: Susan R McGurk
Co-Chair: Robert E Drake
10:00 am
THE ROLE OF NEUROCOGNITION WITHIN A RANDOMISED CONTROLLED TRIAL
OF INDIVIDUAL PLACEMENT AND SUPPORT FOR FIRST-EPISODE PSYCHOSIS
Eoin Killackey, K Allott, S M Cotton, G Chinnery, H J Jackson, G Baksheev
10:30 am
A DOUBLE-BLIND CONTROLLED TRIAL OF COMPUTERIZED COGNITIVE TRAINING
IN A COMMUNITY MENTAL HEALTH SUPPORTED EMPLOYMENT PROGRAM
Sophia Vinogradov, P Alexander, Z Quittner, Melissa Fisher, G Jarasitis, D Fariello
11:00 am
COGNITIVE REMEDIATION AND SUPPORTED EMPLOYMENT: NEUROCOGNITIVE
ENHANCEMENT THERAPY
Morris D Bell
11:30 am
COGNITIVE REMEDIATION AND SUPPORTED EMPLOYMENT: THE THINKING
SKILLS FOR WORK PROGRAM
Susan R McGurk, K T Mueser
56
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
AEROBIC EXERCISE IN SCHIZOPHRENIA: CLINICAL CONSEQUENCES AND
NEUROBIOLOGICAL EFFECTS OF A NOVEL TREATMENT STRATEGY
Coquina Ballroom
Chair: Peter G Falkai,
Co-Chair: W G Honer
Poster No.
A
EFFECTS OF INDOOR CYCLING ON HIPPOCAMPAL STRUCTURE, METABOLISM AND
CLINICAL FEATURES OF SCHIZOPHRENIA. DATA FROM A PILOT STUDY AND A NEW
REPLICATION SAMPLE
Berend Malchow, K Keller, H Fleige, S Doerfler, J Huber, O Gruber, T G Schulze, A Schmitt,
W G Honer, Peter G Falkai
A
THE IMPACTS OF AEROBIC EXERCISE AND MIND-BODY EXERCISE (YOGA) ON
COGNITION IN EARLY PSYCHOSIS
Eric Chen, J Lin, G M Joe, C W Chung, E Lee, S Chan, C Hui, G Wong, P L Khong, M Tse,
W G Honer
A
EXERCISE THERAPY, CARDIORESPIRATORY FITNESS AND THEIR EFFECT ON BRAIN
VOLUMES; A RANDOMISED CONTROLLED TRIAL IN PATIENTS WITH SCHIZOPHRENIA
AND HEALTHY CONTROLS
Rene Kahn
A
DOES EXERCISE ALTER THE METABOLIC EFFECTS OF OLANZAPINE IN AN ANIMAL
MODEL?
Alasdair M Barr, H Boyda, A Ramos-Miguel, W G Honer, E Hawkes, E Topfer, H T Choy, R
Wong, L Li, C Wong, C Pang, R M Procyshyn
ALTERED OLFACTORY FUNCTION IN SCHIZOPHRENIA: FROM GENETICS TO
NEUROBIOLOGY AND PREDICTION OF PSYCHOSIS
Coquina Ballroom
Chair: Larry J Seidman,
Co-Chair: L Kopala
B
DECREASING ODOR SENSITIVITY IS RELATED TO PARENTAL AGING IN HEALTHY
SUBJECTS, BUT PREDICTS COGNITIVE DEFICITS IN SCHIZOPHRENIA
Dolores Malaspina
B
OLFACTORY IMAGING MARKERS OF HEIGHTENED NEURODEVELOPMENTAL RISK FOR
SCHIZOPHRENIA
Bruce I Turetsky, D Roalf, V Kamath, K Ruparel, M Elliott, M Calkins, R E Gur, P J Moberg
B
UNDERSTANDING THE PREDICTIVE ABILITY OF OLFACTORY DYSFUNCTION IN FIRST
EPISODE PSYCHOSIS: EFFECTS ON SYMPTOMS AND FUNCTIONAL OUTCOME
Kimberley P Good, D Lewis, P Tibbo, H I Milliken, M Alexiadis, N Robertson, D Whitehorn,
M Armstrong, L Kopala
Comorbid Abstracts
/
Clinical Abstracts
57
12:00–
2:30 p.m.
B
Coquina Ballroom
DOES OLFACTORY IDENTIFICATION PROGRESS IN EARLY PSYCHOSIS?: FROM
PRODROME TO FIRST EPISODE AND BEYOND
Larry J Seidman, R Mesholam-Gately, K A Woodberry, Robert McCarley, Jean Addington, C
Bearden, Tyrone Cannon, K Cadenhead, B A Cornblatt, D Mathalon, D Perkins, T
McGlashan, M T Tsuang, E Walker, S Woods
BRAIN BEHAVIOR MEASURES IN YOUTHS AT-RISK FOR PSYCHOSIS: THE
PHILADELPHIA NEURODEVELOPMENTAL COHORT
Coquina Ballroom
Chair: Raquel E Gur
C
EARLY IDENTIFICATION OF CHILDREN AND ADOLESCENTS AT-RISK FOR PSYCHOSIS
IN THE COMMUNITY: FINDINGS FROM THE PHILADELPHIA NEURODEVELOPMENTAL
COHORT
Monica E Calkins, Daniel Wolf, T Satterthwaite, C G Conroy, K R Merikangas, M Burstein, D
Abrams, R Chiavacci, H Hakonarson, R C Gur, R E Gur
C
NEUROBEHAVIORAL ASSESSMENT OF PSYCHOSIS PRONE YOUTHS
Ruben C Gur, Monica E Calkins, H Hakonarson, Raquel E Gur
C
STRUCTURAL NEUROIMAGING OF PSYCHOSIS PRONE YOUTHS
Raquel E Gur, C Davatzikos, R Verma, T Satterthwaite, K Ruparel, Monica E Calkins, H
Hakonarson, Ruben C Gur
C
FUNCTIONAL NEUROIMAGING ABNORMALITIES IN YOUTH AT CLINICAL RISK FOR
PSYCHOPATHOLOGY
Daniel Wolf, T D Satterthwaite, K Ruparel, M Calkins, M A Elliott, H Hakonarson, R C Gur, R
E Gur
NOT JUST PSYCHOSIS: THE CLINICO-PATHOLOGICAL SIGNIFICANCE OF
PSYCHOTIC SYMPTOMS
Coquina Ballroom
Chair: Mary Cannon,
Discussant: Alison Yung
D
MULTIMORBIDITY, SUICIDALITY, AND POOR FUNCTIONING AMONG ADOLESCENTS
WITH PSYCHOTIC SYMPTOMS ATTENDING A MENTAL HEALTH SERVICE
Mary Cannon, I Kelleher, N Devlin, C Fitzpatrick
D
SUICIDAL IDEATION AND BEHAVIOURS IN AUSTRALIAN ADOLESCENTS WITH
PSYCHOTIC EXPERIENCES: A WORRYING EXAMPLE OF UNMET NEED FOR
INTERVENTION
James Scott, G Martin, H Thomas, T Andrews, P Hasking
58
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
D
THE PRESENCE OF ATTENUATED PSYCHOTIC SYMPTOMS PREDICTS POOR
OUTCOME IN PERSONS WITH DEPRESSION AND ANXIETY
Mark Weiser, N Werbeloff, Y Levav, B Dohrenwend
D
SUBCLINICAL PSYCHOTIC EXPERIENCES AND BIPOLAR SPECTRUM FEATURES IN
MAJOR DEPRESSIVE DISORDER: ASSOCIATION WITH OUTCOME OF
PSYCHOTHERAPY
Johanna Wigman, Jim van Os, L Abidi, M J Huibers, J Roelofs, A Arntz, I Kelleher, F P
Peeters
METACOGNITION: FROM CONCEPT TO TREATMENT
Coquina Ballroom
Chair: Paul H Lysaker
E
THE CONTRIBUTION OF METACOGNITION TO UNDERSTANDING THE DEVELOPMENT
AND MAINTENANCE OF NEGATIVE SYMPTOMS
Hamish McLeod, Andrew Gumley, Paul H Lysaker, Matthias Schwannauer
E
METACOGNTION: FROM THE EMPIRICAL BASES OF THE CONCEPT TO TREATMENT
Paul H Lysaker
E
METACOGNITIVE TRAINING FOR PATIENTS WITH SCHIZOPHRENIA (MCT)
Steffen Moritz
E
REFLEX: A METACOGNITIVE GROUP TREATMENT TO IMPROVE INSIGHT IN
PSYCHOSIS
Marieke Pijnenborg, L Van der Meer, A De Vos, C Bockting, Mark van der Gaag, Andre
Aleman
NEW DIRECTIONS IN COGNITIVE REMEDIATION RESEARCH: INTEGRATION WITH
PSYCHOSOCIAL REHABILITATION IN SCHIZOPHRENIA
Coquina Ballroom
Chair: Matthew M Kurtz,
Discussant: Susan R McGurk
F
INTEGRATING THE TREATMENT OF SOCIAL AND NON-SOCIAL COGNITIVE
IMPAIRMENTS IN SCHIZOPHRENIA WITH COGNITIVE ENHANCEMENT THERAPY
Shaun M Eack, Matcheri Keshavan
F
COGNITIVE REMEDIATION AND SOCIAL SKILLS TRAINING FOR SCHIZOPHRENIA
Matthew M Kurtz, K T Mueser, B Wexler
F
EFFECTIVENESS OF COGNITIVE REMEDIATION IN IMPROVING EMPLOYMENT
OUTCOMES IN SUPPORTED EMPLOYMENT NON RESPONDERS
K T Mueser, Susan R McGurk
Comorbid Abstracts
/
Clinical Abstracts
59
12:00–
2:30 p.m.
F
Coquina Ballroom
ADVANTAGES OF INTEGRATED BEHAVIOR THERAPY APPROACHES IN COMPARISON
TO ONE-TRACK INTERVENTIONS IN SCHIZOPHRENIA
Volker Roder, D Mueller
CHILDHOOD TRAUMA AS A RISK FACTOR IN PSYCHOTIC DISORDERS- IN SEARCH
OF MECHANISMS
Coquina Ballroom
Chair: Ingrid Melle
G
PROSPECTIVE INVESTIGATION OF COGNITIVE AND AFFECTIVE PATHWAYS FROM
CHILDHOOD TRAUMA TO PSYCHOTIC SYMPTOMS IN A UK BIRTH COHORT
Helen Fisher, A Schreier, S Zammit, G Lewis, D Wolke
G
CHILDHOOD TRAUMA AND ITS ASSOCIATION TO PERSONALITY, CLINICAL AND
COGNITIVE FACTORS IN A LARGE SCHIZOPHRENIA SAMPLE
Kathryn McCabe, E Moore, C M Loughland, H Stain, V J Carr
G
CHILDHOOD TRAUMA INFLUENCES THE CLINICAL EXPRESSION OF BIPOLAR
DISORDERS
Bruno Etain, Monica Aas, F Bellivier, Ingrid Melle, C Henry, O Andreassen, M Leboyer
G
INTERACTION BETWEEN (BDNF) VAL66MET, CHILDHOOD ADVERSE EVENTS AND
IMPAIRED COGNITION IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM AND BIPOLAR
DISORDER
Monica Aas, S Djurovic, L Athanasiu, M S Tesli, T Hellvin, N E Steen, I Agartz, S Lorentzen,
K Sundet, O A Andreassen, Ingrid Melle
INNOVATIONS IN SOCIAL COMMUNICATION AND MISCOMMUNICATION IN
NEUROPSYCHIATRIC DISORDERS
Coquina Ballroom
Chair: David I Leitman,
Co-Chair: R L Mitchell
H
VISUAL SCANNING OF EMOTIONAL GAIT IN SCHIZOPHRENIA
Joel S Peterman, A M Christensen, M Giese, Sohee Park
H
RELATIONAL-ECOLOGICAL APPROACHES TO STUDYING AND DIFFERENTIATING
SOCIAL COMMUNICATION ABNORMALITIES IN SCHIZOPHRENIA
David I Leitman, R L Mitchell
H
THE EFFECTS OF OXYTOCIN ON SOCIAL COGNITION AND OLFACTION IN PATIENTS
WITH SCHIZOPHRENIA AND HEALTHY CONTROLS
Josh Woolley, B Chuang, O Lam, Daniel H Mathalon, K Rankin, Sophia Vinogradov
H
DELUSIONS OF REFERENCE AND SOCIAL COGNITION IN SCHIZOPHRENIA
Aaron L Mishara
60
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
POSTER SESSIONS
ABSTRACT CATEGORIES: NEUROIMAGING, STRUCTURAL; NEUROIMAGING, FUNCTIONAL;
COGNITIVE NEUROSCIENCE
001
PERINATAL AND OBSTETRICAL COMPLICATIONS AND THEIR RELATIONSHIP WITH
STRUCTURAL IMAGING CHANGES AND SCHIZOPHRENIA
Anvi K Vora, Nancy Andreasen
002
CSD TRACTOGRAPHY REVEALS EARLY WHITE MATTER CHANGES IN PREPRODROMAL ADOLESCENTS WITH SUBCLINICAL PSYCHOTIC SYMPTOMS
Erik O’Hanlon, A Leemans, I Kelleher, S Roddy, T Frodl, Mary Cannon
003
PITUITARY GLAND VOLUME IN PATIENTS WITH SCHIZOPHRENIA, PATIENTS AT ULTRA
HIGH RISK OF DEVELOPING PSYCHOSIS AND HEALTHY CONTROLS: A SYSTEMATIC
REVIEW AND METAANALYSIS
Dorte Nordholm, J Krogh, Valeria Mondelli, Paola Dazzan, C Pariante, Merete Nordentoft
004
STRUCTURAL AND CONNECTIVE TRACT CORRELATES OF SPONTANEOUS
MOVEMENT ABNORMALITIES IN HIGH-RISK YOUTH
Vijay A Mittal, J Orr
005
ALTERED WHITE MATTER INTEGRITY IN SCHIZOPHRENIA: THE ROLE OF
ENVIRONMENTAL AND FAMILIAL RISKS
Patrick Domen, E Gronenschild, S Michielse, P Habets, A Roebroeck, Jim van Os, M
Marcelis for GROUP
006
POLYGENIC RISK FOR SCHIZOPHRENIA: ASSOCIATIONS WITH QUANTITATIVE
STRUCTURAL AND FUNCTIONAL BRAIN MEASURES
Machteld Marcelis, Sanne Peeters, E Gronenschild, P Habets, Patrick Domen, Ruud van
Winkel, A Richards, Michael O’Donovan, Jim van Os
007
VOLUMETRIC MRI ABNORMALITIES OF THE SUPERIOR TEMPORAL GYRUS IN
MONOZYGOTIC TWINS CONCORDANT AND DISCORDANT FOR SCHIZOPHRENIA
Timothea Toulopoulou, S Waters Metenier, Robin M Murray, Marco Picchioni
008
IMPAIRED ANATOMICAL CONNECTIVITY AMONG SCHIZOPHRENIA SUBJECTS AND
FIRST DEGREE RELATIVES: A DTI STUDY
Konasale Prasad, C Upton, S Goodnow, Vishwajit Nimgaonkar, Matcheri Keshavan
009
ARE ABNORMALITIES IN SOCIAL COGNITIVE NEURAL CIRCUITRY RELATED TO
PSYCHOTIC SYMPTOMS IN 22Q11.2 MICRODELETION SYNDROME?
Maria Jalbrzikowski, A Patel, C Carter, R Jonas, C Chow, C D Gilbert, K H Karlsgodt, Carrie
E Bearden
010
MAPK14 AND CNR1 GENE VARIANT INTERACTIONS: EFFECTS ON BRAIN VOLUME
DEFICITS IN SCHIZOPHRENIA PATIENTS WITH MARIJUANA MISUSE
Obiora Onwuameze, Beng Ho
Comorbid Abstracts
/
Clinical Abstracts
61
12:00–
2:30 p.m.
Coquina Ballroom
011
THE EFFECT OF A MUSCARINIC M1 RECEPTOR SEQUENCE ON COGNITION AND
BRAIN VOLUME IN SCHIZOPHRENIA AND HEALTHY CONTROLS
Vanessa L Cropley, A Fornito, C Bousman, C Pantelis, E Scarr, B Dean
012
META-ANALYSIS OF STRUCTURAL MRI STUDIES IN NEUROLEPTIC NAIVE
SCHIZOPHRENIA
Matthew J Kempton, P K McGuire
013
LONGITUDINAL STUDY OF CORTICAL VOLUME CHANGES IN FIRST-EPISODE
PSYCHOSIS PATIENTS
Elisabeth H Lange, Unn Kristin Haukvik, R Nesvåg, D Holland, L M Rimol, C Roddey, L
Mørch-Johnsen, I Melle, O A Andreassen, A M Dale, I Agartz
014
OLFACTION AND ENTORHINAL THICKNESS IN DRUG-NAïVE FIRST EPISODE
PSYCHOSIS
Cassie B MacRae, G N Smith, L Kopala, Vina Goghari, G W MacEwan, W G Honer, W Su,
Donna J Lang
015
CORTICAL THICKNESS AND PERSISTENT NEGATIVE SYMPTOMS IN NON-AFFECTIVE
FIRST-EPISODE PSYCHOSIS
Martin Lepage, M Bodnar, Lisa Buchy, C Hovington, A Malla, R Joober
016
WHITE MATTER ALTERATIONS IN FIRST-EPISODE ANTIPSYCHOTIC-NAIVE
SCHIZOPHRENIA PATIENTS. PRELIMINARY RESULTS
Jayachandra Mitta Raghava, B Ebdrup, M Nielsen, S Wulff, E Rostrup, B Glenthøj
017
BRAIN VOLUME IN FIRST EPISODE SCHIZOPHRENIA, AN SMRI STUDY
Laura Koenders, M W Machielsen, W A Vingerhoets, A C van Gasselt, Carin Meijer, M Caan,
P Groot, D Veltman, M Koeter, A Nederveen, S Shahand, J Cousijn, A den Braber, M Rive,
M de Ruiter, E G van de Giessen, C Huyser, O Bloemen, Bart D Peters, B de Kwaasteniet, L
Schmaal, R van Holst, F da Silva Alves, M van der Tol, L de Haan
018
GLOBAL WHITE MATTER INFLAMMATION PATTERN IN FIRST-EPISODE
SCHIZOPHRENIA - A FREE-WATER MRI STUDY
Ofer Pasternak, Carl-Fredrik Westin, Sylvain Bouix, Larry J Seidman, Jill M Goldstein, TsungUng W Woo, Tracey L Petryshen, Raquelle I Mesholam-Gately, Robert McCarley, Ron
Kikinis, Martha Shenton, Marek Kubicki
019
VOLUMETRIC CHANGES IN THE BASAL GANGLIA AFTER ANTIPSYCHOTIC
MONOTHERAPY: A SYSTEMATIC REVIEW
Bjørn H Ebdrup, Henrik Nørbak, Stefan Borgwardt, Birte Glenthøj
020
LONGITUDINAL STUDIES ON ASSOCIATIONS BETWEEN USE OF ANTIPSYCHOTICS
AND BRAIN MORPHOMETRIC CHANGES IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Sanna Huhtaniska, E Jääskeläinen, N Hirvonen, J Remes, G K Murray, J Veijola, M Isohanni,
J Miettunen
62
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
021
LIPID CORRELATES OF ANTIPSYCHOTIC-INDUCED WHITE MATTER CHANGES IN
FIRST-EPISODE PSYCHOSIS
Philip Szeszko, D Robinson, Toshikazu Ikuta, Bart D Peters, Juan A Gallego, John M Kane,
Anil K Malhotra
022
PROGRESSIVE THALAMOCORTICAL NETWORK PATHOLOGY IN SCHIZOPHRENIA
Derin Cobia, Matthew J Smith, John G Csernansky, Mokhtar Gado, Charlene Ng, Lei Wang
023
EFFECTS OF FOLATE AND B12 SUPPLEMENTATION ON CORTICAL THICKNESS IN
SCHIZOPHRENIA
Joshua L Roffman, A S Tanner, A Z Nitenson, N Ho, Donald Goff
024
IMPACT OF GRAY MATTER REDUCTIONS ON ” IMPLICIT” MENTALIZING ABILITIES IN
SCHIZOPHRENIA
Katja Koelkebeck, Kazuyuki Hirao, Jun Miyata, Ryousaku Kawada, Udo Dannlowski, Shiho
Ubukata, Jochen Bauer, Patricia Ohrmann, Anya Pedersen, Hidenao Fukuyama, Nobukatsu
Sawamoto, Hidehiko Takahashi, Toshiya Murai
025
SEX DIFFERENCES IN THE EFFECT OF CHILDHOOD EMOTIONAL ABUSE ON
HIPPOCAMPAL VOLUME
Pamela DeRosse, Erin Samplin, Toshikazu Ikuta, Anil K Malhotra, Philip Szeszko
026
FUNCTIONAL AND STRUCTURAL ABNORMALITIES IN LANGUAGE NETWORK IN
SCHIZOPHRENIA: A COMBINED DTI, ANATOMICAL AND FMRI APPROACH IN PATIENTS
WITH SCHIZOPHRENIA
Leroux Elise, Delcroix Nicolas, Alary Mathieu, Lamberton Franck, Razafimandimby Annick,
Delamillieure Pascal, Brazo Perrine, Dollfus Sonia
027
BEYOND “WHITE MATTER INTEGRITY” DISRUPTIONS IN SCHIZOPHRENIA
Marek Kubicki, P Savadjiev, O Pasternak, T Crow, A James, L DeLisi, M Shenton
028
CLASSIFICATION OF STRUCTURAL MRI SCANS OF PATIENTS WITH SCHIZOPHRENIA
AND BIPOLAR DISORDER: CAN MACHINE LEARNING AID IN CLINICAL DIAGNOSIS?
Hugo Schnack, Mireille Nieuwenhuis, Neeltje van Haren, Rene Kahn
029
NEUROANATOMICAL SUBSTRATES OF SCHIZO-OBSESSIVE DISORDER
Dhanya Raveendranathan, Janardhanan C Narayanaswamy, Vijay Danivas, Sunil V Kalmady,
Ganesan Venkatasubramanian, YC Janardhan Reddy
030
DO STRUCTURAL BRAIN ABNORMALITIES UNDERLIE SELF-HARM IN PATIENTS WITH
PSYCHOTIC DISORDERS?
Christoforos I Giakoumatos, Neeraj Tandon, I T Mathew, E R Howard, A N Francis, B A
Clementz, Godfrey D Pearlson, J A Sweeney, G Thaker, C A Tamminga, M S Keshavan
031
A LARGE-SCALE STRUCTURAL MRI STUDY ACROSS THE PSYCHOSIS SPECTRUM
Neeraj Tandon, Shaun M Eack, I T Mathew, E R Howard, A N Francis, B A Clementz,
Godfrey D Pearlson, J A Sweeney, G Thaker, C A Tamminga, Matcheri Keshavan
Comorbid Abstracts
/
Clinical Abstracts
63
12:00–
2:30 p.m.
Coquina Ballroom
032
SUPPLEMENTARY MOTOR AREA (SMA) VOLUME CORRELATES WITH PSYCHOTIC
SYMPTOMS ASSOCIATED WITH DYSREGULATION OF THE MOTOR SYSTEM. A VOXELBASED MORPHOMETRY (VBM) STUDY
Katharina Stegmayer, Helge Horn, A Federspiel, N Razavi, Werner Strik, R Wiest, Sebastian
Walther
033
VENTRAL STRIATUM VOLUME AND THE PARANOID SYMPTOM COMPLEX. A VOXELBASED MORPHOMETRY STUDY
Werner Strik, Katharina Stegmayer, Sebastian Walther
034
APPLICATION OF SOURCE BASED MORPHOMETRY FOR AN AGGREGATED GRAY
MATTER DATASET
Navin Gupta Cota, Vince Calhoun, S Rachakonda, Jessica Turner
035
DELUSIONS OF CONTROL AND THE STRUCTURAL INTEGRITY OF THE CINGULUM
BUNDLE IN PATIENTS WITH SCHIZOPHRENIA
Thomas Whitford, Marek Kubicki, Paula Pelavin, Diandra Lucia, Jason Schneiderman,
Christos Pantelis, Robert McCarley, Martha Shenton
036
BIPOLAR – SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP):
HIPPOCAMPAL VOLUMES CONTRASTING MANUAL TRACINGS AND FREESURFER IN
THE PSYCHOSIS DIMENSION
Sara J Arnold, T A Gopal, S Dantu, A Hu, A P Reddy, M Wallace-Servera, C B Sacco, A S
Bidesi, Elena I Ivleva, A Francis, Godfrey D Pearlson, J Sweeney, B Clementz, G Thaker,
Matcheri Keshavan, C Tamminga
037
VOXEL-BASED GREY AND WHITE MATTER MORPHOMETRY CORRELATES OF
AUDITORY VERBAL HALLUCINATION IN SCHIZOPHRENIA: RELEVANCE OF POSTERIOR
PARIETAL AREAS
Marie-Jose van Tol, Lisette van der Meer, R Bruggeman, G Modinos, H Knegtering, Andre
Aleman
038
MR-DTI FRONTOSTRIATAL TRACTOGRAPHY FINDINGS IN CHRONIC SCHIZOPHRENIA
James J Levitt, Y Rathi, T R Raviv, R Eckbo, J C Simpson, R W McCarley, M E Shenton
039
INVESTIGATING BRAIN VOLUMES AS BIOMARKERS OF TREATMENT RESISTANT
SCHIZOPHRENIA
Bruce R Russell, Meghan E Mcilwain, R R Kydd, V M Anderson
040
WORKING MEMORY DEPENDENT PREFRONTAL-PARIETAL CONNECTIVITY AND
MODEL-BASED DIAGNOSTIC CLASSIFICATION IN SCHIZOPHRENIA
Lorenz Deserno, Kay Brodersen, Zhihao Lin, Will D Penny, Andreas Heinz, Klaas E Stephan,
Florian Schlagenhauf
041
FAILURE TO ACTIVATE IN DLPFC AND DEACTIVATE IN PRECUNEUS: A PARAMETRIC
FMRI STUDY OF CENTRAL EXECUTIVE DYSFUNCTION IN FIRST-EPISODE
SCHIZOPHRENIA
Xiang Wang, X Wang, Z Fei, T Sun, W Situ, S Yao
64
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
042
ACQUIRED EQUIVALENCE TASK IN SCHIZOPHRENIA WITH FMRI BOLD
Yan Fang, C Sacco, P Mihalakos, H Lu, A Wagner, C Tamminga
043
RELATIONSHIP BETWEEN PERIPHERAL BDNF LEVELS AND FRONTAL-STRIATAL
ACTIVITY DURING PROBABILISTIC ASSOCIATION LEARNING IN SCHIZOPHRENIA
Ashley Skilleter, A Vercammen, R Lenroot, C S Weickert, T W Weickert
044
NEURAL OSCILLATIONS DURING VISUAL REPETITION PRIMING IN SCHIZOPHRENIA: A
MEG-STUDY
Andreas Sauer, N P Castellanos, W Singer, P J Uhlhaas
045
NEUROANATOMICAL SUBSTRATES UNDERLYING EPISODIC MEMORY ENCODING AND
RECOGNITION DEFICITS IN FIRST-EPISODE PSYCHOSIS
Michael M Francis, B C McDonald, J D West, N F Mehdiyoun, T A Hummer, J Vohs, E
Liffick, A J Saykin, A Breier
046
SENTENCE-LEVEL LANGUAGE COMPREHENSION IN SCHIZOPHRENIA: A
COORDINATE-BASED ANALYSIS AND SYSTEMATIC REVIEW OF THE IMAGING
EVIDENCE
Alexander M Rapp, A E Steinhäuser
047
DYSREGULATION OF THE LEFT HEMISPHERIC LANGUAGE NETWORK DURING
FORMAL THOUGHT DISORDERS
Helge Horn, K Laimboeck, K Jann, A Federspiel, Sebastian Walther, R Wiest, Werner Strik
048
NEURAL CORRELATES OF IMPAIRED RECOGNITION MEMORY FOR SOCIAL
INFORMATION IN SCHIZOPHRENIA
Philippe-Olivier Harvey, Martin Lepage
049
NEURAL CORRELATES OF BLUNTED AFFECT IN PATIENTS WITH SCHIZOPHRENIA: AN
FMRI STUDY
Jung Suk Lee, Ji Won Chun, Hae-Jeong Park, Jae-Jin Kim
050
DECREASED FRONTO-PARIETAL ACTIVATION RELATED TO APATHY IN PATIENTS WITH
SCHIZOPHRENIA
Edith Liemburg, H Knegtering, R Renken, L Bais, J Dlabac-De Lange, M Van Osch, A
Aleman
051
HYPERACTIVITY OF THE NEURAL RESPONSES O ANTICIPATORY AND
CONSUMMATORY HEDONIC EXPERIENCE IN INDIVIDUALS WITH SCHIZOTYPAL
PERSONALITY TRAITS
Chao Yan, Yi Wang, M X Fan, Z X Wang, C P Deng, D Z Yin, W Wei, Z Jin, Raymond C Chan
052
ABERRANT ACTIVATION OF REWARD AND MENTALIZING REGIONS IN SIBLINGS OF
PATIENTS WITH PSYCHOSIS DURING TRUST-RELATED BEHAVIOUR
Paula M Gromann, S Shergill, L de Haan, Anne-Kathrin Fett, L Krabbendam
Comorbid Abstracts
/
Clinical Abstracts
65
12:00–
2:30 p.m.
Coquina Ballroom
053
BRAIN ACTIVITY DURING SELF-REFERENTIAL PROCESSING IN YOUNG PEOPLE WITH
AN AT-RISK MENTAL STATE FOR DEVELOPING PSYCHOSIS
Esther Opmeer, Edith Liemburg, Jorien van der Velde, R Nieboer, L Wunderink, A Aleman
054
BRAIN ACTIVATION DURING A THEORY OF MIND TASK IN INDIVIDUALS WITH FIRST
EPISODE PSYCHOSIS: A PILOT STUDY
Cali F Bartholomeusz, Sarah L Whittle, Ping Liu, Kelly Allott, Andrew Thompson, Eoin
Killackey, Stephen Wood
055
FUNCTIONAL NEUROIMAGING FAMILY STUDY OF EMOTION PROCESSING DEFICITS IN
SCHIZOPHRENIA
Vina Goghari, Cameron M Clark, J Prentice, I Liu, A Moir
056
ALTERED FUNCTIONAL CONNECTIVITY DURING EMOTION REGULATION IN FIRSTDEGREE RELATIVES OF PATIENTS WITH SCHIZOPHRENIA
Jorien van der Velde, M Swart, D Wiersma, R Bruggeman, A Aleman
057
LINK BETWEEN RESTING STATE DEFAULT-MODE NETWORK, SALIENCE NETWORK
AND SYMPTOMATOLOGY IN SCHIZOPHRENIA
François Orliac, Mickael Naveau, Marc Joliot, Nicolas Delcroix, Annick Razafimandimby,
Perrine Brazo, Sonia Dollfus, Pascal Delamillieure
058
THE NEURAL BASES OF IMPAIRED LEARNING FROM REWARD IN UNMEDICATED
Florian Schlagenhauf, Q Huys, Lorenz Deserno, M Rapp, A Beck, A Heinz
059
THE EFFECTS OF OXYTOCIN ON BRAIN ACTIVITY DURING A ‘TRUST GAME’ IN
SCHIZOPHRENIA
Mahesh Menon, A Naber, F Caravaggio, Philip Gerretsen, P J Zak, Gary Remington, Ariel
Graff-Guerrero
060
MULTISENSORY EMOTIONAL PROCESSING IN FIRST EPISODE PSYCHOSIS:
PRELIMINARY RESULTS FROM AN FMRI STUDY OF AUDIOVISUAL EMOTION
RECOGNITION
Huai-Hsuan Tseng, Irina Falkenberg, G Modinos, C Samson, P McGuire, Paul Allen
061
REDUCED NEURAL RESPONSES DURING SOCIAL REFLECTION IN FIRST-DEGREE
RELATIVES OF PERSONS WITH SCHIZOPHRENIA
Benjamin Brent, Larry J Seidman, G Coombs, J Moran, Matcheri Keshavan, D J Holt
062
THE EFFECT OF TYPICAL AND ATYPICAL ANTIPSYCHOTIC DRUG TREATMENT ON
LEARNING AND MEMORY GENERALIZATION IN SCHIZOPHRENIA. THE NORTHERN
FINLAND 1966 BIRTH COHORT STUDY
Eero Rönkkö, Laura Kukkohovi, M Kyllönen, Matti K Isohanni, T Starck, V Kiviniemi, J
Veijola, C Tamminga, A Alaräisänen
063
COGNITIVE REMEDIATION TRAINING AFFECTS DEFAULT MODE NETWORK
COHERENCE IN PATIENTS WITH SCHIZOPHRENIA
Ian S Ramsay, Angus W MacDonald
66
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
064
DOES TARGETED SOCIAL COGNITIVE TRAINING ENHANCE CORTICAL AND
SUBCORTICAL ACTIVATION IN SCHIZOPHRENIA DURING REWARD PROCESSING?
Karuna Subramaniam, S Nagarajan, C Hooker, Sophia Vinogradov
065
GENETIC ASSOCIATIONS OF THE DEFAULT-MODE NETWORK DERIVED USING
PARALLEL-ICA: A BIPOLAR – SCHIZOPHRENIA NETWORK ON INTERMEDIATE
PHENOTYPES (B-SNIP) STUDY
Shashwath Meda, Balaji Narayanan, Matcheri Keshavan, J Sweeney, B Clementz, G Thaker,
C Tamminga, G Ruano, A Windermuth, Godfrey D Pearlson
066
SPECIFICITY OF DECREASED FUNCTIONAL LANGUAGE LATERALIZATION IN
SCHIZOPHRENIA: A COMPARATIVE FUNCTIONAL MAGNETIC RESONANCE IMAGING
STUDY IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDERS
Mathieu Alary, A Razafimandimby, N Delcroix, E Leroux, P Delamillieure, P Brazo, Sonia
Dollfus
067
DELINEATING THE FUNCTIONAL NEUROANATOMY OF ILLNESS DENIAL OR
ANOSOGNOSIA IN SCHIZOPHRENIA
Philip Gerretsen, Mahesh Menon, David Mamo, Bruce G Pollock, Ariel Graff
068
CORTICAL CONTRIBUTION TO PREPULSE INHIBITION IN HUMANS
Morris Goldman, L Heidinger, Z Zhang, T Parrish
069
SEEING LINES: CONTEXT INFLUENCES CONTOUR DETECTION DEFICITS IN
SCHIZOPHRENIA
Scott R Sponheim, Seung Suk Kang, M P Schallmo, N Van Meerten, C A Olman
070
<β>2*-NACHR AVAILABILITY IN SCHIZOPHRENIA: EFFECTS OF SMOKING AND
RELATIONSHIP TO SYMPTOMS
Deepak C D’Souza, F Bois, L Shearer, M Krasenics, A Sewell, M Ranganathan, K Cosgrove,
I Esterlis
071
TOBACCO CUE-REACTIVITY IN SMOKING PATIENTS WITH PSYCHOTIC DISORDERS:
PRELIMINARY DATA FROM A BEHAVIORAL AND FMRI STUDY
Kimberley P Good, S Barrett, M Armstrong, H Schlagintweit, D M Lewis, P Tibbo, H I
Milliken, M Alexiadis, N Robertson, A Pencer, R A Leslie, J Morrison, S Stewart
072
VISUAL DISCRIMINATION & SMOKING CUES SEGREGATES SCHIZOPHRENIA VS.
SMOKING RELATED BRAIN ACTIVATIONS
Florian Muellerklein
073
GENETIC MODERATORS OF SENSITIVITY TO THE SYMPTOMATIC AND NEURAL
EFFECTS OF CANNABIS ON PSYCHOSIS
Sagnik Bhattacharyya, Z Atakan, R Martin-Santos, J A Crippa, J Kambeitz, D Prata, S
Williams, M Brammer, D A Collier, P K McGuire
074
BRAIN METABOLISM IN SUBSTANCE INDUCED PSYCHOSIS AND SCHIZOPHRENIA: A
PRELIMINARY PET STUDY
Alfredo C Altamura, F Dragogna, M C Mauri, G Marotta, F T Armao, P Brambilla
Comorbid Abstracts
/
Clinical Abstracts
67
12:00–
2:30 p.m.
Coquina Ballroom
075
GENETIC AND ENVIRONMENTAL INFLUENCES ON FRONTO-TEMPORAL FUNCTION
AND CONNECTIVITY IN SCHIZOPHRENIA: AN FMRI STUDY IN THE MAUDSLEY TWIN
AND FAMILY COHORTS
Marco Picchioni, Timothea Toulopoulou, A Pauli, Isabel Valli, U Ettinger, C Fu, M H Hall, V
Giampietro, J Sato, M Brammer, D Gasston, Robin M Murray, P K McGuire
076
RESTING-STATE FUNCTIONAL CONNECTIVITY IN EARLY-ONSET SCHIZOPHRENIA AND
THE ULTRA-HIGH RISK STATE
Rabindra Tambyraja, Christopher Bell, Sanjiv Kumra, Daniel Jensen, Kelvin O Lim
077
TEST-RETEST RELIABILITY OF ICA AND GLM ANALYSIS IN SCHIZOPHRENIA PATIENTS
DURING A COGNITIVE TASK
Andrew Poppe, Deanna M Barch, Cameron Carter, D Ragland, S Silverstein, Angus W
MacDonald
078
THALAMUS AND WERNICKE’S AREA SHOW HEIGHTENED CONNECTIVITY AMONG
INDIVIDUALS WITH SCHIZOPHRENIA DURING RESTING STATE AND TASK
PERFORMANCE ON A SENSORY LOAD HIERARCHY
Mustafa S Cetin, Fletcher Christensen, J Stephen, A Mayer, C Abbott, V Calhoun
079
DISRUPTION OF ANTERIOR INSULA MODULATION OF LARGE SCALE BRAIN
NETWORKS IN SCHIZOPHRENIA
Lauren V Moran, Malle Tagamets, Hemalatha Sampath, Elliot A Stein, Peter Kochunov, L
Elliot Hong
080
ALTERED DEFAULT MODE NETWORK ACTIVITY IN SCHIZOPHRENIA PATIENTS
Anne Pankow, Lorenz Deserno, Felix Bermpohl, Martin Walter, Andreas Heinz, Florian
Schlagenhauf
081
EVOKED NEURAL OSCILLATION SIGNALS IN SCHIZOPHRENIA: COMPARE SINGLE
TRIAL VERSUS AVERAGING METHODS ACROSS DISCRETE WAVELET, CONTINUOUS
WAVELET, AND FOURIER TRANSFORMS
Xiaoming Du, A Summerfelt, L E Hong
082
COMPARISON OF MULTIPLE RESTING STATE NETWORKS IN SCHIZOPHRENIA AND
PSYCHOTIC BIPOLAR PROBANDS AND THEIR UNAFFECTED FIRST DEGREE
RELATIVES
Sabin Khadka, Shashwath Meda, M C Stevens, David Glahn, Vince Calhoun, J Sweeney, C
Tamminga, Matcheri Keshavan, G Thaker, K O Neil, D Schretlen, Godfrey D Pearlson
083
STRUCTURAL ABNORMALITIES PREDICT FUNCTIONAL AUDITORY ABNORMALITIES IN
SCHIZOPHRENIA: MAGNETOENCEPHALOGRAPHY, CORTICAL THICKNESS AND
DIFFUSION TENSOR IMAGING DATA
Yu-Han Chen, Arvind Caprihan, J Christopher Edgar, Mingxiong Huang, Breannan C Howell,
Michael A Hunter, Emerson Epstein, Jose M Canive
084
CHILDHOOD TRAUMA AND FUNCTIONAL CONNECTIVITY IN PSYCHOTIC DISORDER
Sanne Peeters, V van de Ven, P Habets, R Goebel, Jim van Os, M Marcelis
68
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
085
NEURONAL SYNCHRONIZATION IN SCHIZOPHRENIA: AN FMRI STUDY
María J Escartí, M de la Iglesia-Vaya, J Molina-Mateo, L Martí-Bonmati, E J Aguilar, G
Garcia-Martí, J Sanjuán
086
CHANGES IN SPONTANEOUS BRAIN ACTIVITY PATTERNS IN ANTIPSYCHOTIC NAïVE
SCHIZOPHRENIA PATIENTS (ANFE) BEFORE AND AFTER ANTIPSYCHOTIC
MONOTHERAPY
Simon Anhoej, E Rostrup, J Raghava, B Glenthoj
087
COMPARISON OF LARGE-SCALE HUMAN BRAIN FUNCTIONAL AND ANATOMICAL
NETWORKS IN SCHIZOPHRENIA
Brent G Nelson, D S Bassett, J Camchong, K O Lim
088
EXAMINING INTENTIONAL AND INCIDENTAL BINDING IN WORKING MEMORY IN
SCHIZOPHRENIA: A PILOT FMRI STUDY
David Luck, A Mendrek, L Nicole, E Stip
089
NORMALIZING WORKING MEMORY FOR SERIAL ORDER IN SCHIZOPHRENIA
David McAllindon, E E Keefe, P G Tibbo, G A Eskes
090
THE USEFUL FIELD OF VIEW TEST PERFORMANCE IN SCHIZOPHRENIA REVEALS
MARKED ABNORMALITIES IN THE DISTRIBUTION OF SPATIAL ATTENTION
James M Gold, B E Gray, B M Robinson, B Hahn, A N Harvey, C J Leonard, S J Luck
091
EPIGENETIC REGULATION AND GENETIC VARIATION OF AKT1 PREDICT WORKING
MEMORY PERFORMANCE
Gianluca Ursini, Tommaso Cavalleri, Leonardo Fazio, Laura Dioni, Marco Colizzi, Marina
Mancini, Annamaria Porcelli, Barbara Gelao, Raffaella Romano, Letizia Tarantini, Rita
Masellis, Lorenzo Sinibaldi, Antonio Rampino, Paolo Taurisano, Annabella Di Giorgio,
Grazia Caforio, Giuseppe Blasi, Valentina Bollati, Alessandro Bertolino
092
LEARNING AND STIMULUS GENERALIZATION IN SCHIZOPHRENIA, OTHER
PSYCHOSES, SIBLINGS, AND CONTROLS. THE NORTHERN FINLAND 1966 BIRTH
COHORT STUDY
Laura Kukkohovi, E Ronkko, M Kyllonen, M Isohanni, T Starck, J Nikkinen, V Kiviniemi, J
Veijola, C Tamminga, A Alaraisanen
093
NEURAL CORRELATES OF NEW INFORMATION PROCESSED DURING EPISODIC
RECOGNITION IN PEOPLE WITH A FIRST EPISODE SCHIZOPHRENIA
Synthia Guimond, M Brodeur, A Benoit, G Charbonneau, C Hawco, H Malla, R Joober,
Martin Lepage
094
ASSOCIATIVE INFERENCE IMPAIRMENT IN FIRST EPISODE PSYCHOSIS
Kristan Armstrong, Lisa E Williams, Stephan Heckers
095
MICE LACKING METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) EXPRESSION
ON PARVALBUMIN-CONTAINING GABAERGIC INTERNEURONS EXHIBIT ALTERED
SENSORIMOTOR GATING AND IMPAIRED SPATIAL- AND REVERSAL-LEARNING
Samuel A Barnes, Terrence J Sejnowski, Margarita M Behrens, Athina Markou
Comorbid Abstracts
/
Clinical Abstracts
69
12:00–
2:30 p.m.
Coquina Ballroom
096
PREFRONTAL CORTEX ACTIVITY DURING RESPONSE SELECTION PREDICTS
PROCESSING SPEED IMPAIRMENT IN SCHIZOPHRENIA
Neil D Woodward, B Duffy-Alberto, H Karbasforoushan
097
BEHAVIORAL RESPONSE INHIBITION IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Melanie Soilleux, J Reilly, Lauren E Ethridge, P Nakonezny, S Hill, J Gold, E Gershon, C
Tamminga, Godfrey D Pearlson, Matcheri Keshavan, J Sweeney
098
CROSS-DIAGNOSTIC COMPARISON OF VISUAL PROCESSING IN BIPOLAR DISORDER
AND SCHIZOPHRENIA
Carol Jahshan, Jonathan K Wynn, Amanda McCleery, Justina Avila, Michael F Green
099
DEFECTIVE TRANSLATION OF EMOTIONAL SALIENCE TO MOTIVATED BEHAVIOR IN
INDIVIDUALS WITH SCHIZOPHRENIA: FURTHER EVIDENCE FROM SAMPLE WITH
EARLY PSYCHOSIS
Simon S Lui, Amy CY Liu, Constance KY Chan, Chi Fong Tsui, Meranda MW Leung, William
WH Chui, Kirby CM Choi, Erin Heerey, Eric FC Cheung, Raymond CK Chan
100
STABLE COGNITIVE CONTROL DEFICITS IN FIRST EPISODE SCHIZOPHRENIA: A ONEYEAR LONGITUDINAL FMRI STUDY
Tyler A Lesh, Tara A Niendam, M J Minzenberg, J H Yoon, John D Ragland, M Solomon, C
S Carter
101
MULTI-SITE FMRI STUDY OF COGNITIVE CONTROL-RELATED BRAIN ACTIVATION IN
EARLY SCHIZOPHRENIA AND CLINICAL-HIGH-RISK YOUTH: PRELIMINARY
ASSOCIATIONS WITH OUTCOME
Tara A Niendam, C S Carter, S F Taylor, Tyler A Lesh, D Fulford, Rachel Loewy, Sophia
Vinogradov, D H Mathalon
102
INTERIM ANALYSES OF A RANDOMIZED CONTROLLED TRIAL OF COMPUTERIZED
COGNITIVE TRAINING IN CLINICAL HIGH RISK FOR PSYCHOSIS
Rachel Loewy, Melissa Fisher, Daniel H Mathalon, Sophia Vinogradov
103
THE FUNCTIONAL SIGNIFICANCE OF ANTIPSYCHOTIC-RELATED CORTICAL THINNING
IN FIRST EPISODE SCHIZOPHRENIA
Cameron Carter, Tyler A Lesh, C Tanase, Tara A Niendam, J Yoon, John D Ragland, M
Minzenberg, M Solomon
104
INTEREST OF A COMBINED REHABILITATION APPROACH IN PATIENTS WITH
SCHIZOPHRENIA: EXAMPLE OF AN ADDITION OF A COGNITIVE REMEDIATION TASK
(SELECTIVE ATTENTION) TO THE “EMOTION MANAGEMENT ” SUB-PROGRAM 5 OF
IPT: PRELIMINARY RESULTS
Thierry Lambert, L Kechid, C Gautier, C Hochard, S Orens, L Geret, Marie-Cecile Bralet
105
ARE COGNITIVE SALIENCE TESTS ASSOCIATED WITH FUNCTIONAL OUTCOME IN A
POPULATION OF CHRONIC MEDICATED SCHIZOPHRENIA PATIENTS?
Philippe Nuss, H Bergaoui, K Sweers, A Frajerman, Marc De Hert, Cédric Tessier
70
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
106
DEVIANT MODULATION OF INTRINSIC NEURAL ACTIVITY AS A FUNCTION OF TASK
DIFFICULTY IN SCHIZOPHRENIA
Matthew E Hudgens-Haney, Anastasia M Bobilev, Jordan P Hamm, W T Oliver, K A
Dyckman, Peter F Buckley, J E McDowell, B A Clementz
107
A MULTIMODAL APPROACH TO SCIZOPHRENIA: HESCHL GYRUS VOLUMETRY,
ELECTROPYSIOLOGY AND DICHOTIC LISTENING TEST
Murat Ozgoren, S Taslica, A Oniz, K Alptekin, N Karabay
108
THE BENEFICIAL INFLUENCE OF INATTENTION IN SCHIZOPHRENIA
Mathieu B Brodeur, M Kiang, J M.Y. Spencer, R E Patrick, B K Christensen
109
ABNORMAL SWITCHING OF SPATIAL ATTENTION IN SCHIZOPHRENIA
Marie-Lou Joly, B K Christensen, M Kiang, R E Patrick, J M.Y. Spencer, Mathieu B Brodeur
110
FMRI BOLD ACTIVATION DURING STROOP PERFORMANCE IN SCHIZOPHRENIA:
EVIDENCE FOR “INEFFICIENT” COGNITIVE PROCESSING
Ammu Lukose, H Halahalli, J N Peruvumba, S Jain, John P John
111
DEFICITS IN GOAL MAINTENANCE IN SCHIZOPHRENIA, SCHIZOAFFECTIVE
DISORDER, AND PSYCHOTIC BIPOLAR PROBANDS (AND SOME OF) THEIR FIRST
DEGREE RELATIVES: FINDINGS FROM THE BSNIP CONSORTIUM
James L Reilly, S K Hill, James M Gold, E Gershon, Matcheri Keshavan, Godfrey D
Pearlson, C Tamminga, G Thaker, J Sweeney
112
ACUTE STRESS EFFECTS ON ANXIETY AND COGNITION IN MICE WITH TARGETED
DELETION OF THE SCHIZOPHRENIA RISK GENE DYSBINDIN-1
Lieve Desbonnet, Colm M O’Tuathaigh, Claire O’Leary, Rachel Cox, Niamh Clarke, Emilie
Petit, Josephine Joel, Alexander Shaw, Steve Sheardown, Alastair D Morrison, Steven
Wilson, Ellen Shapland, James N Kew, John L Waddington
113
EFFECT OF YOGA THERAPY ON PLASMA OXYTOCIN AND FACIAL EMOTION
RECOGNITION DEFICITS IN PATIENTS OF SCHIZOPHRENIA
Naveen Jayaram, Rishikesh V Behere, Shivarama Varambally, Ganesan Venkatsubramanian,
Rita Christofer, Bangalore N Gangadhar
114
EYE-TRACKING EVIDENCE FOR AN EMOTION REGULATION ABNORMALITY IN
SCHIZOPHRENIA: ATTENTIONAL DEPLOYMENT STRATEGIES FAIL TO DECREASE
NEGATIVE AFFECT
Adam J Culbreth, Gregory P Strauss, James M Gold
115
DIFFERENTIAL ROLES OF BASIC VISUAL INFORMATION IN FEAR AND HAPPINESS
PERCEPTION IN SCHIZOPHRENIA
Yue Chen, R McBain, D Norton, Dost Ongur
116
REWARD-RELATED NEURAL RESPONSES AS PREDICTORS OF PSYCHOTIC
SYMPTOMS IN CHRONIC SCHIZOPHRENIA PATIENTS
James A Waltz, T J Ross, B J Salmeron, J B Schweitzer, E J Rose, James M Gold, E A Stein
Comorbid Abstracts
/
Clinical Abstracts
71
12:00–
2:30 p.m.
Coquina Ballroom
117
THE TAPPING FOR REWARD TASK (TRT): A SELF-CALIBRATING, NOVEL REWARD
PARADIGM FOR PSYCHOSIS RESEARCH
Anna Docherty, Scott R Sponheim, J G Kerns
118
REWARD PROCESSING IN SCHIZOPHRENIA AND RISK FOR PSYCHOSIS
David C Cicero, Elizabeth A Martin, Theresa M Becker, John G Kerns
119
PERCEPTUAL CORRELATES OF INTERPERSONAL ATTACHMENT AND FEELINGS OF
LONELINESS IN SCHIZOPHRENIA
Krystal G Ludwig, S A Zerbe, Monica E Calkins, E S Neustadter, C Kohler, Bruce I Turetsky,
F Irani, David I Leitman
120
EFFECT OF MATERNAL DEPRIVATION IN THE BEHAVIORAL CHANGES INDUCED BY
KETAMINE IN THE ANIMAL MODEL OF SCHIZOPHRENIA
Josiane Budni, I Miranda, R Luca, P Deroza, M Oliveira, A S Heylmann, F R Silveira, P G
Wessler, J Quevedo, Alexandra Zugno
121
AGE OF ONSET AND COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA: AN ECOLOGICAL
CROSS-SECTIONAL STUDY IN CLINICALLY STABILIZED PATIENTS
Elisabetta Caletti, Massimiliano Buoli, R Paoli, A Caldiroli, S Zago, A C Altamura
122
RELATIONS OF PARANOIA WITH ATTRIBUTION STYLE AND SELF-CONSCIOUSNESS IN
YOUNG COLLEGE STUDENTS
Seul Bee Lee, S Koo, Y Song, Y Jeong, J Park, J Kang, S Kim, S An
123
ATTRIBUTIONAL STYLE IN FIRST EPISODE OF SCHIZOPHRENIA AND SCHIZOPHRENIA
SPECTRUM DISORDERS
Yulia Zaytseva, Vitalina Burova, Zanna Garakh, Isaac Y Gurovich
124
MIRROR NEURON DYSFUNCTION IN SCHIZOPHRENIA AND ITS ASSOCIATION WITH
SOCIAL COGNITION
Urvakhsh M Mehta, Rakshathi Basavaraju, Jagadisha Thirthalli, Bangalore N Gangadhar
125
MIRROR SYSTEMS AND SOCIAL COGNITION IN SCHIZOPHRENIA
Sophie C Andrews, P G Enticott, K E Hoy, P B Fitzgerald
126
INVESTIGATION OF BODY PERCEPTION IN SUBJECTS AT ULTRA-HIGH RISK FOR
PSYCHOSIS AND PATIENTS WITH SCHIZOPHRENIA
MinAh Kim, M Byun, S Nam, N Shin, S Kim, Jun Soo Kwon
127
TO TRUST OR NOT TO TRUST: THE DYNAMICS OF SOCIAL INTERACTIONS IN EARLY
PSYCHOSIS
Anne-Kathrin Fett, Paula M Gromann, Sukhi Shergill, Lydia Krabbendam
128
MOTOR CONSCIOUSNESS DURING INTENTION-BASED AND STIMULUS-BASED
ACTIONS: A SPECIFIC DEFICIT OF INTENTIONALITY IN PATIENTS WITH
SCHIZOPHRENIA
Yvonne N Delevoye-Turrell, C Bobineau
72
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
129
SCHIZOPHRENIA AND SOCIAL COGNITION: ON ACCESSING AGENT-RELEVANT
SCHEMATA
Paul T Lewis, T M Gongora
130
FACTOR STRUCTURE OF SOCIAL COGNITION IN SCHIZOPHRENIA: IS EMPATHY
PRESERVED?
Silvia Corbera, Morris D Bell, S Ikezawa, B Wexler
131
REAL WORLD FUNCTIONAL MILESTONES AND SELF ASSESSMENT OF FUNCTIONAL
ABILITIES IN SCHIZOPHRENIA:CURRENT ACHIEVEMENT PREDICTS ACCURATE SELFASSESSMENT?
Samir Sabbag, Felicia Gould, Dante Durand, Philip D Harvey
132
THE RELATION BETWEEN INSIGHT AND USE OF FEEDBACK ON THE WISCONSIN
CARD SORTING TEST IN PATIENTS WITH SCHIZOPHRENIA
Annerieke E de Vos, Marieke Pijnenborg, Andre Aleman, P Croeze, Lisette van der Meer
133
BIMANUAL COORDINATION OF GRIP FORCE IN SCHIZOPHRENIA
M Teremetz, I Amado, J P Bleton, R Gaillard, M A Maier, M O Krebs, P Lindberg
134
DELETERIOUS EFFECTS OF VISUAL ORGANIZATION ON RHYTHMIC MANUAL TAPPING
IN PATIENTS WITH CLINICAL DISORGANIZATION
Anne Giersch, H Wilquin, Y Delevoye-Turrell
135
FORMING VERY FIRST IMPRESSIONS: EFFECTS OF STIMULUS DURATION AND
SPATIAL FREQUENCY IN SCHIZOPHRENIA
Julia Vakhrusheva, V Zemon, M Bar, N G Weiskopf, E Petkova, A Glass, F Tremeau, P D
Butler
136
THE MAGNOCELLULAR VISUAL PATHWAY AND FACIAL EMOTION IDENTIFICATION IN
SCHIZOPHRENIA
Jeffrey S Bedwell, C C Chan, O Cohen, Y Karbi, E Shamir, Y Rassovsky
137
REDUCED SENSITIVITY TO VISUAL ILLUSIONS IS STATE RELATED IN SCHIZOPHRENIA:
IMPLICATIONS FOR A BIOMARKER OF PSYCHOSIS
Steven M Silverstein, B P Keane, K Feigenson, Y Wang, D Mikkilineni, D Paterno, J Joseph,
T V Papathomas
138
SEEING IN DEPTH: A BEHAVIORAL EXAMINATION OF DEPTH PERCEPTION IN
INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS
Mariapaola Barbato, Jean Addington
139
IS DISORGANIZATION A FEATURE OF SCHIZOPHRENIA OR AN INDIVIDUAL
DIFFERENCE THAT MODIFIES CLINICAL PRESENTATION?
Keith Feigenson, Brian Keane, Deepthi Mikkilineni, Yushi Wang, Danielle Paterno, Steven M
Silverstein
140
STUDY OF CONTEXT EFFECTS ON OBJECT RECOGNITION IN SCHIZOPHRENIA
Melissa Maguire, Mathieu B Brodeur, Martin Lepage, M Bouras
Comorbid Abstracts
/
Clinical Abstracts
73
12:00–
2:30 p.m.
Coquina Ballroom
141
PERCEPTUAL AND CONCEPTUAL DISORGANIZATION IN SCHIZOPHRENIA: TWO SIDES
OF THE SAME COIN?
Brian P Keane, J Joseph, Steven M Silverstein
142
ALTERATIONS OF THE MISMATCH NEGATIVITY (MMN) AND NOVELTY P300 IN
SCHIZOPHRENIA PATIENTS WITH AUDITORY HALLUCINATIONS
Derek Fisher, Dylan Smith, Alain Labelle, Verner Knott
143
COMPARING THE EXECUTIVE FUNCTION IN SCHIZOPHRENIA AND BIPOLAR
DISORDER: A META-ANALYSIS WITH HAYLING SENTENCE COMPLETION TEST
Kui Wang, Li-ling Song, Eric Cheung, Simon S Lui, David Shum, Raymond C Chan
144
PRELIMINARY FINDINGS OF THE DYNAMIC SOCIAL COGNITION BATTERY (DSCB), A
COMPREHENSIVE TOOLKIT FOR SOCIAL COGNITION IN PATIENTS WITH
SCHIZOPHRENIA
Luka Lucic, Anzalee Khan, B Rothman, Christian Yavorsky, Mark G Opler
145
THE COMT GENE IS ASSOCIATED WITH NEUROLOGICAL ABNORMALITIES AND
POORER EXECUTIVE FUNCTION IN CAUCASIAN PATIENTS WITH PSYCHOSIS
Sarah Tosato, Elisa Ira, Manuela Russo, Conrad Iyegbe, Marta M Di Forti, Antonio Lasalvia,
Kevin Morgan, Chiara Bonetto, Craig Morgan, Tiago Reis Marques, David Collier, Avi
Reichenberg, Robin M Murray, Michele Tansella, Mirella Ruggeri, Paola Dazzan
146
CORRELATES OF COGNITIVE DYSFUNCTION AMONG PATIENTS WITH
SCHIZOPHRENIA IN A NIGERIAN HOSPITAL
Adeniran Okewole, Abiodun Adewuya, Roger Makanjuola
147
INFANT BRAIN STRUCTURE AND COGNITIVE DEVELOPMENT IN CHILDREN AT HIGHRISK FOR SCHIZOPHRENIA
Sarah Short, B D Goldman, M Styner, S Woolson, J H Gilmore
148
COGNITIVE FUNCTIONING ASSOCIATED WITH STIMULANT USE IN PATIENTS WITH
NON-AFFECTIVE PSYCHOSIS, THEIR UNAFFECTED SIBLINGS AND HEALTHY
CONTROLS
Floor J van der Meer, J H Meijer, Carin Meijer, W van den Brink, Eva Velthorst, R S Kahn, D
H Linzen, Jim van Os, D Wiersma, R Bruggeman, W Cahn, L Krabbendam, I MyinGermeys, L de Haan
149
PHYSICAL MANIFESTATIONS OF SCHIZOPHRENIA
Mohamad Motaz Al Samman, M M Ramadan
150
THE NEUROTOXICITY HYPOTHESIS REVISITED
Bjørn R Rund
151
CENTRAL OBESITY AND SERUM LIPID LEVELS DIFFERENTLY CORRELATE WITH
COGNITIVE FUNCTION IN SCHIZOPHRENIA
Yoichiro Takayanagi, Nicola G Cascella, Akira Sawa, William W Eaton
74
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
152
CAT BITES IN CHILDHOOD AND SCHIZOTYPY IN EARLY ADULTHOOD
Jenya Kolpakova, Jeffrey S Bedwell
153
AKT DEFICIENCY IN PREFRONTAL CORTEX ALTERS DOPAMINE SENSITIVITY
Yanchun Li, W Gao
154
PREDICTION OF QUETIAPINE DOSE BY COGNITIVE MEASURES USING A SUPPORT
VECTOR MACHINE ALGORITHM IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA
PATIENTS. PRELIMINARY RESULTS
Nikolaj Bak, Bjørn H Ebdrup, Hans Rasmussen, B Fagerlund, B Y Glenthoj
155
CATECHOL-O-METHYLTRANSFERASE (COMT) GENOTYPE AS A PREDICTOR OF
RESPONSE TO COMPUTERIZED COGNITIVE REMEDIATION IN SCHIZOPHRENIA AND
SCHIZOAFFECTIVE DISORDERS
Saurabh Kaushik, Jean-Pierre Lindenmayer, Anzalee Khan, H Lachman, Susan R McGurk
156
INTERLEUKIN-6 AND COGNITION IN NON-AFFECTIVE PSYCHOSIS
Brian Miller, A Mellor, Peter F Buckley
157
EXPRESSION OF AMPA RECEPTORS AND THEIR AUXILIARY PROTEINS, TARPS, IN AN
ISOLATED ENDOPLASMIC RETICULUM FRACTION FROM POSTMORTEM BRAIN IN
SCHIZOPHRENIA
Jana B Drummond, Vahram Haroutunian, R E McCullumsmith, James H Meador-Woodruff
158
CANNABIS EXPERIENCES, COGNITION AND SCHIZOTYPY
Emma Barkus, S De Leede Smith, E Walter, R Spencer, B Lender, E Jackson, S Princess, C
McCrudden, M Wilson, A Malmqvist
159
FACIAL RECOGNITION OF EMOTIONS IN SCHIZOPHRENIC PATIENTS, SIBLINGS
PATIENTS AND NON-SCHIZOPHRENIC SUBJECTS
Ricardo A Saracco-Alvarez
160
SPATIAL NAVIGATION IN SCHIZOPHRENIA USING A REALISTIC VIRTUAL CITY
John A Zawadzki, G Foussias, A Rodrigues, I Siddiqui, J Lerch, T A Girard, G Remington, C
Grady, A Wong
161
PREDICTION ERROR DISEQUILIBRIUM IN SCHIZOPHRENIA
Yuichi Yamashita, R Izawa, J Tani
162
NEUROCOGNITIVE ANALYSIS OF AGING AND YOUNGER ADULTS WITH
SCHIZOPHRENIA
Jasmine O Wilson, Shaun M Eack
163
FUNCTIONAL CONNECTIVITY OF REWARD CIRCUITRY IN SCHIZOPHRENIA AND COOCCURRING CANNABIS USE DISORDER: EFFECTS OF SMOKED CANNABIS AND ORAL
DELTA-9-TETRAHYDROCANNABINAL
Adina Fischer, Susan Whitfield-Gabrieli, Robert M Roth, Mary F Brunette, Alan I Green
Comorbid Abstracts
/
Clinical Abstracts
75
12:00–
2:30 p.m.
Coquina Ballroom
164
THE EFFECTS OF ANTIPSYCHOTIC MEDICATION ON REGIONAL CEREBRAL BLOOD
FLOW (RCBF) IN SCHIZOPHRENIA AND ASSOCIATIONS WITH CLINICAL VARIABLES
AND TREATMENT RESPONSE: A SYSTEMATIC REVIEW
Rhianna Goozee, Rowena Handley, Matthew J Kempton, Paola Dazzan
165
NEUROINFLAMMATION IN FIRST EPISODE PSYCHOSIS: MYELIN CONTENT AND
PERIPHERAL INFLAMMATORY MARKERS
Annalisa Giordano, Sean Deoni, Katrina McMullen, Anum Farid, Andy Simmons, Craig
Morgan, Tiago Reis Marques, Valeria Mondelli, Carmine Pariante, Federico Turkheimer,
Steven Williams, Paola Dazzan
166
A PROSPECTIVE META-ANALYSIS OF BRAIN MEASURES IN SCHIZOPHRENIA VIA THE
ENIGMA CONSORTIUM
Jessica Turner, Derrek Hibar, Jerod Rasmussen, Ole Andreassen, Unn Kristin Haukvik,
Ingrid Agartz, Steven G Potkin, Roel Ophoff, Hilleke Hulshoff Pol, Neeltje van Haren, Oliver
Gruber, Bernd Krämer, Stefan Ehrlich, Johanna Hass, Kathryn Alpert, Lei Wang, Godfrey D
Pearlson, David Glahn, Paul Thompson, Theo G van Erp
167
BODY MASS INDEX (BMI) AND CORTICAL AREA AND THICKNESS AMONG PATIENTS
WITH SEVERE MENTAL ILLNESS AND HEALTHY CONTROLS
Kjetil N Jørgensen, Lynn Mørch-Johnsen, Elisabeth H Lange, Unn Haukvik, Ragnar Nesvåg,
Ingrid Melle, Ole A Andreassen, Ingrid Agartz
168
HIPPOCAMPAL SUBFIELD ALTERATIONS IN PSYCHOTIC DISORDERS IN THE B-SNIP
STUDY
Tova Gardin, Neeraj Tandon, Alan N Francis, Ian T Mathew, Christoforos I Giakoumatos,
Brett A Clementz, Godfrey D Pearlson, J Sweeney, C Tamminga, Matcheri Keshavan
169
CORTICAL GYRIFICATION IN FIRST-DEGREE RELATIVES OF PATIENTS WITH
PSYCHOTIC DISORDERS
Pranav Nanda, Ian T Mathew, Neeraj Tandon, Christoforos I Giakoumatos, E R Howard,
Brett A Clementz, Godfrey D Pearlson, J Sweeney, G Thaker, C Tamminga, Matcheri
Keshavan
170
TYPE 3 METABOTROPIC GLUTAMATE RECEPTOR (GRM3) VARIANTS ARE ASSOCIATED
WITH SPATIAL WORKING MEMORY AND SYMPTOM CHANGES AFTER ANTIPSYCHOTIC
TREATMENT
Jeffrey R Bishop, James L Reilly, Margret S Harris, Shitalben Patel, Rick Kittles, Judith A
Badner, Konasale Prasad, Vishwajit Nimgaonkar, Matcheri Keshavan, John A Sweeney
171
EMOTION PERCEPTION IN UNAFFECTED FIRST-DEGREE RELATIVES OF PATIENTS
WITH SCHIZOPHRENIA
Nicky Klaasen, Jorien van der Velde, Paula M Gromann, Marte Swart, Esther Opmeer, Durk
Wiersma, Richard Bruggeman, Lieuwe de Haan, Lydia Krabbendam, Andre Aleman
76
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
172
OXIDATIVE STRESS AND MEMORY FUNCTION IN EARLY ONSET PSYCHOSIS: A TWO
YEARS FOLLOW-UP STUDY
Marta Rapado-Castro, Maria Álvarez, David Fraguas, Ana Calvo, Charles Gasparovic,
Dolores Moreno, Juan Antonio Mico, Ana González-Pinto, Josefina Castro-Fornieles, Celso
Arango
173
PATTERN SEPARATION DEFICITS IN SCHIZOPHRENICS SUPPORT ANIMAL &
POSTMORTEM WORK TO PROVIDE BREAKING HUMAN BEHAVIOURAL EVIDENCE OF
IMPAIRED NEUROGENESIS IN THE CONDITION
Keith A Wesnes
174
CONTRASTING READING COMPREHENSION IMPAIRMENTS IN DEVELOPMENTAL
DYSLEXIA AND SCHIZOPHRENIA: DIFFERENTIAL EFFECTS OF PHONOLOGICAL
PROCESSING AND EXECUTIVE FUNCTION
Veronica Whitford, Gillian A O’Driscoll, Vanessa Maggio, Christopher C Pack, Ridha Joober,
Ashok Malla, Debra Titone
175
THE EFFECT OF COMT INHIBITION ON BEHAVIOUR AND BRAIN FUNCTION DEPENDS
ON COMT VAL158MET GENOTYPE
Elizabeth Tunbridge, S M Farrell, S Braeutigam, C Mackay, P J Harrison
176
RESTING-STATE FUNCTIONAL CONNECTIVITY IN HIGH RISK GROUP FOR PSYCHOSIS:
ULTRA-HIGH RISK AND SCHIZOTYPAL PERSONALITY GROUP
Jun Soo Kwon, W Jung, Ji-Won Hur, J Jang, S Kim, N Shin, C Choi
177
NEURAL CORRELATES OF EMOTION REGULATION IN INDIVIDUALS AT ULTRA-HIGH
RISK FOR PSYCHOSIS
Andreas Aleman, Edith Liemburg, Esther Opmeer, Jorien van der Velde, R Nieboer, A
Wunderink
Comorbid Abstracts
/
Clinical Abstracts
77
ORAL SESSION 3-1
THE EMERGING GENETIC ARCHITECTURE OF SCHIZOPHRENIA
Palazzo Ballroom A
Chair: Deborah Levy
3:00 pm
THE BURDEN OF RARE COPY NUMBER VARIANTS IN COMMUNITY-BASED
SCHIZOPHRENIA SUGGESTS A POTENTIAL ROLE FOR CLINICAL MICROARRAYS
Anne S Bassett
3:15 pm
GENE COEXPRESSION NETWORK ANALYSIS IN SCHIZOPHRENIA
Panos Roussos, Menachem Fromer, Douglas M Ruderfer, Hywel Williams, Jennifer L
Moran, Kimberly Chambert, Jessica S Johnson, Steven A McCarroll, Michael C
O’Donovan, Michael J Owen, George Kirov, Shaun M Purcell, Bin Zhang, Eric Schadt,
Pamela Sklar
3:30 pm
EPISTATIC INTERACTIONS BETWEEN HISTONE DEACETYLASE (HDAC) GENES
INFLUENCE THE RISK OF SCHIZOPHRENIA: A FAMILY-BASED ASSOCIATION
STUDY
Oussama Kebir, Caroline Dubertret, Mar Fatjo-Vilas, Ridha Joober, Philip Gorwood,
Lourdes Fananas, Nicolas Ramoz, Marie-Odile Krebs
3:45 pm
TRANSCRIPTOME STUDY IMPLICATES HISTONES IN SCHIZOPHRENIA
Alan R Sanders, H H Göring, J Duan, W Moy, E I Drigalenko, J Freda, J Jacobi, D He,
J Shi, M G Sz, P V Gejman
4:00 pm
ABERRANT HYPOXIA-ISCHEMIA REGULATION IN PSYCHOSIS: A GENEENVIRONMENT INTERACTION STUDY IN THE GENERAL POPULATION
Sinan Guloksuz, Marjan Drukker, Gunter Kenis, Catherine Derom, Evert Thiery, Rainald
Schmidt-Kastner, Jim van Os, Gunter Kenis
4:15 pm
QUALITATIVE AND QUANTITATIVE THOUGHT DISORDER ENDOPHENOTYPES IN
SCHIZOPHRENIA
Charity J Morgan, Michael J Coleman, Xiawei Tu, Nancy R Mendell, Deborah L Levy
4:30 pm
EYE TRACKING PERFORMANCE AS AN INTERMEDIATE PHENOTYPE IN GENETIC
ASSOCIATION STUDIES OF PSYCHOTIC DISORDERS
Rebekka Lencer, J Bishop, M S Harris, J L Reilly, S Patel, R Kittles, K M Prasad, V L
Nimgaonkar, Matcheri Keshavan, J A Sweeney
4:45 pm
GENETIC MODIFIERS AND SUBTYPES IN SCHIZOPHRENIA: INVESTIGATIONS OF
AGE AT ONSET, SEVERITY, SEX AND FAMILY HISTORY
Sarah E Bergen, Colm T O’Dushlaine, Phil H Lee, Ayman H Fanous, Douglas M
Ruderfer, Stephan Ripke, Patrick F Sullivan, Jordan W Smoller, Shaun Purcell, Aiden
Corvin
5:00 pm
NO ASSOCIATION BETWEEN SCHIZOPHRENIA AND OBESITY SUSCEPTIBILITY
GENES IN A BRITISH POPULATION
Colette Mustard, P D Whitfield, I L Megson, J Wei
5:15 pm
AN INFLAMMATORY PATHWAY RELATED TO PSYCHOSIS IN BIPOLAR DISORDER
Goran Engberg, c Sellgren, M Kegel, C J Ekman, M Landén, Sophie Erhardt
78
Clinical Abstracts
/
Comorbid Abstracts
ORAL SESSION 3-2
PHENOMONOLOGY AND DIAGNOSIS IN SCHIZOPHRENIA
Palazzo Ballroom D
Chair: Dieter Naber
3:00 pm
SPECIFICITY OF CHILDHOOD PSYCHOTIC SYMPTOMS IN PREDICTING
SCHIZOPHRENIA BY 38 YEARS OF AGE: A BIRTH COHORT STUDY
Helen Fisher, Avshalom Caspi, Richie Poulton, Louise Arseneault, Terrie Moffitt
3:15 pm
TRANSITION TO FIRST EPISODE PSYCHOSIS IN ULTRA HIGH RISK POPULATIONS:
DOES BASELINE FUNCTIONING HOLD THE KEY?
Eva Velthorst, Barnaby Nelson, Suzanne Wiltink, Lieuwe de Haan, Stephen J Wood,
Ashleigh Lin, Alison R Yung
3:30 pm
PREDICTIVE BIOMARKERS FOR SCHIZOPHRENIA SPECTRUM DISORDERS USING
SVM: AN ANALYSIS OF A COHORT OF CHILDREN AND ADOLESCENTS WITH A
FIRST EPISODE OF PSYCHOSIS
Laura Pina-Camacho, Juan Garcia-Prieto, Mara Parellada, Covadonga M Diaz-Caneja,
Josefina Castro-Fornieles, Ana González-Pinto, Dolores Moreno, Montse Graell,
Soraya Otero, Elena de la Serna, Inmaculada Baeza, Celso Arango
3:45 pm
AFFECTIVE INDICATORS OF RISK FOR SCHIZOPHRENIA DURING CHILDHOOD
Diane C Gooding, C Zahn-Waxler, S Light, S A Roberts, C Kestenbaum, L ErlenmeyerKimling
4:00 pm
DIAGNOSTIC STABILITY 10 YEARS POST FIRST EPISODE PSYCHOSIS – FINDINGS
FROM THE AETIOLOGY AND ETHNICITY IN THE STUDY OF SCHIZOPHRENIA AND
OTHER PSYCHOSES (AESOP) COHORT
Ben Lomas, Margaret Heslin, Craig Morgan, Paola Dazzan, Robin M Murray, Peter B
Jones, Gillian A Doody
4:15 pm
HOW FAR DO COGNITION AND SELF CONCEPT AFFECT INSIGHT AFTER FIRST
EPISODES OF SCHIZOPHRENIA?
Richard J Drake
4:30 pm
CAPTURING THE INDIVIDUAL ENVIRONMENT OF PATIENTS. BASIS FOR
TARGETED PSYCHOTHERAPY
Inez Myin-Germeys, Dina Collip, M Oorschot, J Lataster, N Geschwind, M Wichers,
Tineke Lataster
4:45 pm
SYMPTOMATIC REMISSION IN PSYCHOSIS AND REAL-LIFE FUNCTIONING
Margreet Oorschot, Tineke Lataster, Viviane Thewissen, Marielle Lardinois, Jim van
Os, Philippe Delespaul, Inez Myin-Germeys
5:00 pm
PATIENTS’ EXPERIENCES AND PERCEPTIONS OF A DIAGNOSED OF
SCHIZOPHRENIA
Carmel M Loughland, B Kelly, S Outram, G Harris, M Cohan, H Sandhu, M Vamos, T
Levin, C Bylund, Y Landa
5:15 pm
EXPERIENTIAL AND EXPRESSIVE FORMS OF NEGATIVE SYMPTOMS: LINKS WITH
METACOGNITION AND SOCIAL COGNITION IN SCHIZOPHRENIA
Kelly D Buck, Hamish McLeod, Andrew Gumley, G Dimaggio, Paul H Lysaker
Comorbid Abstracts
/
Clinical Abstracts
79
ORAL SESSION 3-3
NEUROPHYSIOLOGIC INVESTIGATIONS OF SENSORY AND COGNITIVE
PROCESSING ACROSS COURSE OF ILLNESS OR RISK FOR ILLNESS?
Palazzo Ballroom E
Chair: James L Reilly
3:00 pm
COMPLEX NETWORK ANALYSIS OF SLOW EEG OSCILLATIONS AS AN INDEX OF
ABERRANT NEURODEVELOPMENT IN ADOLESCENT-ONSET SCHIZOPHRENIA
Peter Bachman, Zachary D Moran, Kelly Tung, Maria Jalbrzikowski, Tyrone Cannon,
Carrie E Bearden
3:15 pm
GENETIC ASSOCIATION BETWEEN THE SCHIZOPHRENIA GWAS RISK GENE
ZNF804A AND THE NOVEL P300B ELECTROPHYSIOLOGICAL COMPONENT
Elisabetta del Re, S Bergen, M Niznikiewicz, S Purcell, Robert McCarley, Tracey
Petryshen
3:30 pm
N1/P2 AND ATTENTION EFFECTS IN FIRST HOSPITALIZED SCHIZOPHRENIA AND
BIPOLAR DISORDER
Dean Salisbury
3:45 pm
EVENT-RELATED POTENTIAL EXAMINATION OF MULTISENSORY INTEGRATION IN
Jonathan K Wynn, C Gibson, A Bender, Michael F Green
4:00 pm
BLUNTED EEG NEURAL RESPONSES TO EMOTIONAL STIMULI IN
SCHIZOPHRENIA AND FIRST DEGREE FAMILY MEMBERS
Aysenil Belger, A Evans, F C Donkers, Elizabeth H Andersen
4:15 pm
ELEVATED BASELINE GAMMA POWER DURING IRRELEVANT STIMULATION WITH
NEGATIVE TASK-INDUCED POWER CHANGES IN SCHIZOPHRENIA
Vanessa Suazo, A Díez, M Martín-Loeches, P Casado, V Molina
4:30 pm
IMPAIRED CORTICAL PLASTICITY, CONNECTIVITY AND EXCITABILITY IN
SCHIZOPHRENIA
Alkomiet Hasan
4:45 pm
ATTENTIONAL CAPTURE PREDICTS WORKING MEMORY IN SCHIZOPHRENIA
Peter A Lynn, Scott R Sponheim
5:00 pm
EFFECTS OF CHLORPROMAZINE, CLOZAPINE AND VALPROATE ON AUDITORY
P300 IN SCHIZOPHRENIA: A PROSPECTIVE LONGITUDINAL RANDOMIZED
CONTROLLED STUDY
Liang Su, Y Xu, S Shi, A Dutt, E Bramon
5:15 pm
CLONIDINE NORMALIZES SENSORY GATING DEFICITS IN PATIENTS WITH
SCHIZOPHRENIA ON STABLE MEDICATION
Bob Oranje, B Y Glenthøj
80
Clinical Abstracts
/
Comorbid Abstracts
NEUROENGINEERING: CHALLENGES AND OPPORTUNITIES
Chair: Bin He
Co-Chair: S C Schulz
3:00 pm
FUNCTIONAL NEUROIMAGING OF HUMAN BRAIN
Bin He
3:30 pm
DEEP BRAIN STIMULATION FOR NEUROPSYCHIATRIC DISORDERS
Cameron McIntyre
4:00 pm
NON-INVASIVE NEUROMODULATION FOR NEUROPSYCHIATRIC DISORDERS
Kelvin Lim
4:30 pm
NEUROPROSTHETICS: A NEW MODALITY FOR THERAPEUTIC TREATMENT OF
MOTOR, SENSORY, AND NEUROPSYCHIATRIC DISORDERS
Justin Sanchez
THE MULTIFACETED ADVANTAGES OF LONG-ACTING INJECTABLE
ANTIPSYCHOTIC MEDICATION AND MEDICATION ADHERENCE AFTER A FIRST
EPISODE OF SCHIZOPHRENIA
Chair: Keith H Nuechterlein
3:00 pm
CLINICAL ADVANTAGES OF LONG-ACTING INJECTABLE RISPERIDONE AFTER AN
INITIAL EPISODE OF SCHIZOPHRENIA
Kenneth L Subotnik, Joseph Ventura, Denise Gretchen-Doorly, L R Casaus, J S Luo, L
Turner, N R DeTore, G S Hellemann, Stephen R Marder, J E Amano, S K Kaiser, Keith H
Nuechterlein
3:30 pm
LONG-ACTING INJECTABLE RISPERIDONE AND MEDICATION ADHERENCE
ENHANCE COGNITION AND WORK FUNCTIONING AFTER A FIRST PSYCHOTIC
EPISODE
Keith H Nuechterlein, K L Subotnik, Joseph Ventura, Denise Gretchen-Doorly, L R
Casaus, J S Luo, L Turner, A S Kurtz, N R DeTore
4:00 pm
THE IMPACT OF ANTIPSYCHOTIC MEDICATION ON INTRACORTICAL
MYELINATION IN SCHIZOPHRENIA
George Bartzokis, P H Lu, A J Couvrette, E P Raven, N R DeTore, C J Kirkpatrick, J P
Finn, P Villablanca, L L Altshuler, J Mintz, J Ventura, L R Casaus, J S Luo, Kenneth L
Subotnik, Keith H Nuechterlein
4:30 pm
NEUROPROTECTION AND THE NATURAL HISTORY OF SCHIZOPHRENIA
Jeffrey A Lieberman, S Schobel, Cheryl M Corcoran, Holly Moore, S Small
Comorbid Abstracts
/
Clinical Abstracts
81
MOLECULAR MECHANISMS OF NEUROLEPTIC ACTION
Chair: Nicola G Cascella
Discussant: Akira Sawa
3:00 pm
UNIQUE PHARMACOLOGICAL ACTIONS OF QUETIAPINE: POSSIBLE ROLE IN
CELL CYCLE/FATE CONTROL
Mari A Kondo, Akira Sawa
3:30 pm
FUNCTIONAL ANALYSIS OF GENE EXPRESSION IN RISPERIDONE TREATED
CELLS PROVIDE NEW INSIGHTS IN MOLECULAR MECHANISM AND NEW
CANDIDATE GENES FOR PHARMACOGENETIC STUDIES
Sergi Mas Herrero, P Gasso, E Parellada, M Bernardo, A Lafuente
4:00 pm
NEUROLEPTICS AS A MODULATOR OF MICROGLIAL INFLAMMATORY/OXIDATIVE
STRESS RESPONSE FROM BOTH IN VITRO AND IN VIVO STUDIES
Takahiro A Kato, S Kanba
4:30 pm
ANTIPSYCHOTIC DRUG EFFECTS ON STRIATUM
Rosalinda C Roberts
WORKSHOP 3-1
7:00 pm
PSYCHOSIS AND COGNITION IN SCHIZOPHRENIA: INDEPENDENT,
INTERACTIVE, OR INTERCORRELATED?
Palazzo Ballroom A
Chair: Larry J Siever
WORKSHOP 3-2
7:00 pm
IF THE PATIENT IS TREATMENT REFRACTORY, WHY CONTINUE TREATMENT
WITH ANTIPSYCHOTICS?
Palazzo Ballroom D
Chair: Michael Davidson
WORKSHOP 3-3
7:00 pm
ISSUES IN SYMPTOM MEASURE QUALITY IN SCHIZOPHRENIA CLINICAL
TRIALS
Palazzo Ballroom E
Chair: Mark G Opler,
Co-Chair: David Daniel
WORKSHOP 3-4
7:00 pm
82
DISSECTING THE HETEROGENEITY OF COURSE AND OUTCOME IN
PSYCHOSIS: NOVEL INSIGHTS AND KEY CHALLENGES
Palazzo Ballroom F
Chair: Paola Dazzan
Clinical Abstracts
/
Comorbid Abstracts
WORKSHOP 3-5
7:00 pm
LESSONS ABOUT PSYCHOSIS LEARNED FROM STUDYING THE EFFECTS OF
WEED, SPECIAL K, MAGIC MUSHROOMS AND MAGIC MINT
Chair: Mohini Ranganathan
WORKSHOP 3-6
7:00 pm
CENTENARY OF KARL JASPERS’ “GENERAL PSYCHOPATHOLOGY“ (1913):
WHY JASPERS’ WORK IS CRUCIAL TO CURRENT DEBATES ABOUT THE
DIAGNOSTIC CLASSIFICATION AND NEUROBIOLOGY OF SCHIZOPHRENIA
Chair: Aaron L Mishara
Comorbid Abstracts
/
Clinical Abstracts
83
Thursday, April 25, 2013
8:00 am
7:00 am
7:00 am
8:15 am
Closing Remarks — Mediterranean Ballroom Salons 4/5
8:30 am
WILLIAM K. WARREN MEDICAL INSTITUTE RESEARCH AWARD FOR
SCHIZOPHRENIA RESEARCH RECIPIENT
9:30 am
BRAINCLOUD: AN INTEGRATIVE APPROACH TO GENOMIC BRAIN RESEARCH
Chair: Joel Kleinman
10:00 am
TRANSCRIPTIONAL PATTERNS OF BRAIN DEVELOPMENT
Andrew E Jaffe, E Fertig, M Ochs, L Marchionni, Barbara K Lipska, Daniel R
Weinberger, Joel Kleinman, Thomas M Hyde, C Colantuoni
10:30 am
GENETIC CONTROL OF EPIGENETICS IN THE HUMAN BRAIN
Barbara K Lipska
11:00 am
TRANSCRIPT ALLELIC EXPRESSION IN SCHIZOPHRENIA
Thomas M Hyde, Barbara K Lipska, Joel Kleinman, Daniel R Weinberger
11:30 am
BRAIN CLOUD AND CLINICAL RESEARCH
Kristin L Bigos, J Trangle, Daniel R Weinberger
TRANSLATING NEUROIMAGING FINDINGS INTO PATIENT BENEFIT:
CHALLENGES AND FUTURE OF MACHINE LEARNING APPROACHES
Palazzo Ballroom A
Chair: Paola Dazzan
Discussant: Janaina Mourao-Miranda
10:00 am
PATTERN RECOGNITION AND CLINICAL NEUROIMAGING: POTENTIAL AND
CAVEATS
Janaina Mourao-Miranda
10:30 am
CLASSIFICATION OF SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS
FROM STRUCTURAL MRI SCANS IN TWO LARGE INDEPENDENT SAMPLES
Hugo Schnack, Mireille Nieuwenhuis, Neeltje van Haren, H Hulshoff Pol, W Cahn,
Rene Kahn
84
Clinical Abstracts
/
Comorbid Abstracts
11:00 am
VALIDATING INDIVIDUALISED PREDICTION OF PSYCHOSIS COURSE WITH
PATTERN RECOGNITION ANALYSIS OF MULTIPLE NEUROIMAGING DATASETS
Paola Dazzan
11:30 am
CEREBRAL BLOOD FLOW IN THE SUBGENUAL CINGULATE CORTEX
DISCRIMINATE MAJOR DEPRESSIVE EPISODE IN MAJOR DEPRESSIVE DISORDER
AND BIPOLAR DISORDER USING PATTERN RECOGNITION ANALYSIS
Jorge Almeida
THE ORIGIN OF IMMUNE-ACTIVATION IN SCHIZOPHRENIA: INFECTIONS AND
GENES
Palazzo Ballroom D
Chair: Sophie Erhardt
Discussant: Joseph T Coyle
10:00 am
ARE MATERNAL CYTOKINE ELEVATIONS SPECIFIC TO SCHIZOPHRENIA AMONG
OFFSPRING WITH PSYCHIATRIC DISORDERS?
Alan S Brown, S Cremers, I McKeague, Y Bao, S V Pollak, L Shen, C A Schaefer
10:30 am
MONOCYTES, MACROPHAGES AND MICROGLIA IN SCHIZOPHRENIA
Hemmo A Drexhage
11:00 am
KYNURENINE PATHWAY METABOLISM REVEALS MOLECULAR LINKS BETWEEN
IMMUNE SYSTEM DYSREGULATION AND PSYCHIATRIC DISEASES
Robert Schwarcz, F M Notarangelo, C A Hunter
11:30 am
DYSREGULATED IMMUNE SIGNALING PATHWAYS IN SCHIZOPHRENIA
Sophie Erhardt
THE LATEST ON CANNABIS AND MENTAL FUNCTION
Palazzo Ballroom E
Chair: Marta M Di Forti
Co-Chair: Jim van Os
10:00 am
ADOLESCENT-ONSET CANNABIS USERS SHOW IQ DECLINE FROM CHILDHOOD
TO MIDLIFE
Madeline H Meier, T E Moffitt, A Caspi
10:30 am
THC & CBD: IT’S THE LACK OF BALANCE IN CANNABIS THAT CAUSES HARM
Amir Englund
11:00 am
THE JOINT CONTRIBUITION OF AKT1 AND COMT TO CANNABIS INDUCED
PSYCHOSIS
Marta M Di Forti, C Iyegbe, H Sallis, Valeria Mondelli, Simona A Stilo, Alessandra
Paparelli, Paola Dazzan, Craig Morgan, J Powell, Robin M Murray
Comorbid Abstracts
/
Clinical Abstracts
85
11:30 am
THC-INDUCED DOPAMINE RELEASE IN PSYCHOSIS AND ASSOCIATION WITH CB1
RECEPTOR AVAILABILITY: EVIDENCE FROM NEUROCHEMICAL IMAGING
Rebecca Kuepper, J Ceccarini, J Lataster, Jim van Os, K van Laere, C Henquet
MODELLING COMPLEX INTERACTIONS BETWEEN ETIOLOGICALLY-RELATED
FACTORS OVER THE LIFETIME TRAJECTORY OF SCHIZOPHRENIA
Palazzo Ballroom F
Chair: John Waddington
Co-Chair: Mikhail Pletnikov
10:00 am
EFFECTS OF MATERNAL IMMUNE ACTIVATION ON BEHAVIOR OF DISC1 MUTANT
MICE PREDISPOSED TO SCHIZOPHRENIA AND DEPRESSION: IMPLICATION TO
THE GENE X ENVIRONMENT INTERACTION MODEL
Tatiana V Lipina, C Zai, D Hlousek, A H Wong, J C Roder
10:30 am
COMMON AND CELL TYPE SPECIFIC PATHWAYS OF INTERACTION OF A GENETIC
RISK FACTOR WITH DIVERSE ETIOLOGICAL ENVIRONMENTAL FACTORS
Mikhail Pletnikov
11:00 am
ADDING INSULT TO INJURY IN SCHIZOPHRENIA: SYNERGISTIC PATHOLOGICAL
INTERACTIONS BETWEEN PRENATAL IMMUNE ACTIVATION AND PUBERTAL
STRESS
Urs Meyer
11:30 am
MODELLING GENE × GENE INTERACTIONS IN SCHIZOPHRENIA USING MUTANT
MODELS OF GENE DISRUPTION
John Waddington
86
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
TREATMENT RESPONSE TO ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA
Coquina Ballroom
Chair: Rosalinda C Roberts,
Co-Chair: Adrienne C Lahti,
Discussant: Robert W Buchanan
Poster No.
A
CHALLENGES IN ASSESSING ANTIPSYCHOTIC RESPONSE IN BIOMARKER STUDIES
OF FIRST EPISODE SCHIZOPHRENIA
Delbert G Robinson, Juan A Gallego, M John
A
GLUTAMATE, DOPAMINE AND ANTIPSYCHOTIC RESPONSE
James M Stone, A Egerton, S Brugger, M Raffin, G J Barker, D J Lythgoe, P K McGuire,
Oliver D Howes
A
ASSOCIATION OF GLUTAMATE AND N-ACETYLASPARTATE IN SCHIZOPHRENIA
BEFORE AND AFTER TREATMENT WITH RISPERIDONE: A PROTON MAGNETIC
RESONANCE SPECTROSCOPY STUDY
Adrienne C Lahti, M Reid, N Kraguljac, D White
A
BIOLOGICAL CORRELATES OF TREATMENT RESPONSE AND RESISTANCE IN
POSTMORTEM TISSUE
Rosalinda C Roberts, J K Roche, S M Somerville
TARGETING THE COGNITIVE DYSFUNCTION OF RECENT ONSET SCHIZOPHRENIA
THROUGH COMPUTERIZED COGNITIVE TRAINING INTERVENTIONS
Coquina Ballroom
Chair: Sophia Vinogradov
B
BROAD-SPECTRUM COGNITIVE REMEDIATION AFTER A FIRST EPISODE OF
SCHIZOPHRENIA: IMPACT ON COGNITION AND WORK/SCHOOL FUNCTIONING
Keith H Nuechterlein, Joseph Ventura, Kenneth L Subotnik, Denise Gretchen-Doorly, L
Turner, L R Casaus, J S Luo, Alice Medalia, Morris D Bell
B
COGNITIVE REMEDIATION COMBINED WITH A COMPREHENSIVE PSYCHOSOCIAL
PROGRAM FOR PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA: THE NEUROCOM
TRIAL
Lone Vesterager, T Christensen, B Olsen, M Melau, G Krarup, Merete Nordentoft
B
NEUROSCIENCE-INFORMED COGNITIVE TRAINING IN RECENT ONSET
SCHIZOPHRENIA USING LAPTOP COMPUTER
Sophia Vinogradov, M Fisher, Rachel Loewy, Tara A Niendam, D Ragland, C Carter
Comorbid Abstracts
/
Clinical Abstracts
87
12:00–
2:30 p.m.
B
Coquina Ballroom
COMBINING COGNITIVE TRAINING AND EXERCISE TO IMPROVE COGNITION AND
FUNCTIONAL OUTCOMES IN THE EARLY COURSE OF SCHIZOPHRENIA: A PILOT
STUDY
Joseph Ventura, Denise Gretchen-Doorly, Kenneth L Subotnik, Sophia Vinogradov, Mor
Nahum, Keith H Nuechterlein
ULTRA-HIGH RISK PHENOTYPES AND NEUROSTEROID TARGETS IN SINGAPORE
TRANSLATIONAL AND CLINICAL RESEARCH
Coquina Ballroom
Chair: Chris Marx,
Discussant: Richard Keefe
C
MIDBRAIN MODULATION OF HIPPOCAMPUS-DEPENDENT LEARNING PREDICTS
PERFORMANCE AND CLINICAL STATUS IN INDIVIDUALS AT-RISK FOR PSYCHOSIS
R Alison A Adcock, Elizabeth B Johnson, J Wilson, J Poh, S Yaakub, K Dorairaj, A
Rapisarda, M Chee, Siow-Ann Chong, M Subramaniam, Richard Keefe, M Kraus, J Lee
Chee Keong, Y Ling Bong
C
COGNITIVE TRAJECTORIES OF ULTRA-HIGH RISK INDIVIDUALS
Max Lam, J Lee, A Rapisarda, M Kraus, M Subramaniam, Siow-Ann Chong, Richard Keefe
C
PREGNENOLONE RESCUES SCHIZOPHRENIA-LIKE BEHAVIOR IN DOPAMINE
TRANSPORTER KNOCKOUT MICE
Xiaodong Zhang, P Wong, C Chang, Chris Marx, M G Caron, W C Wetsel
C
PROOF-OF-CONCEPT RANDOMIZED CONTROLLED TRIAL OF PREGNENOLONE IN
SCHIZOPHRENIA
Chris Marx, J Lee Chee Keong, M Subramaniam, S Verma, E Pui Wai, J Hariram, S Kang, R
Jacob, R Keefe, Siow-Ann Chong
PHYSICAL HEALTH IN SCHIZOPHRENIA - A CALL FOR CHANGE
Coquina Ballroom
Chair: Merete Nordentoft,
Discussant: John W Newcomer
D
EXCESS MORTALITY, CAUSES OF DEATH AND LIFE EXPECTANCY IN MAIN GROUPS OF
PATIENTS WITH RECENT ONSET OF MENTAL DISORDERS IN 2000-2006 IN DENMARK,
FINLAND AND SWEDEN
Merete Nordentoft, J Westmann, K Wahlbeck, M Gissler, T M Laursen
D
PREDICTORS OF ADVERSE CARDIOMETABOLIC RISK MODIFICATION IN YOUTH WITH
SCHIZOPHRENIA-SPECTRUM DISORDERS AND NON-PSYCHOTIC DISORDERS
RECEIVING ANTIPSYCHOTICS
Christoph U Correll
88
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
D
COMORBID PHYSICAL ILLNESS IN THOSE WITH PSYCHOTIC DISORDERS; THE
AUSTRALIAN NATIONAL PSYCHOSIS SURVEY
John J McGrath, C Galletly, A Waterreus, A Jablensky, A Mackinnon, V Carr, R Bush, D
Castle, M Cohen, C Harvey, H J Stain, A Neil, P McGorry, B Hocking, S Shah, J Badcock, S
Saw, V A Morgan
D
WHAT FACTORS MAY HELP IDENTIFYING INDIVIDUALS VULNERABLE TO POORER
LIFE-QUALITY AND -EXPECTANCY FROM THE TIME OF THEIR FIRST PSYCHOTIC
EPISODE?
Paola Dazzan, M Heslin, U Reininghaus, Julia M Lappin, P Fearon, T Croudache, G Doody,
K Donoghue, P Jones, Robin M Murray, Craig Morgan
COGNITIVE BEHAVIOUR THERAPY FOR PSYCHOSIS: WHAT DO WE KNOW ABOUT
ITS EFFECTIVENESS AND NEURAL CORRELATES?
Coquina Ballroom
Chair: Tilo Kircher
E
PREVENTING A FIRST EPISODE OF PSYCHOSIS: META-ANALYSIS OF RANDOMIZED
CONTROLLED PREVENTION TRIALS
Mark van der Gaag, F Smit, A Bechdolf, P French, D H Linszen, A R Yung, P McGorry, P
Cuijpers
E
HOW DOES CBT AFFECT THE BRAIN OF PATIENTS OF SCHIZOPHRENIA: A
MULTICENTER FMRI STUDY
Tilo Kircher
POSTER SESSIONS
ABSTRACT CATEGORIES; THERAPEUTICS: TREATMENT TRIALS; DRUG SIDE EFFECTS &
PHYSICAL ILLNESS; HEALTH ECONOMICS & SERVICES RESEARCH; NEUROANATOMY,
ANIMAL; NEUROCHEMISTRY, ANIMAL; NEUROCHEMISTRY, CLINICAL; NEUROIMAGING,
NEUROCHEMICAL; NEUROPATHOLOGY, HISTOLOGY; NEUROPATHOLOGY, BIOCHEMISTRY
001
EFFECTS OF ATYPICAL ANTIPSYCHOTIC DOSE REDUCTION ON COGNITIVE
FUNCTION IN STABLE PATIENTS WITH SCHIZOPHRENIA: A RANDOMIZED
CONTROLLED TRIAL
Hiroyoshi Takeuchi, Hiroyuki Uchida, Takefumi Suzuki, Robert R Bies, Koichiro Watanabe,
Gary Remington, Masaru Mimura
002
HOW NEGATIVE SYMPTOMS CAN BE IMPROVED THROUGH COGNITIVE REMEDIATION
Aida Farreny, Jaume Aguado, Susana Ochoa, Elena Huerta-Ramos, Judith Usall
003
GREATER TOLERABILITY OF ABT-288, A HISTAMINE-3 RECEPTOR ANTAGONIST, IN
PATIENTS WITH SCHIZOPHRENIA THAN IN HEALTHY VOLUNTEERS
Ahmed Othman, G Haig, H Florian, C Locke, S Dutta
Comorbid Abstracts
/
Clinical Abstracts
89
12:00–
2:30 p.m.
Coquina Ballroom
004
NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. A QUANTITATIVE COMPUTER-BASED
SYSTEMS PHARMACOLOGY APPROACH
Hugo Geerts, A Spiros, P Roberts
005
A PILOT STUDY ON THE EFFECTS OF SINGLE DOSE INTRANASAL OXYTOCIN ON
SOCIAL COGNITION IN SCHIZOPHRENIA
Michael C Davis, Junghee Lee, William P Horan, Michael F Green, Stephen R Marder
006
MINDFULNESS-BASED THERAPY IN PATIENTS RECOVERING FROM RECENT ONSET
PSYCHOSIS
Carin Meijer, R van der Valk
007
THE HISTAMINE-3 RECEPTOR ANTAGONIST ABT-288 IN TREATMENT OF COGNITIVE
DEFICITS IN SCHIZOPHRENIA: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND
PHASE 2 STUDY
George M Haig, E Bain, W Robieson, Ahmed Othman, J Baker, R Lenz
008
MEANINGFUL CHANGE WITH THE METHOD GUIDED SELF-DETERMINATION – A
RANDOMISED CONTROLLED STUDY FOR OUT-PATIENTS DIAGNOSED WITH
SCHIZOPHRENIA
Rikke Jørgensen, P Munk-Jørgensen, L Hansson, V Zoffmann
009
COMBINED COGNITIVE AND PHYSICAL EXERCISE TRAINING FOR RECENT-ONSET
SCHIZOPHRENIA PATIENTS: CHANGES IN PHYSICAL HEALTH AND HEALTH ATTITUDES
FROM A 10-WEEK PILOT STUDY
Denise Gretchen-Doorly, Kenneth L Subotnik, Joseph Ventura, Keith H Nuechterlein
010
A NOVEL AUTOMATED TEST SUITABLE FOR THE REPEATED ASSESSMENT OF
EXECUTIVE FUNCTION IN CLINICAL TRIALS IN SCHIZOPHRENIA
Keith A Wesnes, R Wojciak, T Feaster, A Butler, D Krefetz, D Pittman, J Fogel, S Kramer, E
Ridolfi, L Brownstein, H Hassman
011
A RANDOMIZED EFFECTIVENESS STUDY OF COGNITIVE REMEDIATION FOR MENTAL
HEALTH AND FORENSIC PATIENTS
Anthony O Ahmed
012
TESTING THE FEASIBILITY OF A NOVEL COMPUTERIZED NEURO-PLASTICITY BASED
TRAINING PROGRAM TO REMEDIATE SOCIAL COGNITION DEFICITS IN
SCHIZOPHRENIA (‘SOCIALVILLE’)
Mor Nahum, Coleman Garrett, Brooke Powell, Gina Poelke, Melissa Fisher, Lindsay Mayott,
Rachel Loewy, Joseph Ventura, Keith H Nuechterlein, Sophia Vinogradov, Michael
Merzenich
013
PATIENT PERCEPTIONS OF COMPUTER-BASED SKILLS TRAINING
Tasha M Nienow, H L Gerould, M D Smith, C E Schwartz, Scott R Sponheim, Angus W
MacDonald
90
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
014
MERIT: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL TO STUDY THE EFFECTS
OF A NEW METACOGNITIVE THERAPY
Steven de Jong, R van Donkersgoed, J Arends, Kelly D Buck, Paul H Lysaker, Lex
Wunderink, M van der Gaag, Andre Aleman, Marieke Pijnenborg
015
ADAPTATION OF INTEGRATED COGNITIVE REMEDIATION THERAPY FOR THE
PREVENTION OF PSYCHOSIS IN PEOPLE AT HIGH RISK
Stefanie J Schmidt, D R Mueller, A Theodoridou, Frauke Schultze-Lutter, Benno G
Schimmelmann, Volker Roder
016
LONG-TERM EFFECT OF REPETITIVE TRANSCRANIAL STIMULATION TREATMENT FOR
AUDITORY VERBAL HALLUCINATIONS
Leonie Bais, A Vercammen, H Knegtering, R Bruggeman, A Aleman
017
EFFICACY OF BILATERAL REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION FOR
NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: PRELIMINARY RESULTS OF A DOUBLEBLIND RANDOMIZED CONTROLLED TRIAL
Jozarni J Dlabac-de Lange, L Bais, Andre Aleman, H Knegtering
018
CLINICAL GLOBAL IMPRESSION SCALE FOR MEASURING ADHERENCE
A Adityanjee
019
WITH : A NEW MANUALIZED TREATMENT FOR RELATIVES OF INDIVIDUALS WITH
EARLY PSYCHOSIS – FINAL RESULTS
Claude Leclerc, T Lecomte
020
DO ANTIPSYCHOTIC MEDICATIONS OVER PROLONGED PERIODS ELIMINATE
PSYCHOSIS AND FACILITATE RECOVERY IN SCHIZOPHRENIA: A 20-YEAR
LONGITUDINAL STUDY
Martin Harrow, T H Jobe, R Faull
021
FIFTEEN YEAR FOLLOW UP OF CLOZAPINE TREATED PATIENTS WITH
SCHIZOPHRENIA
Elizabeth Gale, Charles M Richardson, Gopal Vyas, F Liu, Heidi J Wehring, Deanna L Kelly
022
CARIPRAZINE EFFICACY IN ACUTE EXACERBATION OF SCHIZOPHRENIA: ANALYSIS
OF PANSS DATA FROM A PHASE III, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIAL
Leslie Citrome, R E Litman, Y Wang, O Mokliatchouk, G Németh, I Laszlovszky, S Durgam
023
ONSET OF PALIPERIDONE ER TREATMENT EFFECT BY SYMPTOM DOMAIN IN
SUBJECTS WITH ACUTE EXACERBATION OF SCHIZOAFFECTIVE DISORDER
Hiren Patel, D J Fu, I Turkoz, C A Bossie, Larry Alphs
024
SWITCHING TO LURASIDONE FROM OTHER ANTIPSYCHOTICS IN PATIENTS WITH
SCHIZOPHRENIA: CHANGES IN CARDIOMETABOLIC PARAMETERS AND METABOLIC
SYNDROME STATUS
Mariam Hassan, Andrei Pikalov, T Niecko, Krithika Rajagopalan, Antony Loebel
Comorbid Abstracts
/
Clinical Abstracts
91
12:00–
2:30 p.m.
Coquina Ballroom
025
A PROSPECTIVE TRIAL OF CUSTOMIZED ADHERENCE ENHANCEMENT PLUS LONGACTING INJECTABLE ANTIPSYCHOTIC MEDICATION IN HOMELESS OR RECENTLY
HOMELESS INDIVIDUALS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
Martha Sajatovic, J Levin, L Ramirez, D Hahn, C Tatsuoka, C Bialko, K Cassidy, E FuentesCasiano, T D Williams
026
EFFECTS OF ARIPIPRAZOLE ONCE-MONTHLY VS. PLACEBO ON DOMAINS OF
PERSONAL AND SOCIAL PERFORMANCE IN YOUNGER AND OLDER PATIENTS WITH
SCHIZOPHRENIA
Ross A Baker, A Eramo, W H Carson, P Perry, R Sanchez, J Zhao, R D McQuade, John M
Kane, W W Fleishhacker
027
REMISSION IN SCHIZOPHRENIA AND PATIENT-FUNCTIONING OUTCOMES: FINDINGS
FROM 3 STUDIES OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS
H L Starr, C A Bossie, D J Fu, J Kern Sliwa, Y W Ma, Larry Alphs
028
PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE IN ACUTE EXACERBATION OF
SCHIZOAFFECTIVE DISORDER
Dong-Jing Fu, I Turkoz, R B Simonson, D Walling, N Schooler, J P Lindenmayer, Larry Alphs
029
ONSET OF EFFICACY ON SPECIFIC SYMPTOM DOMAINS WITH LONG-ACTING
INJECTABLE PALIPERIDONE PALMITATE IN SUBJECTS WITH SCHIZOPHRENIA
Jennifer Kern Sliwa, C A Bossie, Dong-Jing Fu, H L Starr, Y W Ma, Larry Alphs
030
50 YEARS OF ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A SYSTEMATIC REVIEW OF
EFFICACY AND SAFETY
Robert Hunter, S J Barry, T M Gaughan
031
EFFICACY OF OLANZAPINE IN COMPARISON WITH CLOZAPINE FOR TREATMENTRESISTANT SCHIZOPHRENIA: EVIDENCE FROM A SYSTEMATIC REVIEW AND METAANALYSES
Monica Kayo, J S Souza, I Tassell, C B Martins, H Elkis
032
DO SECOND-GENERATION ANTIPSYCHOTICS INCREASE REMISSION IN
SCHIZOPHRENIA? A METANALYSIS
Bandar AlAqeel, Soham Rej, Lawrence Annable, Howard C Margolese
033
DO BENZODIAZEPINES AFFECT THE PLACEBO RESPONSE IN ANTIPSYCHOTIC
TRIALS? A SYSTEMATIC REVIEW OF BENZODIAZEPINES IN THE TREATMENT OF
SCHIZOPHRENIA
Maxine X Patel, F Sim, I Sweetman
034
PATTERNS OF CLOZAPINE TREATMENT DISCONTINUATION IN SCHIZOPHRENIA WITH
CO-MORBID SUBSTANCE ABUSE
Eric Konicki, H B Seel, George E Jaskiw
035
UNDERREPORTING OF DRUG USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA:
PREVALENCE AND PREDICTORS
Amber L Bahorik, C E Newhill, C C Queen, S M Eack
92
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
036
DOPAMINE D2 RECEPTOR OCCUPANCY AND SERUM PROLACTIN CONCENTRATION IN
PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA
Takashi Tsuboi, H Uchida, T Suzuki, R R Bies, B G Pollock, M Mimura
037
LODENAFIL CARBONATE FOR ERECTILE DYSFUNCTION IN OUTPATIENTS WITH
SCHIZOPHRENIA AND SPECTRUM: A RANDOMIZED, DOUBLE-BLIND, CROSSOVER,
PLACEBO- CONTROLLED TRIAL
Luciana V Nunes, Luciana V Nunes, R Bressan, S Nunes, J Mari
038
RASAGILINE IN THE TREATMENT OF THE PERSISTENT NEGATIVE SYMPTOMS OF
SCHIZOPHRENIA
Robert W Buchanan, E Weiner, D Kelly, R P McMahon, J M Gold, D A Gorelick
039
DOES TREATMENT OF LOW VITAMIN D IN PEOPLE WITH SCHIZOPHRENIA MAKE ANY
DIFFERENCE? THE RESULTS OF A PILOT STUDY OF 40 SUBJECTS
Nigel Bark, S A Kim, C Kim, F Yasmin, J Chen, S Urs, B Rodriguez, B Jones, R Gohil
040
SAFETY OF MULTIPLE ASCENDING DOSES OF ADJUNCTIVE LISDEXAMFETAMINE
DIMESYLATE (50-250MG) TO ESTABLISHED DOSE OF ANTIPSYCHOTIC MEDICATION IN
ADULTS WITH CLINICALLY STABLE SCHIZOPHRENIA
James Ermer, Bryan Dirks, P Martin, L Gertsik, D Walling, A Stevenson, M Corcoran, A
Raychaudhuri
041
OPEN-LABEL ADJUNCT MINOCYCLINE TO CLOZAPINE RESOLVES SYMPTOMS IN
CHRONIC SCHIZOPHRENIA
Gopal Vyas, Charles M Richardson, Kelli M Sullivan, Deanna L Kelly
042
TRUST OF PATIENTS WITH SCHIZOPHRENIA IN THEIR PSYCHIATRISTS: A CROSSSECTIONAL SURVEY
Atsumi Minamisawa, H Uchida, T Suzuki, H Takeuchi, S Nakajima, K Watanabe, M Mimura
043
TELEHEALTH MONITORING OF SUICIDAL IDEATION IN PATIENTS SCHIZOPHRENIA
John Kasckow, Gretchen L Haas, J Cornelius, J Luther
044
STEPPING UP TO THE PLATE: A NEW INTERVENTION FOR THOUGHT DISORDER
Katherine Holshausen, M Gupta, B Elvevåg, J Choi, C R Bowie
045
CHANGE- A RANDOMIZED CLINICAL TRIAL FOR TWO HEALTH PROMOTING
PROGRAMS VERSUS STANDARD TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA
Helene Speyer, J Krogh, C Pisinger, M Nordentoft
046
A GLUTEN–FREE DIET IN PEOPLE WITH SCHIZOPHRENIA AND ANTI-TISSUE
TRANSGLUTAMINASE OR ANTI-GLIADIN ANTIBODIES
Stephanie M Feldman, J Jackson, Nicola G Cascella, W Eaton, A Fasano, D Warfel, D
Santora, C M Richardson, G Vyas, K Warren, William T Carpenter, Deanna L Kelly
047
EFFECTS OF EXERCISE ON SYMPTOM SEVERITY IN CHRONIC SCHIZOPHRENIA
Donna J Lang, K Gicas, B Humphries, W G Honer, S W Flynn, A E Thornton, G N Smith, W
Su, A Philips, D E Warburton
Comorbid Abstracts
/
Clinical Abstracts
93
12:00–
2:30 p.m.
Coquina Ballroom
048
EFFICACY OF THE GUIDELINES FOR DIAGNOSIS AND TREATMENT OF ADOLESCENTS
WITH SCHIZOPHRENIA: A COMPARATIVE STUDY VS USUAL TREATMENT
Rosa E Ulloa, R Apiquian, P Calle, E Sarmiento, N González, J Saucedo, V Velázquez, A T
Díaz, M del Valle, G Victoria, D Coronel
049
EFFECTS OF YOGA THERAPY ON POSTURAL STABILITY IN SCHIZOPHRENIA: A
SINGLE-BLIND RANDOMIZED CONTROLLED TRIAL
Ikai Saeko, U Hiroyuki, S Takefumi, T Kenichi, M Masaru, F Yasuo
050
ASPECT-R: A TOOL TO RATE THE PRAGMATIC (EFFECTIVENESS) / EXPLANATORY
(EFFICACY) CHARACTERISTICS OF A CLINICAL TRIAL DESIGN
Cynthia A Bossie, Larry Alphs
051
SCHIZOPHRENIA TRIALS COMPARING LONG-ACTING INJECTABLE VS DAILY ORAL
ANTIPSYCHOTIC TREATMENTS: DO PRAGMATIC VS EXPLANATORY STUDY DESIGNS
MATTER?
Joseph F Hulihan, Cynthia A Bossie, L Alphs
052
DECISIONAL CAPACITY OF PATIENTS WITH SCHIZOPHRENIA ABOUT CONSENT TO
RESEARCH FOR A DRUG TRIAL – A STUDY FROM INDIA
Vishal Kasal, Prabha Chandra
053
RESCALING THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS): EFFECTS ON
PERCENT CHANGE FROM BASELINE
Christian Yavorsky, Mark G Opler, Anzalee Khan, Luka Lucic, B Rothman, S Jovic
054
A COMPARISON OF MOTIVATIONAL MEASURES IN SCHIZOPHRENIA
Joanna Fiszdon, Kee-Hong Choi, Jimmy Choi
055
AMG 747, A NOVEL GLYCINE TRANSPORTER TYPE-1 (GLYT1) INHIBITOR WITH
COGNITION-ENHANCING AND ANTIPSYCHOTIC-LIKE EFFECTS IN PRECLINICAL
RODENT MODELS OF SCHIZOPHRENIA
James Treanor, H Chen, O Murphy, M Cueva, J Danao, C Dias, C Ilch, K Taborn, A
Amegadzie, D Reid, S Chen, J Allen, J Chen, W Qian, T Kornecook
056
THERAPEUTIC POTENTIAL OF α-LIPOIC ACID ON PPI DEFICITS IN A JUVENILE TWOHIT ANIMAL MODEL OF SCHIZOPHRENIA
Jessica Deslauriers, P Sarret, S Grignon
057
A 10-YEAR OUTCOME STUDY OF AN EARLY INTERVENTION PROGRAM FOR
PSYCHOSIS IN HONG KONG (EASY) COMPARE WITH STANDARD CARE SERVICE
Kit Wa Sherry Chan, J Tang, G Wong, Wing C Chang, E Lee, C Hui, E Y Chen
058
INSULIN RESISTANCE AND SECRETION IN VIVO: CENTRALLY-MEDIATED
ANTIPSYCHOTIC EFFECTS IN AN ANIMAL MODEL
Margaret K Hahn, Araba Chintoh, Gary Remington, Celine Teo, Steve Mann, Tamara
Arenovich, Paul Fletcher, Melanie Guenette, Tony Cohn, Adria Giacca
94
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
059
SUSTAINED WEIGHT LOSS IN AN OBESE, DIABETIC SCHIZOPHRENIA PATIENT AFTER
ADJUNCTIVE TREATMENT WITH A GLP-1 RECEPTOR AGONIST: A CASE REPORT
Pelle L Ishøy, F K Knop, T Vilsbøll, B Glenthøj, Bjørn H Ebdrup
060
ROLE OF FATTY ACID DESATURASE 1 (FADS1) RS1535 VARIANT AND DIETARY FATTY
ACID INTAKE ON TOTAL CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN LEVELS IN
Kyle Burghardt, K N Gardner, Vicki L Ellingrod
061
TARGETING THE OBESOGENIC ENVIRONMENT OF SEVERE MENTALLY ILL
RESIDENTIAL PATIENTS IS EFFECTIVE IN LOWERING THE PATIENTS’
CARDIOMETABOLIC RISK
Frederike Jörg, E I Metting, R Bruggeman, L Van der Meer, E Corpeleijn
062
VITAMIN D DEFICIENCY IN SCHIZOPHRENIA-A NEED FOR INCREASED VIGILANCE?
John Lally, P Gardner Sood, S Smith, Oliver D Howes, Robin M Murray, F Gaughran
063
THE IMPACT OF CHANGES IN EXECUTIVE AND MEMORY FUNCTIONING ON COSTS
FOLLOWING COGNITIVE REMEDIATION THERAPY
Clare H Reeder, A Pickles, V Harris, T Wykes
064
PREDICTORS OF RISK PERCEPTION AMONG SMOKERS WITH AND WITHOUT
SCHIZOPHRENIA
Heidi J Wehring, G Burton, W Kowalczyk, H Raley, Stephanie M Feldman, S Heishman,
Deanna L Kelly
065
A FIDELITY SCALE FOR FIRST EPISODE PSYCHOSIS SERVICES
Donald Addington, E McKenizie, J Wang, R Norman, G Bond
066
PREDIABETES AND DIABETES IN SCHIZOPHRENIA
Frank van der Heijden, P Steylen, W Verhoeven
067
MECHANISMS OF WEIGHT GAIN AND METABOLIC DISTURBANCES WITHIN THE FIRST
MONTHS OF TREATMENT WITH SECOND-GENERATION ANTIPSYCHOTICS IN
ANTIPSYCHOTIC-NAïVE CHILDREN AND ADOLESCENTS
Covadonga Martínez Díaz-Caneja, Laura Pina-Camacho, María Álvarez-Blázquez, Elena
Mérida, Margarita García-Amador, Cecilia Tapia-Casellas, Pamela Rodríguez-Latorre, Celso
Arango
068
PERSISTENT USAGE OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS IS
ASSOCIATED WITH REDUCTIONS IN HOSPITALIZATION RATES AND COSTS FOR
MEDICAID INSURED PATIENTS WITH SCHIZOPHRENIA
Craig Karson, Rimal Bera, S Offord, D Zubek, G Lau, J Lin
069
LONG-TERM COSTS & OUTCOMES OF PATIENTS WITH SCHIZOPHRENIA WHO HAVE
PREVIOUSLY FAILED AN ATYPICAL ANTIPSYCHOTIC
Krithika Rajagopalan, M Hassan, K O’Day, K Meyer, F Grossman
Comorbid Abstracts
/
Clinical Abstracts
95
12:00–
2:30 p.m.
Coquina Ballroom
070
DIFFERENTIAL STIGMATIZING ATTITUDES OF HEALTH CARE PROFESSIONALS:
SOMETHING TO WORRY ABOUT? A PILOT STUDY
Stynke Castelein, L M Gras, C Slooff, M Swart, J van Weeghel, H Knegtering
071
EARLY INTERVENTION AT THE PREVENTION AND RECOVERY CENTER FOR EARLY
PSYCHOSIS (PARC): ASSESSMENT OF OUTCOMES
Nicole F Mehdiyoun, E Liffick, J L Vohs, M M Gaunnac, M M Francis, A Breier
072
FACILITATORS AND BARRIERS TO EARLY YOUTH ENGAGEMENT IN FIRST EPISODE
PSYCHOSIS SERVICES (THE EYE PROJECT): THE SUBJECTIVE EXPERIENCE OF
ENGAGEMENT OF SERVICE USERS, CARERS AND YOUNG PEOPLE
Kathryn Greenwood, R Chandler, k Labuschagne, R de-Visser, Emmanuelle Peters, A Field,
L Holt, P Garety
073
STIMULANT USE PRIOR TO FIRST BREAK OF PSYCHOTIC ILLNESSES
Elizabeth S Liebson, R Rajarethinam, Dost Ongur, B Cohen
074
THE RISK OF DIABETES IN DEFICIT SCHIZOPHRENIA
Bernard A Fischer, W R Keller, C Vidal, E S Park, G P Strauss
075
REDUCED FREQUENCY OF HOSPITALIZATIONS AND USE OF PSYCHOTROPIC
MEDICATIONS IN SCHIZOPHRENIC PATIENTS FOLLOWING INTRODUCTION OF LONG
ACTING DEPOT INJECTIONS
Rimal B Bera, N C Puchakayala
076
PREVALENCE AND ASSOCIATIONS OF CHRONIC KIDNEY DISEASE (CKD) IN PATIENTS
WITH PSYCHOTIC DISORDERS
John Lally, P Gardner Sood, S Jayawardene, S Smith, Z Atakan, Kathryn Greenwood, Robin
M Murray, F Gaughran
077
COMMUNICATION SKILLS TRAINING IN PSYCHIATRY: AN AUSTRALIA EXPERIENCE
Martin Cohen, P Ditton-Phare, H Sandhu, Y Landa, T Levin, C Bylund, D Kissane, S Outram,
C Loughland, B Kelly
078
LANGUAGE BARRIER AND ACCESS TO TREATMENT FOR PSYCHIATRIC CONDITIONS
INCLUDING SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Ai Ohtani, T Suzuki, H Uchida
079
THE ECONOMIC BURDEN OF DISEASE ASSOCIATED WITH COGNITIVE DEFICITS IN
Nicolas Furiak, J Meyers, A Pitts, Amy Duhig, S Hass
080
IS THE PREVALENCE OF METABOLIC SYNDROME AND METABOLIC ABNORMALITIES
INCREASED IN EARLY SCHIZOPHRENIA? A COMPARATIVE META-ANALYSIS OF FIRST
EPISODE, UNTREATED AND TREATED PATIENTS
Marc De Hert, D Vancampfort, Amber De Herdt, W Yu, A Mitchell
96
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
081
OVERSIGHT OF CONSTIPATION IN INPATIENTS WITH SCHIZOPHRENIA: A CROSSSECTIONAL STUDY
Teruki Koizumi, H Uchida, T Suzuki, H Sakurai, M Nishimoto, T Ishigaki, Ai Ohtani, K
Tsunoda, M Mimura
082
IMPACT OF WEIGHT AND CENTRAL ADIPOSITY ON QUALITY OF LIFE IN OVERWEIGHT
PEOPLE WITH SCHIZOPHRENIA
Kimberly R Warren, L Boucher, J Linthicum, Robert W Buchanan, Stephanie M Feldman, D
Gorelick, F Liu, Deanna L Kelly
083
CHANGING ATTITUDE TO SCHIZOPHRENIA AMONG MEDICAL STUDENTS IN
SOUTHWESTERN NIGERIA
Olukayode Abayomi, Adegoke O Adelufosi, Adeoye Oyewole
084
POLYPHARMACY AND MEGA-DOSING IN SCHIZOPHRENIA: FINDINGS FROM A SAMPLE
OF NIGERIAN PSYCHIATRIC IN-PATIENTS
Adegboyega Ogunwale
085
THE USE OF BUS ADVERTISING FOR PARTICIPANT RECRUITMENT
AnnMarie Kearns, Stephanie M Feldman, H Raley, Heidi J Wehring, Kimberly R Warren, D
Warfel, Kelli M Sullivan, Amber K Earl, Deanna L Kelly, F Liu
086
EVALUATION OF QTC INTERVALS IN DRUG- NAïVE PATIENTS WITH SCHIZOPHRENIA
Kumiko Fujii, Y Ozeki, H Okayasu, Y Okuri, H Hori, M Orui, M Horie, H Kunugi, K Shimoda
087
IN VIVO BINDING OF THE DOPAMINE-1 RECEPTOR PET TRACERS [11C]NNC112 AND
[11C]SCH23390: A COMPARISON STUDY IN INDIVIDUALS WITH SCHIZOPHRENIA
Ragy R Girgis, Eline Poels, Mark Slifstein, Anissa Abi-Dargham
088
DOPAMINE D2/D3 BLOCKADE RELATED TO THE IMPROVEMENT OF BRAIN REWARD
ABNORMALITIES IN SCHIZOPHRENIA - A LONGITUDINAL STUDY IN ANTIPSYCHOTICNAIVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS.
Sanne Wulff, M Ø Nielsen, Hans Rasmussen, L T Jensen, E Rostrup, E Frandsen, L H
Pinborg, C Svarer, G M Knudsen, B Y Glenthøj
089
DELTA-9-TETRAHYDROCANNABINOL-INDUCED DOPAMINE RELEASE AS A FUNCTION
OF PSYCHOTIC ILLNESS AND VULNERABILITY: 18F-FALLYPRIDE POSITRON EMISSION
TOMOGRAPHY STUDY
Rebecca Kuepper, Jenny Ceccarini, Johan Lataster, Jim van Os, Marinus van
Kroonenburgh, Joop van Gerven, Machteld Marcelis, Koen van Laere, Cecile Henquet
090
ELEVATED PLASMA LEVELS OF VON WILLEBRAND FACTOR IS ASSOCIATED WITH
INCREASED BASAL GANGLIA VOLUME IN SCHIZOPHRENIA
Ingrid Dieset, Unn Kristin Haukvik, Ingrid Melle, S Hope, J Røssberg, T Ueland, P Aukrust, I
Agartz, O Andreassen
Comorbid Abstracts
/
Clinical Abstracts
97
12:00–
2:30 p.m.
Coquina Ballroom
091
CAN CORTISOL LEVELS PREDICT CLINICAL OUTCOME IN PATIENTS WITH FIRSTEPISODE PSYCHOSIS?
Valeria Mondelli, R Handley, T R Marques, H Taylor, P Zunszain, Marta M Di Forti, Robin M
Murray, P Dazzan, C M Pariante
092
INCREASED CIRCULATING ANTI-ANGIOGENIC FACTOR IN INDIVIDUALS WITH FAMILIAL
HIGH RISK FOR SCHIZOPHRENIA
Ravinder Reddy, Matcheri Keshavan, D Montrose, Konasale Prasad, Jeffrey K Yao
093
THE SEROTONIN 2A RECEPTOR IS ASSOCIATED WITH WEIGHT GAIN IN
ANTIPSYCHOTIC-NAIVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS AFTER LONG
TERM ANTIPSYCHOTIC MONOTHERAPY
Hans Rasmussen, B H Ebdrup, B Oranje, B Aggernæs, H Lublin, L H Pinborg, G M
Knudsen, B Y Glenthøj
094
THYROID FUNCTION IN FIRST EPISODE NAïVE PSYCHOSIS
Clemente Garcia-Rizo, Emilio Fernandez-Egea, Cristina Oliveira, Miquel Bioque, Alicia
Valiente, Ana Meseguer, Miguel Bernardo, Brian Kirkpatrick
095
IS THE LIPID MEMBRANE COMPOSITION ASSOCIATED WITH PSYCHOPATHOLOGY IN
PATIENTS WITH SCHIZOPHRENIA?
Haifa Bergaoui, K Sweers, Marc De Hert, Cédric Tessier, Philippe Nuss
096
COMPARISON OF NIACIN-INDUCED FLUSHING BETWEEN SCHIZOPHRENIA AND
BIPOLAR DISORDER PATIENTS USING A LASER DOPPLER FLOWMETER
Jeffrey K Yao, G G Dougherty, Gretchen L Haas, R Condray, B Kisslinger, John Kasckow, E
Messamore
098
SIGNIFICANT DOWN-REGULATION OF THE EIF2 PROTEIN PATHWAY IN ONS CELL
MODEL OF SCHIZOPHRENIA
David R Cotter, Jane A English, Melanie Foecking, Y Fan, J McGrath, A Mackay Sims, G
Cagney
099
SERUM S100B: AN ENDOPHENOTYPIC MARKER FOR PSYCHOTIC DISORDER?
Christine van der Leeuw, M Marcelis, S Peeters, M Verbeek, P Menheere, L de Haan, Jim
van Os, N van Beveren
100
CENTRAL INTERLEUKIN-6 ACTIVATION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA
Lilly Schwieler, Elisabeth Skogh, Martin Samuelsson, Magdalena Kegel, Sophie Erhardt,
Göran Engberg
101
POSSIBLE PATHOPHYSIOLOGICAL ROLE OF NITRIC OXIDE IN PATIENTS WITH
SCHIZOPHRENIA
Amra Memic, Abdulah Kucukalic, Jasminko Huskic, Lilijana Oruc, Lejla Burnazovic
98
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
102
ASYMMETRICAL DISTRIBUTION OF LYSO PHOSPHATIDYL ETHANOLAMINE IN THE
ERYTHROCYTE MEMBRANE OF TREATED PATIENTS WITH SCHIZOPHRENIA. A MASS
SPECTROMETRY STUDY
Cédric Tessier, A Frajerman, A Lamazière, K Sweers, Haifa Bergaoui, Marc De Hert,
Philippe Nuss
103
SCHIZOPHRENIA BIOMARKERS IN PLASMA PROTEOME
Zoran Zimolo, K Stone, T Wu, Deepak C D’Souza, K Williams, J Krystal
104
CHANGES OF SOME OXIDATIVE STRESS MARKERS IN SCHIZOPHRENIA:
COMPARISON BETWEEN TYPICAL AN ATYPICAL ANTIPSYCHOTICS EFFECTS
Alin Stelian Ciobica, Manuela Padurariu, Cristinel Stefanescu, Vlad Artenie
105
GENE EXPRESSION PROFILING OF OLIGODENDROCYTES IN DORSOLATERAL
PREFRONTAL CORTEX DEEP WHITE MATTER IN BIPOLAR DISORDER AND
SCHIZOPHRENIA
Sarah Mauney, C Y Pietersen, Jill M Goldstein, Tracey Petryshen, Larry J Seidman, M E
Shenton, Robert McCarley, T W Woo
106
EXPRESSION OF RETINOID RECEPTORS AND INFLAMMATION GENES IN THE
DORSOLATERAL PREFRONTAL CORTEX IN SCHIZOPHRENIA
Shan-Yuan Tsai, S G Filman, Samantha J Fung, V S Catts, Cyndi S Weickert
107
ALTERED ERBB4 SPLICE VARIANT EXPRESSION IN THE HUMAN PREFRONTAL
CORTEX IN SCHIZOPHRENIA
Dipesh Joshi, Cynthia Shannon Weickert
108
DEVELOPMENTAL PATTERNS OF PREFRONTAL CORTICAL PERINEURONAL NETS AND
THEIR ABNORMALITIES IN SCHIZOPHRENIA
Katina Athanas, Sarah Mauney, N Shaskan, T W Woo
109
INCREASED VIRAL RESTRICTION FACTOR LEVELS IN ENDOTHELIAL CELLS IN THE
PREFRONTAL CORTEX IN SCHIZOPHRENIA
David Volk, B Siegel, E Sengupta, J Edelson, D Lewis
110
MICROGLIA AND ASTROGLIA CELL DENSITY AND SIZE IN THE CEREBRAL CORTEX IN
SCHIZOPHRENIA AND MAJOR DEPRESSION
John F Smiley, C Bleiwas, L Haxhija, G Rosoklija, A J Dwork
111
AGE EFFECTS ON BRAIN MICROSTRUCTURE IN SCHIZOPHRENIA: A META-ANALYSIS
AND META-REGRESSION OF NEURON DENSITY
Kirran Bakhshi, C Bourne, B Funchal, S Chance
112
COMPUTATIONAL MODELING OF PREFRONTAL CORTEX CIRCUITRY IN
SCHIZOPHRENIA
Peter J Siekmeier, Tsung-Ung W Woo
Comorbid Abstracts
/
Clinical Abstracts
99
12:00–
2:30 p.m.
Coquina Ballroom
113
ABNORMALITIES OF THE UBIQUITIN-PROTEASOME AND UBIQUITIN-LIKE SYSTEMS IN
THE SUPERIOR TEMPORAL GYRUS IN SCHIZOPHRENIA
Maria D Rubio, Krista Woods, Vahram Haroutunian, James H Meador-Woodruff
114
GLUTAMATE SIGNALING IS REDUCED IN HIPPOCAMPUS IN SCHIZOPHRENIA
Ana D Stan, Subroto Ghose, Perry Mihalakos, Masaya Yanagi, Yan Fang, Sandeep Ganji,
Changho Choi, C Tamminga
115
EVALUATION OF CB1-RECEPTOR EXPRESSION IN THE HIPPOCAMPUS OF
SCHIZOPHRENIA, BIPOLAR AND MAJOR DEPRESSIVE DISORDER
Dagmar Koethe, J M Bump, A Spiess, L Liebke, S Weis, E F Torrey, F M Leweke
116
INCREASED WHITE MATTER NEURON DENSITY IS RELATED TO HIGH
NEUROINFLAMMATION IN PEOPLE WITH SCHIZOPHRENIA
Samantha J Fung, Dipesh Joshi, Stu Fillman, Cyndi S Weickert
117
CHONDROITIN SULFATE PROTEOGLYCAN ABNORMALITIES IN SCHIZOPHRENIC
SUBJECTS
Harry Pantazopoulos, Anna Wallin, Sabina Berretta
118
ALTERED EXPRESSION OF TGF-BETA 1 IN THE AMYGDALA OF SCHIZOPHRENIC
SUBJECTS
Matej Markota, Harry Pantazopoulos, Sabina Berretta
119
GABAA RECEPTOR SUBUNITS, FRAGILE X MENTAL RETARDATION PROTEIN AND
METABOTROPIC GLUTAMATE RECEPTOR 5 ARE ALTERED IN BRAINS OF SUBJECTS
WITH SCHIZOPHRENIA AND MOOD DISORDERS
S Hossein Fatemi, T D Folsom
120
INHIBITORY CATECHOLAMINE RECEPTORS MODULATE NEUROCHEMICAL EFFECTS
OF TYROSINE DEPLETION
George E Jaskiw, Z Brodnik, M Double
121
PRENATAL POLYIC AND NEONATAL LPS HAVE DIFFERENTIAL EFFECTS ON THE
INTEGRITY OF SEROTONIN 5HT1A AND CANNABINOID CB1 RECEPTORS IN
ADULTHOOD
Katerina Zavitsanou, M Verdurand, V S Dalton, A Walker, C Shannon-Weickert, L Sominsky,
D M Hodgson
122
SCHIZOPHRENIA-LIKE PHENOTYPE IN A RAT MODEL TRANSGENIC FOR THE HUMAN
SPINOCEREBELLAR ATAXIA SUBTYPE 17 (SCA17) MUTATION
Sally Makady, Y K Urbach, F Canneva, A C Plank, A Schulze-Krebs, D Amato, P Bauer, H P
Nguyen, C Müller, O Riess, S von Hörsten
123
EVALUATION OF THE EFFECT OF RIVASTIGMINE IN THE BEHAVIORAL AND
ACETILCHOLINESTERASE ACTIVITY IN A RODENT MODEL OF SCHIZOPHRENIA
INDUCED BY KETAMINE
Emilio L Streck, R F Juliao, Josiane Budni, D B Fraga, F D Pacheco, P F Deroza, R D Luca,
M B Oliveira, A S Heylmann, J Quevedo, Alexandra Zugno
100
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
124
ADOLESCENT CANNABINOID ADMINISTRATION LEADS TO PERSISTENT
ENDOCANNABINOID PATHWAY CHANGES IN FRONTOSTRIATAL BRAIN REGIONS
Subroto Ghose, K Gleason, M Shanks, A Shukla, S Birnbaum
125
EFFECTS OF OMEGA-3 DIETARY SUPPLEMENT IN ACTIVITY AND MRNA EXPRESSION
OF ACETYLCHOLINESTERASE ON KETAMINE-INDUCED ANIMAL MODEL OF
SCHIZOPHRENIA
Alexandra Zugno, H Chipindo, L Canever, B Panizzutti, A Heylmann, P Deroza, Josiane
Budni, P Gomes, f Silveira, M Bogo, C Gama
126
BRIDGING OXIDATIVE STRESS TO GLUTAMATERGIC DYSFUNCTION - GLUTATHIONE
AS A NEURAL RESERVOIR OF GLUTAMATE
Thomas W Sedlak, M Koga, S H Snyder, Akira Sawa
127
THE EFFECT OF POST-WEANING SOCIAL ISOLATION ON GAD 67, BDNF, AND TRKβ IN
THE PREFRONTAL AND HIPPOCAMPAL CORTICES OF ADULT RATS
Ali Shahbazi, Mohammad Taghi Joghataei, Nahid Aboutaleb, Mohammad Reza Zarrindast
128
TRANSMEMBRANE DOMAIN NRG1 MUTATION ALTERS NRG1 AND INTERNEURON
MARKER EXPRESSION
Leonora Long, E Frank, X Huang, T Karl, Cyndi S Weickert
129
INTERACTIVE EFFECTS OF CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITION
AND Δ-9-TETRAHYDROCANNABINOL (THC) ON BRAIN EXTRACELLULAR DOPAMINE IN
MICE
Katharina Stumpenhorst, M Käenmäki, P J Harrison, T Sharp, Elizabeth Tunbridge
131
PROTEOMIC STUDY OF THE BRAIN FOLLOWING N-3 FATTY ACID DEFICIENCY SHOWS
DYSREGULATION OF PROTEINS INVOLVED IN CLATHRIN MEDIATED ENDOCYTOSIS
AND MITOCHONDRIAL FUNCTION
Jane A English, C Scaife, M Focking, G Cagney, T Moriguchi, David R Cotter
132
POLY IC INDUCED INFLAMMATION CAUSES MYELIN AND IRON CHANGES WHICH CAN
BE REVERSED BY RISPERIDONE
Lorna A Farrelly, Melanie Foecking, P Dicker, Jane A English, M Cannon, Y Pionkewitz, I
Weiner, G Cagney, David R Cotter
133
PRENATAL HYPOXIA-INDUCED MOLECULAR AND BEHAVIORAL CHANGES IN
HETEROZYGOUS REELER MICE: RELEVANCE TO SCHIZOPHRENIA
Kristy R Howell, Anilkumar Pillai
134
IMPAIRED GABAERGIC FUNCTION UNDERLIES COGNITIVE DEFICITS IN THE
NEONATAL PHENCYCLIDINE RAT MODEL OF SCHIZOPHRENIA
Brian V Broberg, Jesper Riise, Sanne Kaalund, Nils Ole Dalby, Niels Plath, Bente
Pakkenberg, Birte Glenthøj, Celia Kjærby
136
ROLE OF NEUROPILIN 1 (NRP1) IN REELIN SIGNALING IN NEURONS
Anilkumar Pillai, C D Pandya, Kristy R Howell
Comorbid Abstracts
/
Clinical Abstracts
101
12:00–
2:30 p.m.
Coquina Ballroom
137
CARIPRAZINE EXHIBITS ANXIOLYTIC EFFECTS AND DOPAMINE D3 RECEPTORDEPENDENT ANTIDEPRESSANT-LIKE ACTIVITY IN THE CHRONIC UNPREDICTABLE
STRESS MODEL
Vanja Duric, R S Duman, M Banasr, N Adham, B Kiss, I Gyertyan
138
TESTOSTERONE DECREASES CELL SURVIVAL IN THE ADOLESCENT PRIMATE
HIPPOCAMPUS
Katherine M Allen, Samantha J Fung, P Noble, Cyndi S Weickert
139
A STUDY OF DIGIT RATIO (2D: 4D) IN SCHIZPHRENIA
Ravi P Bangalore, Ravi S Pandey
140
SUICIDAL BEHAVIOUR IN SCHIZOPHRENIA IS MEDIATED BY EGF SYSTEM
DYSFUNCTION: A MECHANISM FOR CLOZAPINE’S ANTI-SUICIDE EFFECT?
Suresh Sundram, A M Pereira, C S Weickert, V Swaminathan
141
DOES CHILDHOOD TRAUMA AFFECT BIOLOGICAL HPA AXIS REACTIVITY TO
STRESSFUL EVENTS?
Simone Ciufolini, Valeria Mondelli, C Pariente, Paola Dazzan
142
COMT VAL158MET GENOTYPE SELECTIVELY ALTERS PREFRONTAL [18F]FALLYPRIDE
DISPLACEMENT AND SUBJECTIVE FEELINGS OF STRESS IN RESPONSE TO A
PSYCHOSOCIAL STRESS CHALLENGE
Dennis Hernaus, Dina Collip, J Lataster, J Ceccarini, G Kenis, L Booij, J Pruessner, K Van
Laere, Ruud van Winkel, Jim van Os, Inez Myin-Germeys
143
HUMAN INDUCED PLURIPOTENT STEM (IPS) CELL-DERIVED MODELS OF LATENT
NEUROTROPIC HERPES VIRUS INFECTION
Vishwajit Nimgaonkar, L D’Aiuto, M Bamne, A Watson, Robert Yolken, P Kinchington
144
PSYCHIATRIC MEDICATION UTILIZATION IN PATIENTS WITH SCHIZOPHRENIA,
PSYCHOTIC BIPOLAR DISORDER, AND SCHIZOAFFECTIVE DISORDER
Jeffrey R Bishop, J L Reilly, M S Harris, E S Gershon, C S Tamminga, G K Thaker, Godfrey
D Pearlson, Matcheri Keshavan, J A Sweeney
145
RANDOMIZED CONTROLLED TRIAL EVALUATING 1-YEAR EXTENDED CASE
MANAGEMENT FOR FIRST-EPISODE PSYCHOSIS PATIENTS DISCHARGED FROM EASY
PROGRAM IN HONG KONG
Wing C Chang, H K Chan, T T Jim, H Y Wong, L M Hui, K W Chan, H M Lee, Y H Chen
146
PREDICTORS OF SERVICE DISENGAGEMENT FROM EASY PROGRAM IN YOUNG
PSYCHOSIS PATIENTS: A 3-YEAR FOLLOW-UP STUDY IN HONG KONG
C W Chan, W C Chang, Y M Tang, L M Hui, H Y Wong, K W Chan, H M Lee, Y H Chen
147
SELECTIVE OVEREXPRESSION OF DOPAMINE D3 RECEPTORS IN THE STRIATUM
DISRUPTS MOTIVATION BUT NOT COGNITION
Eleanor H Simpson, Eric R Kandel, Christoph Kellendonk
102
Clinical Abstracts
/
Comorbid Abstracts
12:00–
2:30 p.m.
Coquina Ballroom
148
PRENATAL KYNURENINE EXPOSURE CAUSES DEFICITS IN HIPPOCAMPUS-MEDIATED
LEARNING AND MEMORY IN ADULT RATS
Ana Pocivavsek, Greg I Elmer, John P Bruno, Robert Schwarcz
149
INTERACTION BETWEEN NITRIC OXIDE AND DOPAMINE ON THE MODULATION OF
SENSORIMOTOR GATING
Cristiane Salum, Joseli P Neves, Michelle C Brosco
150
HISTORY OF ADOLESCENT MARIJUANA ABUSE PREDICTS GABAERGIC DYSFUNCTION
IN ADULT SCHIZOPHRENIA
Juan R Bustillo, Yuhan Chen, Thomas Jones, Hongji Chen, Nick Lemke, Chris Abbott, Jose
Canive
151
INCREASED SNARE PROTEIN-PROTEIN INTERACTIONS IN SCHIZOPHRENIA
PREFRONTAL CORTEX
Alfredo Ramos-Miguel, Alasdair M Barr, Andrew J Dwork, Gorazd B Rosoklija, John Mann,
William G Honer
152
THE USE OF PROTON MAGNETIC SPECTROSCOPY TO DIFFERENTIATE PRIMARY
VERSUS METHAMPHETAMINE-INDUCED PSYCHOSIS
Philip Tibbo, Denise Bernier, Candice E Crocker, Bonnie Lakusta, Christopher Hanstock,
Peter Seres, Scot E Purdon
153
PHARMACOLOGICAL CHARACTERIZATION OF THE GLYCINE TRANSPORTER-1
INHIBITOR RG1678 IN ANIMAL MODELS RELATED TO NEGATIVE AND COGNITIVE
SYMPTOMS OF SCHIZOPHRENIA
Holger Rosenbrock, Anelise Marti, Riccardo Giovannini, Roberto Arban, Cornelia DornerCiossek
154
GALANTAMINE REVERSES ACUTE PHENCYCLIDINE-INDUCED ATTENTIONAL SETSHIFTING IMPAIRMENT IN RATS WITH RETAINED EFFECT ALSO IN THE PRESENCE OF
RISPERIDONE
Marie-Louise G Wadenberg
155
OPEN, RANDOMIZED TRIAL OF THE EFFECTS OF ARIPIPRAZOLE VERSUS
RISPERIDONE ON SOCIAL COGNITION IN SCHIZOPHRENIA
Arija Maat, Wiepke Cahn, Harm Gijsman, Hans E Hovens, Rene Kahn, Andre Aleman
156
AZD8529, A POSITIVE ALLOSTERIC MODULATOR AT THE MGLUR2 RECEPTOR, DOES
NOT IMPROVE SYMPTOMS IN SCHIZOPHRENIA: A PROOF OF PRINCIPLE STUDY
Robert E Litman, Mark A Smith, Jim Doherty, Alan Cross, Shane Raines, Stephen R Zukin
157
PSYCHOPATHOLOGICAL CHARACTERISTICS OF FIRST EPISODE, CHRONIC
INPATIENTS AND AMBULATORY PATIENTS WITH SCHIZOPHRENIA: A NONPARAMETRIC ITEM RESPONSE ANALYSIS
Anzalee Khan, Philip D Harvey, Jean-Pierre Lindenmayer, Mark G Opler, Christian Yavorsky
Comorbid Abstracts
/
Clinical Abstracts
103
12:00–
2:30 p.m.
Coquina Ballroom
158
WHEN PATIENTS WITH SCHIZOPHRENIA ARE ASSESSED USING COMPUTERISED
COGNITIVE TESTS, THE DOMINANT IMPAIRMENTS ARE TO ATTENTION AND
INFORMATION PROCESSING
Keith A Wesnes
159
TWO CANDIDATE GENE-BASED ASSOCIATION STUDIES OF ANTIPSYCHOTIC-INDUCED
MOVEMENT DISORDERS IN LONG-STAY PSYCHIATRIC PATIENTS: PROSPECTIVE
STUDIES
P Roberto Bakker, Egbert Bakker, Asmar F Al Hadithy, Najaf Amin, Cornelia M van Duijn, Jim
van Os, Peter N van Harten
160
ANTIPSYCHOTIC-INDUCED MOVEMENT DISORDERS IN LONG-STAY PSYCHIATRIC
PATIENTS: A PROSPECTIVE STUDY
P Roberto Bakker, Izaäk de Groot, Jim van Os, Peter N van Harten
161
PREVALENCE OF VITAMIN D DEFICIENCY IN INPATIENT PSYCHOSIS HEALTH CARE
SETTINGS
Tony Hirving, Bo Wynn, Fiona P Gaughran, Tom Craig, Matthew Crews, Raj Mohan, David
O’Flynn, Sukhi Shergill, Stephanie Young, James MacCabe
162
EARLY INTERVENTION TO MODIFY MEDICAL STUDENTS’ ATTITUDES TOWARDS
PEOPLE LIVING WITH SCHIZOPHRENIA AND RELATED DISORDERS
Bruce R Stevens, Robert Averbuch, Kyle Dalton, Travus White, Veronica Novosad, Beverly
Vidaurreta, Lou Ann Cooper
163
ABNORMALITIES IN MITOCHONDRIAL FUNCTION IN HUMAN NEURAL CELLS
DIFFERENTIATED FROM HAIR FOLLICLE-DERIVED INDUCED PLURIPOTENT STEM
CELLS (IPSC) IN SCHIZOPHRENIA
Dorit Ben-Shachar, O Robicsek, R Karry, I Petit, N Salman-Kesner, F J Muller, D Aberdam
164
THE RELATIONSHIP BETWEEN OXIDATIVE STRESS AND DOPAMINERGINC SYSTEM IN
PSYCHOSIS
Trevor Young, H Kim, A Andreazza
165
OXIDATIVE STRESS: THE CROSSTALK BETWEEN CENTRAL AND PERIPHERAL
BIOMARKERS IN PSYCHOSIS
Ana Andreazza, G Scola, H Kim, T Young
166
ABNORMAL CEREBRAL BIOENERGETICS IN SCHIZOPHRENIA MEASURED IN VIVO
USING 31P MAGNETIZATION TRANSFER SPECTROSCOPY
Dost Ongur, B M Cohen, F Du
167
THE ROLE OF STEP IN SCHIZOPHRENIA
Paul Lombroso
168
STUDYING CULTURED ASTROCYTES, OLIGODENDROCYTES AND NEURONS TO
REVEAL WHERE ARE THE PROTEOMIC DIFFERENCES OBSERVED IN SCHIZOPHRENIA
BRAINS
Daniel Martins-de-Souza
104
Clinical Abstracts
/
Comorbid Abstracts
169
EFFECTIVENESS OF WEB-BASED MULTI-FAMILY TREATMENT DELIVERED TO THE
HOMES OF PERSONS WITH SCHIZOPHRENIA AND THEIR SUPPORTERS
Armando J Rotondi, G Haas, C Anderson, K Mueser
ORAL SESSION 4-1
COGNITION IN PSYCHOSIS
Palazzo Ballroom A
Chair: Cameron Carter
3:00 pm
MODELLING THE EFFECT OF COGNITIVE REMEDIATION ON REINFORCEMENT
LEARNING IN SCHIZOPHRENIA
Matteo Cella, Anthony Bishara, Evelina Medin, Sarah Swan, Til Wykes
3:15 pm
THE EFFECTS OF OXYTOCIN ON SOCIAL COGNITION AND OLFACTION IN
PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS
Josh Woolley, Brandon Chuang, Olivia Lam, Daniel H Mathalon, Kate Rankin, Sophia
Vinogradov
3:30 pm
EXAMINING THE NICOTINIC PARTIAL AGONIST VARENICLINE ON COGNITIVE
PERFORMANCE IN CIGARETTE SMOKERS WITH SCHIZOPHRENIA UNDER
SMOKING SATIATION AND ABSTINENCE
Victoria C Wing, Caroline E Wass, Tony P George
3:45 pm
RESOLVING THE PSYCHOMETRIC CONFOUND WITH AN OPTIMIZED MEASURE
OF DISCRIMINATING POWER
Seung Suk Kang, Angus W MacDonald
4:00 pm
INHIBITION AND MONITORING OF SACCADES IN A DOUBLE-STEP TASK IN
SCHIZOPHRENIA
Katy N Thakkar, Jeffrey D Schall, Gordon D Logan, Sohee Park
4:15 pm
SUSTAINED ATTENTION TO EMOTIONAL FACES IN SCHIZOPHRENIA:
RELATIONSHIP WITH FACIAL EMOTION RECOGNITION
Sung-Hyouk Park, C Kim, K Lee
4:30 pm
DYNAMIC ASSESSMENT IN SCHIZOPHRENIA: ASSOCIATIONS BETWEEN
LEARNING POTENTIAL AND NEUROCOGNITIVE, CLINICAL AND FUNCTIONAL
MEASURES
Amy L Barnes, Melisa Rempfer
4:45 pm
COGNITIVE CHANGES IN NON-AFFECTIVE PSYCHOSIS THE FIRST 4-6 WEEKS
AFTER ADMISSION TO A PSYCHIATRIC ACUTE WARD: EFFECTS OF SUBSTANCE
USE
Siri Helle, R Gjestad, E Johnsen, R A Kroken, H A Jørgensen, E M Løberg
5:00 pm
ASSOCIATIONS BETWEEN INSIGHT AND COGNITIVE IMPROVEMENT FOLLOWING
COGNITIVE REMEDIATION THERAPY IN SCHIZOPHRENIA
Audrey Benoit, P O Harvey, L Bherer, Martin Lepage
5:15 pm
ASSOCIATION BETWEEN STRESSFUL LIFE EVENTS, DISTRESS TOLERANCE AND
CLINICAL OUTCOMES IN PERSONS WITH SCHIZOPHRENIA
Katie L Nugent, Joshua Chiappelli, H Sampath, S Daughters, L E Hong
Comorbid Abstracts
/
Clinical Abstracts
105
ORAL SESSION 4-2
NEW DIRECTIONS IN SOCIAL AND COGNITIVE NEUROSCIENCE OF
SCHIZOPHRENIA
Palazzo Ballroom D
Chair: Sohee Park
3:00 pm
SOCIAL COGNITION, SELF REGULATION AND NEUROHORMONES IN
SCHIZOPHRENIA
David L Roberts, C Walss-Bass, D I Velligan, H Carr, C Sierra
3:15 pm
HEAD MOVEMENT SYNCHRONY IN SOCIAL INTERACTIONS OF PATIENTS WITH
SCHIZOPHRENIA INDICATES SYMPTOMS, COGNITION AND SOCIAL
FUNCTIONING
Zeno Kupper, F Ramseyer, H Hoffmann, Wolfgang Tschacher
3:30 pm
MODULATION OF THE DORSOMEDIAL PREFRONTAL CORTEX IN
SCHIZOPHRENIA: ATTRIBUTING EMOTION TO SELF VERSUS OTHERS
Junghee Lee, Jonathan K Wynn, Philippe-Olivier Harvey, Michael F Green
3:45 pm
DISTINCT PATTERN OF SEX DIFFERENCES IN CEREBRAL ACTIVATIONS DURING
EMOTIONAL MEMORY VS. VISUO-SPATIAL PROCESSING IN SCHIZOPHRENIA
Adrianna Mendrek, N Lakis, E Stip
4:00 pm
EVALUATING MOTIVATION IN SCHIZOPHRENIA IN A VIRTUAL ENVIRONMENT: A
NOVEL OBJECTIVE ASSESSMENT METHODOLOGY
George Foussias, I Siddiqui, K McDonald, N Hasan, S Thavabalasingam, C
Plagiannakos, J Zawadzki, K K Zakzanis, P Fletcher, A Wong, Gary Remington
4:15 pm
INDIVIDUAL VARIABILITY IN NEURAL PREDICTION ERROR RESPONSE PREDICTS
PARADOXICAL MEMORY STRENGTHENING EFFECTS OF KETAMINE:
IMPLICATIONS FOR BELIEF PERSISTENCE AND DELUSIONS
Philip R Corlett, Jane R Taylor, John H Krystal, Paul C Fletcher
4:30 pm
ELUCIDATING MECHANISMS OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA VIA
PHARMACOLOGICAL NEUROIMAGING AND COMPUTATIONAL MODELING
Alan Anticevic, John D Murray, Mark Gancsos, Grega Repovs, Naomi R Driesen,
Megan Ichinose, Debra Ennis, Mark J Niciu, Peter T Morgan, Toral S Surti, Michael
Bloch, Ramachandran Ramani, Mark A Smith, Xiao-Jing Wang, John H Krystal, Phil
Corlett
4:45 pm
INTERSENSORY TEMPORAL INTEGRATION IN SCHIZOPHRENIA
Wolfgang Tschacher, C Bergomi
5:00 pm
INDIVIDUALS WITH SCHIZOPHRENIA FAIL TO SHOW NORMATIVE INVERTED-U
ACTIVATION IN RESPONSE TO FINE-GRAINED WORKING MEMORY LOAD
MANIPULATION
Jared X Van Snellenberg, Ragy R Girgis, Christina Read, Judy L Thompson, Jochen
Weber, Tor D Wager, Mark Slifstein, Jeffrey A Lieberman, Anissa Ab-Dargham, Edward
E Smith
106
Clinical Abstracts
/
Comorbid Abstracts
5:15 pm
RESTING STATE NEURAL OSCILLATIONS IN SCHIZOPHRENIA AND HIGH AND
LOW WORKING MEMORY
Anastasia M Bobilev, Jordan P Hamm, W T Oliver, Matthew E Hudgens-Haney, Peter F
Buckley, K A Dyckman, J E McDowell, B A Clementz
ORAL SESSION 4-3
TREATMENT AND SIDE-EFFECTS
Palazzo Ballroom E
Chair: Deepak C D’Souza
3:00 pm
A POPULATION-LEVEL PREDICTION TOOL FOR THE INCIDENCE OF FIRST
EPISODE PSYCHOSIS: TRANSLATIONAL EPIDEMIOLOGY BASED ON CROSSSECTIONAL DATA
James B Kirkbride, Daniel Jackson, Jesus Perez, David Fowler, Francis Winton,
Jeremy Coid, Robin M Murray, Peter B Jones
3:15 pm
SELECTIVE EFFECT S OF INDIVIDUAL ANTIPSYCHOTIC COTREATMENTS ON
CARDIOMETABOLIC AND HORMONAL RISK STATUS: RESULTS FROM A
SYSTEMATIC REVIEW AND META-ANALYSIS
Christoph U Correll, V Agarwal, D Cohen, Marc De Hert, J Nielsen
3:30 pm
MITOCHONDRIAL UNCOUPLING DYSFUNCTION AS SUSCEPTIBILITY PATHWAY TO
WEIGHT-GAIN INDUCED BY ANTIPSYCHOTICS IN SCHIZOPHRENIA PATIENTS
Vanessa F Gonçalves, Arun K Tiwari, Jeff A Lieberman, Herb Y Meltzer, Daniel J Müller,
James L Kennedy
3:45 pm
COMPARISON OF HEALTHCARE RESOURCE USAGE AND COSTS BEFORE AND
AFTER INITIATING LONG-ACTING INJECTABLE ANTIPSYCHOTICS AMONG
MEDICAID INSURED PATIENTS WITH SCHIZOPHRENIA
Rimal Bera, C Karson, S Offord, D Zubek, G Lau, J Lin
4:00 pm
PROSPECTIVE STUDY OF METABOLIC ABNORMALITIES IN SCHIZOPHRENIA
PATIENTS LIVING IN A RURAL COMMUNITY
Somashekhar Bijjal, J Thirthalli, C Naveenkumar, G Bangalore, B Manjuladevi, S
Reddy, D Renuka, V Rawath, N Manjunath
4:15 pm
THE IMPACT OF PROLACTIN-RAISING ANTIPSYCHOTICS ON BONE MINERAL
DENSITY IN PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A LONGITUDINAL
OBSERVATIONAL STUDY
Tatsuichiro Takahashi, H Uchida, M John, K Watanabe, M Mimura, C U Correll, Taishiro
Kishimoto
4:30 pm
CLOZAPINE TREATMENT IN SCHIZOPHRENIA PATIENTS WITH BENIGN
NEUTROPENIA: A CASE SERIES
Charles M Richardson, Gopal Vyas, Stephanie M Feldman, J S Coulter, K Jackson,
Heidi J Wehring, R Love, Deanna L Kelly
4:45 pm
PHARMACOGENETIC RESPONSE TO CLOZAPINE TREATMENT IN
SCHIZOPHRENIA: NEW INSIGHTS FROM A GENETIC FORM OF SCHIZOPHRENIA
Nancy J Butcher, W L Fung, E Cheung, L Slade, E W Chow, Anne S Bassett
Comorbid Abstracts
/
Clinical Abstracts
107
BIOMARKERS: GENERAL RISK FACTORS OR SPECIFIC PREDICTORS OF
PSYCHOSIS
Palazzo Ballroom F
Chair: Jean Addington
3:00 pm
SOCIAL AND ROLE RISK FACTORS: PREDICTORS OF PSYCHOSIS OR NONSPECIFIC INDICATORS OF POOR OUTCOME
B Cornblatt, R E Carrion, Andrea Auther, Larry J Seidman, Carrie E Bearden, Kristin
Cadenhead, Tyrone Cannon, R Heinssen, Daniel H Mathalon, Thomas H McGlashan,
D Perkins, M Tsuang, Elaine F Walker, Scott W Woods, Jean Addington
3:30 pm
STRESS, CORTISOL, AND RISK FOR PSYCHOSIS
Elaine F Walker, Tyrone Cannon, Jean Addington, Scott W Woods, Larry J Seidman,
Daniel H Mathalon, Kristin Cadenhead, B Cornblatt
4:00 pm
DISTURBANCES OF INFORMATION PROCESSING IN SUBJECTS CLINICALLY AT
HIGH RISK OF DEVELOPING PSYCHOSIS
Stephan Ruhrmann, M Bodatsch, A Nikolaides, R Müller, S Miess, J Klosterkötter
4:30 pm
IDENTIFYING BIOMARKERS OF RISK FOR AND PROGRESSION TO PSYCHOSIS
USING HIGH-RISK STRATEGIES
Tyrone Cannon
EPIGENETICS AT THE INTERSECTION BETWEEN GENETIC AND
ENVIRONMENTAL RISK FACTORS FOR BRAIN FUNCTION RELATED WITH
SCHIZOPHRENIA
Chair: Alessandro Bertolino
3:00 pm
NEURAL MECHANISMS OF SOCIAL RISK FOR PSYCHIATRIC DISORDERS
Andreas Meyer-Lindenberg
3:30 pm
ALTERED MOMENTARY TRANSFER OF ABERRANT SALIENCE (AMTAS) AS THE
BASIC UNIT OF PSYCHOTIC PSYCHOPATHOLOGY IN INTERACTION WITH
FAMILIAL, ENVIRONMENTAL, COGNITIVE AND EMOTIONAL FACTORS
Jim van Os, Dina Collip, M Wichers, P Delespaul, C Derom, E Thierry, W Vollebergh, I
Myin-Germeys, H Wigman
4:00 pm
HYPOXIA-RELATED METHYLATION OF THE BDNF RS6265 VAL ALLELE
DIFFERENTIALLY PREDICTS RISK FOR PHENOTYPES RELATED TO
SCHIZOPHRENIA IN HOMOZYGOUS AND HETEROZYGOUS INDIVIDUALS
Alessandro Bertolino, G L Ursini, L Tarantini, T Angrisano, L Fazio, R Romano, A Di
Giorgio, P Taurisano, B Gelao, G Caforio, L Ferranti, G Maddalena, T Cavalleri, S
Keller, V Bollati, Marco A Riva, L Chiariotti, G Blasi
4:30 pm
ADVERSE LIFE EVENTS DURING GESTATION AND LONG-TERM BRAIN
DYSFUNCTION: MOLECULAR AND EPIGENETIC MECHANISMS
Marco A Riva
108
Clinical Abstracts
/
Comorbid Abstracts
HIGH RATES OF SCHIZOPHRENIA AMONG BLACK PEOPLE IN EUROPE AND
THE USA; IS IT THE SAME OR A DIFFERENT PHENOMENON?
Chair: Robin M Murray
3:00 pm
THE SOCIAL CAUSES OF THE HIGH RATES OF PSYCHOSIS IN BLACK PEOPLE IN
EUROPE
Robin M Murray, Craig Morgan, Paola Dazzan, P Jones, G Doody, p Fearon, j Lappin
3:30 pm
RACE, SCHIZOPHRENIA, AND NEIGHBORHOOD CONTEXT IN THE U.S.: EVIDENCE
FROM A CALIFORNIA BIRTH COHORT
Dana March, E Susser, M Bresnahan, C Schaefer
4:00 pm
ETHNICITY AND THE LONG-TERM COURSE AND OUTCOME OF PSYCHOSIS:
INITIAL FINDINGS FROM AESOP-10
Craig Morgan, M Heslin, J Lappin, T Croudace, G Doody, K Donoghue, B Lomas, P B
Jones, Robin M Murray, P Fearon, Paola Dazzan
4:30 pm
ARE AFRICAN-AMERICANS MORE LIKELY TO BE MISDIAGNOSED WITH
SCHIZOPHRENIA?
Stephen M Strakowski
Comorbid Abstracts
/
Clinical Abstracts
109
INTERNATIONAL CONGRESS ON
SCHIZOPHRENIA RESEARCH
Fifteenth Bienniel Meeting
28 March - 01 April 2015
THE BROADMOOR HOTEL
AND EVENTS CENTER COMPLEX
Colorado Springs, Colorado, USA
www.schizophreniacongress.org
ICOSR13_Covers 3/15/13 4:49 PM Page 2
www.schizophreniacongress.org

Program Book - International Congress on Schizophrenia Research

Transcription

Similar documents

SCHIZOPHRENIA

January 2628, 2015 Pavia, Italy Ken Wexler, MIT, the International

Stakeholder mapping - Service Design Toolkit

16th Bandung Scientific Meeting Of Indonesian Society

Prospettive Sociali e Sanitarie

Resort Map 1206

PHYTOBALNEOTHERAPY (“HAY BATHS”) : BETWEEN TRADITION

Presentazione standard di PowerPoint

Presentazione di PowerPoint

Di Minno: Panoramica delle malattie